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Improved understanding of how the liver regenerates would be of great value, particularly 
given the dearth of therapies for end-stage liver disease. Currently, the only effective 
treatment for total liver failure is transplantation. Such an invasive, costly and specialised 
intervention is unable to address the enormous global impact from diseases of the liver. 
Ironically, the liver has the greatest regenerative potential of any organ in the mammalian 
body. However, this capacity for repair is overwhelmed in the face of massive or repeated 
injury. Understanding the key factors driving or inhibiting successful liver regeneration offers 
the potential for novel, targeted therapies to promote regeneration of a patient’s own liver. 
Animal models are widely used when studying complex, dynamic, multicellular 
processes such as liver injury and regeneration. Continued progress in transgenic 
modification of mice, combined with ongoing advances in microscopy techniques, means that 
the opportunity now exists to observe labelled cells, and subcellular structures, in real time 
and in vivo, with previously unobtainable resolution and fidelity. Not only does this afford 
the opportunity for novel insights into both normal physiology and the response to injury or 
disease, it can vastly expand the amount of biologically relevant information that can be 
obtained from each experimental animal. Hence, it is possible to advance scientific knowledge 
and reduce experimental animal use simultaneously. 
This thesis examines the role of αv integrins in liver regeneration. Integrins are expressed 
on the surface of cells and can perform a range of functions, including signalling and 
extracellular matrix adhesion. The most well-characterised role for αv integrins is activation 
of transforming growth factor beta, a molecule which has been shown to inhibit hepatocyte 
proliferation and liver regeneration. Partial hepatectomy was used as an experimental model 
of liver injury and regeneration. It was performed in mice, in which one or more αv integrins 
had been genetically depleted from specific cell types in the liver, namely hepatocytes, hepatic 
stellate cells or liver sinusoidal endothelial cells. These investigations revealed that depletion 
of integrin αvβ8 from hepatocytes led to increased hepatocyte proliferation and accelerated 
liver regeneration. The possible mechanisms through which hepatocyte integrin αvβ8 may 
exert its braking effect on liver regeneration following injury were also explored. 
In parallel, a novel experimental system to permit intravital multiphoton microscopy of 
the regenerating liver following partial hepatectomy in mice was developed and validated. 
Intravital imaging of mouse liver was performed with a range of cellular labels, combined 
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with a fluorescent cell cycle reporter and label-free imaging modalities. This demonstrated the 
enormous potential of the system to study the dynamics of hepatocytes and non-parenchymal 
cells in the regenerative niche, reconstruct the sinusoidal vascular network in three 
dimensions during angiogenesis, and measure sinusoidal blood flow and parenchymal lipid 
deposition. Advances in experimental animal models such as this drive forward our 
understanding of the cellular and molecular mechanisms of liver regeneration whilst refining 
and reducing experimental animal use. Novel insights into the process of liver regeneration 
will permit the development of innovative therapeutic strategies to allow this remarkable 
organ to heal itself even in the face of massive or sustained insult. 
	 v	
Lay Summary 
This thesis describes experiments that examine how a group of cell-surface molecules (αv 
integrins) affect liver regeneration after injury. The experiments revealed that if one particular 
αv integrin (αvβ8) is absent from the surface of hepatocytes, the main cell in the liver, then 
the liver regenerates more quickly after injury. This may be because integrin αvβ8 can activate 
a molecule called transforming growth factor beta, which has previously been shown to slow 
the rate at which hepatocytes divide during liver regeneration. Therefore, interfering with 
integrin αvβ8 releases this natural brake on liver regeneration. 
This work also showed that integrin αvβ8 is present on human hepatocytes, in samples 
from both healthy and diseased liver. As such, designing a drug to block the effects of integrin 
αvβ8 may help injured livers to regenerate, reducing the need for liver transplants and helping 
more patients to survive. 
As well as studying αv integrins, this thesis describes a new method to study liver 
regeneration in mice. Currently, one of the commonest ways to study liver regeneration in 
mice involves performing a surgical procedure to remove some of the liver tissue. The 
remaining liver then regenerates, returning to its original size within a week. The procedure 
is quick to perform, and modern anaesthetics and painkillers are used to minimise any 
suffering. However, to study how the liver is regenerating, it is then necessary to sacrifice mice 
to obtain liver tissue. The liver tissue is studied only once it has been removed from the mouse, 
which can limit the information that can be obtained. Also, each sample provides only a 
snapshot of what was happening at the time the mouse was killed. 
The new procedure implants a titanium ‘window’ onto the liver surface at the same time 
as liver tissue is removed to trigger the process of regeneration. This means that, instead of 
sacrificing mice, a microscope can be used to examine the regenerating liver while mice are 
anaesthetised. Fewer mice are used because each mouse can be imaged more than once. Also, 
the liver is studied in its native environment, so new information about blood flow and 
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Chapter 1 - Introduction 
Outline 
Effective therapies other than transplantation for both acute and end-stage liver failure do not 
exist. It has not yet been possible to harness the exceptional regenerative capacity of the liver, 
which fails in the face of massive or persistent insult. This thesis examines the role that αv 
integrins, specifically integrin αvβ8, play in the regulation of hepatocyte proliferation. 
Experimental evidence is presented that shows integrin αvβ8 on the surface of hepatocytes 
acts as a regulator of hepatocyte proliferation following injury. Depletion of hepatocyte 
integrin αvβ8 in mice results in increased hepatocyte proliferation and accelerated liver 
regeneration. Examination of possible mechanisms by which this regulation of hepatocyte 
proliferation might occur suggests that inhibition of hepatocyte integrin αvβ8 alters the 
expression of transforming growth factor beta (TGFβ)-responsive genes. This fits with the 
well-known role for integrin αvβ8 in activating TGFβ. Targeting hepatocyte integrin αvβ8 
could represent a promising therapeutic strategy to promote regeneration of a patient’s own 
liver. 
Accompanying the investigations into the role of αv integrins in liver regeneration, this 
thesis also describes the development and validation of a new model in which the process of 
liver regeneration can be studied, at a cellular level, in the living animal. The widely-used 
mouse model of liver regeneration, two-thirds partial hepatectomy, was modified and 
combined with the implantation of an abdominal imaging window (AIW) onto the surface of 
the liver. This permits multiphoton microscopy to be performed, intra-vitally, throughout the 
time course of liver regeneration. The new procedure is most informative when performed in 
mice expressing fluorescent reporter proteins, allowing multiple cell types and sub-cellular 
structures to be labelled fluorescently. This facilitates the study of dynamic processes, such as 
sinusoidal blood flow, and of hepatocyte proliferation itself, paving the way for novel insights 
into the process of liver regeneration. 
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Background 
The global burden of liver disease 
The spectre of liver disease casts a long shadow worldwide. Despite a range of aetiologies, 
diseases of the liver can broadly be categorised as acute or chronic. Of the two, chronic liver 
disease places by far the greater burden on healthcare systems around the world. All chronic 
liver diseases invariably share a common progression: inflammation leads to fibrosis, which 
progresses to cirrhosis, accompanied by loss of function.1 Once a liver has reached an end-
stage, only transplantation can prevent death ensuing. The Global Burden of Disease 2015 
study estimated that, between them, cirrhosis and liver cancer (90% of the latter occur in 
patients with the former2) accounted for almost 4% of the 55.8 million deaths in that year – 
this equates to 1 in 25 deaths worldwide.3 Notwithstanding the advances in healthcare in 
many countries, overall death rates from liver disease have remained static since 1990.3 The 
principal causes of chronic liver disease are viruses (Hepatitis B and C), alcohol, and obesity 
(leading to non-alcoholic steatohepatitis).4 Unfortunately, the progress made in preventing 
and treating viral hepatitis is currently being undermined by a voracious societal trend to eat, 
and drink alcohol, in ever-increasing amounts. 
It is for these lifestyle reasons that the situation closer to home gives even greater cause 
for concern. Liver disease is the third leading cause of premature death in the UK, after 
ischaemic heart disease and self-harm.5 The figures calculated for years of working life lost 
are staggering (Box 1). Worse still, deaths from liver disease are rising year by year: the 
standardised mortality rate for liver disease in the under-65s has increased five-fold since 1970 
(Figure 1 - 1).5 Although the vast majority of cases of chronic liver disease may be preventable,6 
several factors combine to mean that most patients present with their disease at an advanced 
stage.5 Hence, whilst prevention is the ultimate goal, effective treatments to reverse fibrosis 
and promote restoration of functional liver mass are urgently required. Liver transplant in 
every case of end-stage liver disease is neither feasible nor desirable. 
Although acute liver disease pales in comparison to the behemoth that is its chronic 
counterpart, acute liver failure still has a huge personal and financial cost, with a frequently 
devastating outcome. All cases require intensive care and, in the absence of a sufficient 
regenerative response (as is the case in the majority of these patients), a liver transplant is the 
only curative treatment.4 Despite being an active field of research, there is currently no 
equivalent to dialysis for the liver. As such, these patients would usually be categorised as 
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‘super-urgent’ and are reliant on a suitable donor organ becoming available in a short time 
frame. ‘Enhancing liver regeneration in acute liver failure’ is listed as a future goal in the 




Box 1: Liver Disease – Facts and Figures 
Liver disease is the 3rd commonest cause of premature death in the UK5 
- 62,000 years of working life are lost each year 
- 500% increase in mortality from liver disease in under 65s since 1970 (Figure 1 - 1)5 
- 80% of liver deaths are alcohol-related6 
Obesity is also a major risk factor6 
- 80-90% of obese individuals have non-alcoholic fatty liver disease 
- 10-15% of these will develop fibrosis / cirrhosis 
- on current predictions, 39 million adults in the UK will be obese by 2030 
In England and Wales (2012):5 
- 600,000 people with liver disease 
- 60,000 hospital admissions 
- 11,000 deaths 
- 695 liver transplants7,8 
29 million people in the EU have chronic liver disease9 
- 170,000 cirrhosis deaths per year 
30 million people in the USA have chronic liver disease10 
Global Burden of Disease, 2015:3 
- 2.32% of all deaths were due to cirrhosis 
- 1.45% of all deaths were due to liver cancer 
	
 
Figure 1 - 1 Standardised UK under-65 mortality rates (1970-2010). 
Data normalised to 1970 (100%). Reprinted from The Lancet,5 ©2014, with permission from Elsevier. 
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We also point out the excellent outcomes for biliary 
atresia and other childhood liver diseases being obtained 
in the three national specialist centres and the need for 
an even greater public awareness of the importance of 
early diagnosis.
Our Commission provides an economic analysis of 
the costs of liver disease and the potential savings 
obtainable through upscaling of preventive and 
treatment services, and by reduction in unnecessary 
referrals to hospital.
In the last section, we consider the new commissioning 
arrangements and public interface with respect to 
increasing the awareness of liver problems and the 
bringing together of specialist societies, liver charities, 
and patients in implementation of the recommendations 
of our Commission.
We have ten key recommendations that have been 
selected for strong endorsement and need to be urgently 
implemented.
Extent of liver disease in the UK
In the past few decades vast improvements have been 
made in health, and death rates have decreased for 
almost all diseases. In some areas (eg, cardiac disease), 
in which large health resources have been invested, the 
decrease in mortality has been substantial. Liver disease 
is the exception; standardised mortality rates have 
increased 400% since 1970, and in patients younger 
than 65 years have increased by almost 500% (fi gure 1). 
Most patients die in working age (18–65 years) and as a 
result, according to the Offi  ce of National Statistics, 
liver disease is the third biggest cause of premature 
mortality with 62 000 years of working life lost every 
year. Only ischaemic heart disease (74 000 years) and 
self-harm (71 000 years) lead to a greater premature loss 
of life5 and indeed, liver disease was included in the 
so-called Big Five targets announced by the Health 
Secretary for reduction of premature mortality.6 In 
England and Wales 600 000 people have some form of 
liver disease of whom 60 000 people have cirrhosis, 
leading to 57 682 hospital admissions and 10 948 deaths 
in 2012.7 These fi gures represent increases of 62% in 
liver disease and 40% in cirrhosis in 10 years.7 Every 
year, admissions to hospital because of liver disease 
increase, with most patients being admitted with 
serious end-stage disease, liver cirrhosis, or liver 
failure. Three-quarters of deaths from liver disease are 
the result of excess alcohol consumption; deaths caused 
by other lifestyle risk factors of obesity and viral 
hepatitis are also increasing. This increase does not 
take into account the number of acute and chronic 
pancreatitis cases (45 000 admissions each per year) 
and the eff ect on cardiovascular disease (at least 50% of 
attributable fractions of alcohol-related admissions to 
hospital), or the emerging problem of alcohol-related 
brain damage on hepatology wards.8 Liver health is a 
barometer for the wider health environment and a 
reminder that lifestyle-induced (ie, non-communicable) 
disease is the major challenge for global health in the 
21st century.9
By contrast with the trend of liver mortality in the UK, 
the opposite has happened in much of western Europe 
(fi gure 2). In 1960, liver mortality in France was 50 in 
100 000 population, 25 times higher than in the UK at the 
same time. The French health services were prepared to 
deal with liver disease at every level, from specialist liver 
units to the widespread use of simple non-invasive 
diagnostic techniques for detection of early disease.10 
Innovative alcohol policies, including controls on 
marketing such as the 1991 Loi Evin law (the prohibition 
of alcohol adverts on television and cinemas and 
inclusion of a warning on bottles stating that alcohol is 
dangerous to your health), were introduced and the 
consumption of cheap strong alcohol (wine in this case) 
decreased,11 further showing that reduction in population 
Figure 1: Standar ised UK mortality rate data
Data were normalised to 100% in 1970, and subsequent trends plotted using the software Statistical Package for 
the Social Sciences. Data are from the WHO-HFA database.4 Analysed by Nick Sheron (September, 2013).
Figure 2: Standardised liver death rates in countries in the European Union before 2004
Decrease in liver mortality in selected European Union countries compared with UK mortality. Data are from the 
WHO-HFA database.4 Analysed by Nick Sheron.
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Promoting liver regeneration 
When healthy, the liver has extraordinary regenerative potential. This may well be the result 
of evolutionary pressure provided by ingested toxins, whose first port of call is the liver 
following absorption from the gastrointestinal tract. When two-thirds partial hepatectomy is 
performed in the mouse, the liver returns to its pre-injury mass within eight days.11 In humans, 
the rate of regeneration of healthy liver is similarly impressive. Living donors in whom right 
lobectomy was performed showed a return to starting liver mass at 60 days post surgery.12 
Opinions vary on the best way to encourage an injured liver to regenerate. One of the 
strategies currently being pursued to drive liver regeneration aims to promote the expansion 
of hepatic progenitor cells, thought to reside within the Canal of Hering,13 which links the bile 
canaliculi with the biliary tree.14 In the context of global hepatocyte senescence, transplanted 
hepatic progenitor cells have been demonstrated to repopulate the injured liver, giving rise to 
both hepatocytes and ductular cells.15 However, there is good evidence to suggest that, in most 
mouse models of liver injury, liver regeneration occurs primarily through duplication of the 
adult hepatocyte population.16,17 Hence, this body of work focuses on the terminally 
differentiated hepatocyte population and examines whether it is possible to promote 
hepatocyte proliferation through targeting of αv integrins. 
αv integrins 
Integrins are often described simply as cell-cell adhesion molecules, but this belies the wide 
range of functions that they have been shown to perform.18 In addition to cell adhesion, 
integrins can interact with the cytoskeleton, act as viral and bacterial receptors, and both 
activate and respond to intracellular signalling. Their wide-ranging effects on cell behaviour 
mean that integrins have important roles in development, angiogenesis, haemostasis, 
inflammation, immune cell behaviour, and cancer. The eponymous ‘αv’ integrins are a subset 
of the 24 mammalian integrins, comprising five members (Box 2). In addition to the common 
alpha subunit, αv integrins share a key structural feature – an arginine-glycine-aspartate 
(RGD) binding domain (Box 2). This feature allows αv integrins to bind and activate latent 
TGFβ.19-24 The ability to activate TGFβ, a major pro-fibrotic cytokine with complex, yet crucial, 
roles in cancer development and metastasis, has contributed to αv integrins being explored as 
potential therapeutic targets for the treatment of fibrosis and several different cancers.25-27 
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Box 2: Integrins and RGD binding 
Integrins are a family of trans-membranous heterodimers, comprised of an alpha and beta 
subunit (Figure 1 - 2). In mammals, there are 18 alpha and 8 beta subunits, between them 
forming 24 different integrins.18 The integrin family may be sub-classified according to form 
and function (Figure 1 - 3). As well as cell adhesion, integrins may engage in bi-directional 
signalling: inside-out and outside-in. Both external ligand binding and changes to the 
cytoplasmic domains can alter activation state and integrin conformation (Figure 1 - 2). 
 
Figure 1 - 2 Integrin structure and signalling. 
The integrin heterodimer consists of alpha (red) and beta (blue) subunits. The bent form (centre) is 
inactive. Binding of either an extracellular ligand (left) or an intracellular activator (such as the 
cytoskeletal protein Talin, right) leads to conformational changes in both intracellular and extracellular 
integrin domains, i.e. integrin activation. Reprinted from Nature Reviews Molecular Cell Biology,28 ©2010, 
with permission from Macmillan Publishers Ltd. 
 
In the context of liver fibrosis, targeting αv integrins has been shown to be anti-fibrotic, 
through reduced activation of TGFβ.29 This effect was seen when αv integrins were depleted 
from hepatic stellate cells (HSCs), or when a novel small molecule inhibitor of αv integrins 
was administered parenterally. 
Whereas HSCs have been demonstrated to express all but one (αvβ6) of the αv integrins,29 
the expression of αv integrins by hepatocytes, biliary epithelium and the remaining non-
parenchymal cells of the liver is less well-characterised.  
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Förster resonance energy 
transfer
(FRET). A phenomenon in 
which one fluorophore (the 
donor) in its electronic excited 
state can transfer its energy  
to another fluorophore (the 
acceptor) in close proximity,  
so that excitation of the donor 
causes the acceptor to emit 
fluorescence. As the FRET  
only occurs when the distance 
between donor and acceptor  
is less than 10 nm, it is useful 
for monitoring interactions 
between two fluorophore-fused 
molecules.
Focal complex
A relatively small dot-like 
adhesion (~ 1 μm in width) 
mainly found in lamellipodia.  
It is a transient adhesion site 
during cell migration and can 
mature into a more stable focal 
adhesion.
Thus, cell adhesion assays typically reflect the combined 
effects o  integrin o formation and va ency regula-
tion on adhesion strength25,33. Even the results f solu-
ble ligand binding assays, the classical method to study 
integrin affinity modulation in non-adherent cells such 
as leukocytes and platelets, can be subject to ambiguity. 
For example, since most integrin ligands are multivalent, 
their binding may be influenced by the cellular regulation 
of integrin clustering. Furthermore, multimeric ligand 
binding itself may modify the nature of the bond between 
integrin and ligand through ligand-induced confor-
mational changes8, microclustering37 and outside–in 
signalling38. Finally, because the application of force 
can prolong the ond lifetimes between integrins and 
their ligands25, this so-called ‘catch bond’ behaviour may 
erroneously be attributed to integrin clustering.
Advances in the detection of protein–protein inter-
actions in living cells by FRET39, bioluminescence resonance 
energy transfer (BRET)37, image correlation spectroscopy40 
and interferometric photoactivated localization microscopy41 
promise to improve our understanding of integrin cluster-
ing at the nanoscale. As certain integrins are expressed at 
high density (for example, αIIbβ3 integrin molecules are 
< 200 Å apart in platelets38), spontaneous integrin micro-
clusters may be favoured. FRET and BRET also show that 
MnCl2 activation of leukocyte αLβ2 integrin or platelet 
αIIbβ3 integrin fails to induce microclustering. Instead, 
microclustering requires the binding of multivalent 
ligands to these integrins and is enhanced by cytochalasins, 
presumably by releasing cytoskeletal constraints37,42.
Transmembrane domains: signalling conduits
Each α- or β-integrin subunit is a typical type 1 trans-
membrane protein with the amino terminus outside 
and a single transmembrane domain that connects to a 
carboxy-terminal cytoplasmic tail (BOX 1). The transmem-
brane domain is therefore an essential connection for the 
transmission of information across the membrane.
The topology of integrin transmembrane domains. 
Ulmer’s laboratory used NMR spectroscopy of the indi-
vidual αIIb integrin and β3 integrin transmembrane 
domains and of the heterodimeric complex, to define 
their structure in phospholipid bicelles and to estimate 
the extent to which they are embedded in the mem-
brane19,43,44 (FIG. 1a). Studies of the transmembrane 
domain of the αIIbβ3 integrin heterodimer subunits 
show that the β3 integrin transmembrane domain adopts 
a long helix19, whereas the αIIb integrin transmembrane 
domain folds into a shorter helix followed by a backbone 
reversal that packs Phe992–Phe993 against the trans-
membrane helix43(FIG. 1b,c). One important contribution 
of these studies was clarifying the membrane embed-
ding of the α- and β-integrin transmembrane domains. 
Prediction methods placed45 the boundaries between 
transmembrane and cytoplasmic domains at conserved 
Lys or Arg residues that precede four to six apolar residues. 
Armulik and co-workers46 used enzymatic glycosyl-
ation mapping, a method that examines the efficiency of 
microsomal membrane glycosylation of Asn-X-(Thr/Ser) 
motifs (where X is any amino acid) placed at varying 
distances from the presumed transmembrane domain. 
They predicted that the conserved Lys residues and the 
C-terminal apolar residues in α1, α2, β1 and β2 integrin 
subunits are lipid-embedded. Protection from solvent 
water or paramagnetic relaxation of αIIb and β3 integrin 
transmembrane domains in bicelles confirmed the 
predictions of the glycosylation mapping studies19,43,44 
(FIG. 1a). Consequently, for α-integrin subunits, the con-
served Gly-Phe-Phe residues C-terminal to Lys-Arg 
are membrane embedded and terminate in a short 
transmembrane helix that is perpendicular to the plane of 
the membrane (FIG. 1b). The β3 integrin transmembrane 
domain is predicted to be tilted by ~ 25º relative to the 
plane of the membrane to enable side chains of corre-
sponding hydrophobic residues in the β-subunit19,43,44  to 
maintain membrane embedding (FIG. 1b). This β3 integrin 
transmembrane helical tilt may also be favoured by the 
propensity of the positively charged side chain of a 
conserved membrane-embedded Lys-Arg to reside in 
proximity to the negatively charged phospholipid head-
groups19. Mutational studies point to a crucial role for 
these membrane embedded, conserved apolar residues 
in both subunits in regulating integrin activation47–49, 
and the structural basis of the role of the transmembrane 
domain in activation has now become clear.
Box 2 | Bidirectional integrin signalling
There are two directions of integrin signalling, which have different biological 
consequences (see the figure). During ‘inside–out’ signalling, an intracellular activator, 
such as talin or kindlins, binds to the β-integrin tail, leading to conformational changes 
that result in increased affinity for extracellular ligands (integrin ‘activation’). The 
relationship between specific conformations and activation remains controversial. 
Inside–out signalling controls adhesion strength and enables sufficiently strong 
interactions between integrins and extracellular matrix (ECM) proteins to allow integrins 
to transmit the forces required for cell migration and ECM remodelling and assembly. 
Integrins also beh ve like traditional signalling receptors in transmitting information into 
cells by ‘outside–in’ signalling. Binding of integrins to their extracellular ligands changes 
the conformation of the integrin and, because many of the ligands are multivalent, 
contributes to integrin clustering. The combination of these two events leads to 
intracellular signals that control cell polarity, cytoskeletal structure, gene expression and 
cell survival and proliferation. Although we conceptually separate the two processes, 
they are often clos ly linked; for exampl , integrin activatio  can incre s  ligand binding, 
resulting in outside–in signalling. Conversely, ligand binding can generate signals that 
cause inside–out signalling.
REVIEWS
290 | APRIL 2010 | VOLUME 11  www.nature.com/reviews/molcellbio
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Box 2 Continued: 
The αv integrins are distinguished by their arginine-glycine-aspartate (RGD) binding domain. 
There are five αv integrin subtypes (Figure 1 - 3) and all can bind the RGD domain on the 
latency associated peptide (LAP) that maintains the TGFβ homodimer in an inactive state. 
Binding of αv integrins to the LAP drives TGFβ activation.20-24 
 
Figure 1 - 3 Mammalian integrins. 
There are 24 integrin heterodimers, formed from 18 possible alpha subunits and eight possible beta 
subunits. Integrins may be grouped into subfamilies based on their form and function. Reprinted from 
Cell,18 ©2002, with permission from Elsevier. 
 
Three other integrins also contain an RGD binding domain, but none have been shown to 
activate latent TGFβ:30 
αIIbβ3 – the principal platelet integrin, not present on the resident liver cells;31 an RGD 
peptidomimetic small molecule, which binds all αv integrins, does not bind integrin αIIbβ3;29 
α5β1 – is a major hepatocyte integrin and also present on HSCs;29,32 
α8β1 – is present on HSCs;33 can bind the LAP but does not activate TGFβ.34 
 
Hepatocytes principally express integrins α1β1, α5β1 and α9β1.32,35 Biliary epithelium is 
reported to express α2, α3, α5 and α6 integrins when uninjured.36 Following injury, integrin 
αvβ6 is expressed on cholangiocytes, and also activated hepatic progenitor cells, and has been 
shown to have an important role in the progression of fibrosis.37-39 Myeloid cells, and 
specifically macrophages, express αv integrins.40,41 Precisely which αv integrins are expressed 
is less clear, although it seems that macrophages might express integrin αvβ3, but little or no 
integrin αvβ8.42,43 Kupffer cells, the liver-resident macrophage, express integrin αvβ5.44 
There is evidence that endothelial cells express αv integrins.45,46 However, the liver 
sinusoidal endothelial cell (LSEC) is a specialised endothelial cell with a different expression 
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profile.47 In endothelium, αvβ3 has been the most studied of the αv integrins. Initially, it 
appeared not to be expressed by LSECs.48,49 However, later studies have contradicted this and 
also showed LSEC expression of integrin αvβ5.50-53 
Whilst αv integrin inhibition in the liver has been demonstrated to be anti-fibrotic, and 
end-stage liver fibrosis is accompanied by a failure of adequate regeneration, whether any of 
the αv integrins have a direct role in regulating liver regeneration has not been explored. 
Integrin αvβ8 in particular has been shown to inhibit growth in vitro in cancer cells and airway 
epithelium.54,55 There is also a large body of literature supporting an important role for αv 
integrins in general, and again integrin αvβ8 in particular, in the activation of TGFβ in 
multiple cell types, organs, and disease contexts.24,29,37,38,40,43,55-63 Hence, it is possible that any 
effect that αv integrins might have on the regulation of liver regeneration may be mediated 
via TGFβ. 
Transforming Growth Factor Beta 
TGFβ is produced as an inactive complex, the active 25 kDa homodimer held within a latency 
associated peptide (LAP) (Box 3). This inactive ‘small latent complex’ is predominantly stored 
anchored to the extracellular matrix through covalent linkage to the latent TGFβ binding 
protein (LTBP). Thus, although the regulation of TGFβ may occur at a number of levels,64 
activation of latent TGFβ is a critical regulatory checkpoint.56 The LAP contains an RGD 
domain, conferring the ability to bind to αv integrins. Crucially, mutation of this domain alone 
in mice, thus preventing αv integrin binding, recapitulates the phenotype of complete TGFβ-
1 knockout.58 Advances in the understanding of the structure of both latent TGFβ and αv 
integrins have demonstrated how integrin-LAP binding at the RGD domain, and the 
subsequent generation of mechanical force between the cell and the extracellular matrix, can 
lead to opening of the LAP and release of active TGFβ into the local environment.65-68 Of note, 
the specifics of αv integrin-mediated TGFβ activation may vary between the different αv 
integrins. For example, it has been shown that MT1-MMP (membrane type 1-matrix 
metalloproteinase, also known as MMP14) is a necessary co-factor for the activation of TGFβ 
by integrin αvβ8.21 TGFβ activation by integrin αvβ6 depends on cytoskeletal contraction and 
force transfer to integrin αvβ6 mediated by RhoA and Rho kinase.69,70 
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Box 3: Transforming Growth Factor Beta 
The TGFβ superfamily contains TGFβ itself, as well as bone morphogenic proteins, activins 
and several other related peptides.71 Active (‘mature’) TGFβ is a 25 kDa homodimer, but it is 
secreted as a larger latent complex (Figure 1 - 4). 
 
 
Figure 1 - 4 The latent TGFβ complex. 
Active TGFβ homodimer is held non-covalently within the LAP, and this small latent complex (SLC) is 
anchored to the extracellular matrix by the latent TGFβ binding protein (LTBP), forming the large latent 
complex (LLC). Reprinted from the European Journal of Cell Biology,72 ©2008, with permission from 
Elsevier. 
 
There are three mammalian isoforms of TGFβ, all with the ability to signal via the same 
receptors.73 TGFβ-1 is the isoform that has been the subject of most research. The three 
isoforms appear to have similar, but not entirely overlapping functions.74 This is demonstrated 
by the different knockout phenotypes in development.75-79 Only the LAPs of TGFβ-1 and 
TGFβ-3 have RGD domains, capable of binding to αv integrins.80 
 
Latent TGF-b is either soluble or a resident of the
ECM
The three isoforms of the TGF-b family, TGF-b1,
TGF-b2, and TGF-b3, are synthesized as homodimeric
pro-TGF-b, consisting of TGF-b that is covalently
linked to the latency associated protein (LAP). Pro-
TGF-b is then intracellularly cleaved by furin-type
enzymes to generate the mature TGF-b (Dubois et al.,
1995; Lawrence et al., 1984), which remains non-
covalently associated with LAP in the so-called small
latent complex (SLC) (Fig. 1). This association prevents
recognition of TGF-b by its high affinity receptors and
further downstream signaling. Because the LAP portion
of the SLC exhibits sequence variations between the
different TGF-b isoforms, they are often termed
accordingly: LAP-b1, LAP-b2, and LAP-b3. Liberation
of biologically active TGF-b requires its dissociation
from LAP in a process termed latent TGF-b activation
(Annes et al., 2003). Binding of active TGF-b to the
TGF-b receptor type II (TGF-b-RII) leads to the
phosphorylation and recruitment of TGF-b receptor
type I into a heteromeric receptor complex. The serine/
threonine kinase activity of the activated complex
phosphorylates Smad2 and Smad3, that both bind to
Smad4 and translocate into the nucleus to enhance gene
transcription by cooperating with DNA transcription
factors (Feng and Derynck, 2005; Massague et al.,
2005).
Only few cell types produce and secrete latent TGF-b
in form of the diffusible SLC, such as the bone cell line
UMR-106 (Dallas et al., 1994). The majority of cell
types secrete TGF-b as part of the large latent complex
(LLC) (Dallas et al., 1994; Miyazono et al., 1991;
Taipale et al., 1998). The LLC is formed within
secretory vesicles by establishing a covalent disulfide
bond between the SLC and a family member of the
‘latent TGF-b-binding proteins’ (LTBPs) (Saharinen
and Keski-Oja, 2000), comprising the four isoforms
LTBP-1, -2, -3, and -4 (Ramirez and Pereira, 1999).
LTBP-1, -3, and -4 bind to the SLC of all three TGF-b1
isoforms whereas LTBP-2 has not been reported to
sequester TGF-b (Saharinen and Keski-Oja, 2000).
LTBPs belong to the superfamily of fibrillin-like ECM
proteins and bind to several other ECM proteins,
including fibrillin-1 (ten Dijke and Arthur, 2007), FN
(Taipale et al., 1994), and vitronectin (Schoppet et al.,
2002) in a process that involves transglutamination
(Nunes et al., 1997). Due to this property, the LLC
provides a reservoir of latent TGF-b in the ECM (Fig. 1)
that is available upon cellular demand (Annes et al.,
2003; Hyytiainen et al., 2004; Koli et al., 2005;
Todorovic et al., 2005; Unsold et al., 2001). In the
following text, we will concentrate on the activation of
latent TGF-b1 from the LTBP-1-containing LLC, in
particular by integrins.
Integrin-independent mechanisms of latent TGF-b1
activation
Latent TGF-b1 is converted into its biologically
active form by various mechanisms, which differ
according to the cell type and the physiological context;
however, all mechanisms involve dissociation of TGF-
b1 from LAP-b1 in the soluble SLC and/or the ECM-
bound LLC. Proteolytic cleavage appears to be the most
prominent cellular mechanism of latent TGF-b1 activa-
tion (Annes et al., 2003). Proteolytic cleavage of LLC
and liberation of active TGF-b1 is performed by BMP-1
(Ge and Greenspan, 2006), by a variety of matrix
metalloproteinases (MMPs), including membrane-type-
1 (MT-1) MMP, MMP-2, MMP-3, MMP-9, and MMP-
13 (D’Angelo et al., 2001; Ge and Greenspan, 2006;
Maeda et al., 2002; Mu et al., 2002; Yu and
Stamenkovic, 2000), by plasmin (Lyons et al., 1990),
ARTICLE IN PRESS
Fig. 1. TGF-b1 is secreted in a large latent complex (LLC).
The LLC consists of TGF-b1, associated with LAP-b1 and the
fibrillin-superfamily member LTBP-1. Together, LAP-b1 and
TGF-b1 form the small latent complex (SLC) which is
intracellularly formed as a homodimer linked by disulfide
bonds. LAP-b1 contains four mannose-6-phosphate moieties
that are required to associate with TGF-b1. LAP-b1 and LAP-
b3 contain the amino acid sequence motif RGD serving as
recognition site for various integrins. LTBP-1 contains three
cysteine-rich domains, 14 Ca2+-binding EGF-like domains,
three non Ca2+-binding EGF-like domains, and one hybrid
domain. The second cysteine-rich domain binds the SLC via
disulfide bonds whereas the third cysteine-rich domain at the
N-terminus of LTBP-1 links the protein complex to the ECM
via transglutamination. The flexible hinge region, separating
the central hybrid domain and the third cysteine-rich domain,
is sensitive to proteolytic digestion (arrowhead). Another
protease-sensitive site is present close to the C-terminus of
LTBP-1 (arrowhead).
P.-J. Wipff, B. Hinz / European Journal of Cell Biology 87 (2008) 601–615 603
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Box 3 Continued: 
Active TGFβ can be freed from the LAP following integrin binding by mechanical or 
proteolytic mechanisms.21,65-70,81,82 Mechanical release occurs following αv integrin binding to 
the RGD domain of the LAP. Cellular contractile force, braced against the extracellular matrix, 
results in a conformational change to the LAP, releasing the active TGFβ homodimer (Figure 
1 - 5A). Alternatively, integrin αvβ8 appears to stabilise the SLC to permit proteolytic cleavage 
of the LAP, for example by MT1-MMP (Figure 1 - 5B). Other proteases, such as plasmin, 
thrombin and metalloproteinases, are able to activate TGFβ independent of integrins.81 
However, the biological significance of these routes is still debated, especially since mutation 
of just the LAP RGD domain, to prevent integrin binding, recapitulates the phenotype of 
TGFβ-1-null mice.58 
 
Figure 1 - 5 Integrin-mediated TGFβ activation mechanisms. 
A) Traction-mediated activation: αv integrin binding to the RGD domain of the LAP facilitates transduction 
of cellular force; this induces a conformational change in the LAP, resulting in release of active TGFβ. 
B) Protease-mediated activation: integrin αvβ8 stabilises the SLC at the cell surface, facilitating 
proteolytic cleavage of the LAP and release of active TGFβ. Reprinted from CSH Perspectives in 
Biology,82 ©2016, with permission from Cold Spring Harbor Laboratory Press. 
 
	  state of the latent complex may be sensitized for
activation by previous modifications of the ma-
trix (Klingberg et al. 2014). The traction mech-
anism is supported by the crystal structure of
TGF-b bound to LAP, which shows that Cys33,
required for LTBP attachment, and the RGD
motif are on opposite sides of the molecule,
with TGF-b sandwiched between two arms of
a LAP “straightjacket” (Shi et al. 2011). This
straightjacket can be deformed by traction ap-
plied to the molecule, as shown by atomic force
microscopy experiments (Buscemi et al. 2011).
The mechanism of latent TGF-b activation
by avb8 is more obscure. Latent TGF-b activa-
tion by this integrin was reported to be blocked
by the presence of matrix metalloproteinase
(MMP) inhibitors and did not require the
cytoplasmic domain of avb8, indicating a trac-
tion-independent mechanism (Mu et al. 2002).
This suggests an alternative protease-dependent
mechanism, perhaps involving recruitment of
MMPs by integrins to facilitate LAP cleavage
and release of TGF-b (Fig. 3B). Alternatively,
binding by the integrin may induce changes in
LAP structure that promote protease cleavage.
MT1-MMP (membrane-type matrix metallo-
proteinase 1) was suggested as a potential can-
didate protease, as it both conferred the ability
to activate latent TGF-b, when transfected into
the avb8-expressing cancer line H1264 and co-
Actin cytoskeleton anchors















A  Traction-mediated activation
B  Protease-mediated activation





















Figure 3. Proposed mechanisms of latent transforming growth factor b (TGF-b) activation by integrins. Two
mechanisms have been proposed by which integrins activate latent TGF-b. (A) Traction between cells and
extracellular matrix (ECM) is transmitted to latency-associated peptide (LAP) via latent TGF-b-binding pro-
teins (LTBPs) bound to the matrix and cell-surface integrins bound to the cell’s actin cytoskeleton. This deforms
LAP and releases active TGF-b. (B) Integrins bind LAP at the cell surface and this may make LAP more accessible
to proteases, such as membrane-type matrix metalloproteinase 1 (MT1-MMP), that cleave LAP and release the
active growth factor, by localizing it and recruiting proteases into its vicinity, or by changing the structure of LAP
so that it is rendered more protease sensitive.
Regulation of the Bioavailability of TGF-b
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TGFβ signalling and functions 
Classically, TGFβ signalling proceeds through the binding of the active homodimer to the 
TGFβ receptor type II, which complexes with TGFβ receptor type I at the cell membrane (Box 
4).71,73,83,84 This receptor complex facilitates sequential phosphorylation and complexing of 
cytosolic SMAD proteins. These phosphorylated complexes, such as phospho-SMAD2/3/4, 
then enter the nucleus and bind to the regulatory elements of genes, thereby modulating 
transcription. It has also been known for some time that the canonical TGFβ signalling 
pathway is by no means the only route through which TGFβ is able to exert its effects. TGFβ 
is able to modulate, and signal via, several other well-known signalling pathways, including 
mitogen-activated protein kinases, small GTPases, and NFκB.85 
Box 4: TGFβ signalling pathways 
All three mammalian isoforms of TGFβ are able to bind the TGFβ type II receptor. This results 
in phosphorylation and the formation of a tetramer with the TGFβ type I receptor (Figure 1 - 
6). Canonically, signalling then proceeds by SMAD phosphorylation and nuclear translocation. 
In the nucleus, the SMAD complex, transcription factors and co-factors, combine to drive gene 
expression. Multiple non-canonical TGFβ signalling pathways also exist, including via Erk, p38 
and JNK mitogen-activated protein kinases, Rho GTPases, and the PI3K-AKT pathway.85  
	
Figure 1 - 6 TGFβ signalling pathways. 




TGFβ – the duplicitous molecule 
Such diverse signalling mechanisms go some way to explaining the pleiotropic functions of 
TGFβ. The cellular effects of TGFβ signalling are also highly context-dependent, with 
profound effects in such varied biological processes as development, inflammation and cancer 
development, as well as in maintaining cellular homeostasis.83 The outcome of TGFβ 
signalling can vary markedly depending on the precise timing of signalling and the local 
environment in which it occurs. Such challenges to achieving a complete understanding of the 
multiple roles of TGFβ are exemplified by the apparently paradoxical roles in cancer. 
Initially, TGFβ was shown to be inhibitory to the growth of transformed cells, thus 
appearing to have a predominantly tumour-suppressive action.87 This was supported by 
animal models that demonstrated an increase in tumour development following disruption 
of the TGFβ signalling pathway.88,89 However, TGFβ has also been shown to enhance tumour 
metastasis and the development of tumour vasculature.86,90 In hepatocarcinogenesis, the role 
of TGFβ is further complicated by its function as a key driver of fibrosis, itself a major 
independent risk factor for the development of liver cancer.2,86,91 
TGFβ and liver regeneration 
In the context of liver regeneration, TGFβ is a potent inhibitor of hepatocyte proliferation. 
Following the identification of TGFβ in the early 1980s,92 a glut of publications demonstrated 
a dose-dependent inhibition of proliferation when TGFβ was provided to hepatocytes in 
vitro.93-97 Subsequently, it was confirmed that hepatocyte DNA synthesis could be inhibited in 
vivo, albeit transiently, by exogenous TGFβ injected at, or shortly after, partial hepatectomy 
in rats.98 An increase in hepatic TGFβ transcription, peaking at 72 hours after partial 
hepatectomy, was postulated to serve as an intrinsic homeostatic mechanism, through which 
hepatocyte proliferation could be suppressed as the hepatectomised liver returns to its pre-
injury state.99 A similar finding was reported following injury with carbon tetrachloride.100 
Evidence was presented for both paracrine and autocrine sources.99-101 
Targeting the TGFβ pathway, either by injection of an anti-TGFβ antibody or through 
genetic depletion of hepatocyte TGFβ type II receptor, both have the expected effect of 
increasing DNA synthesis and hepatocyte proliferation following partial hepatectomy.102,103 
Increased hepatocyte proliferation was also observed to accompany reduced fibrosis when 
TGFβ signalling was inhibited in a rat model of chronic fibrosis.104 Furthermore, TGFβ appears 
to play a homeostatic role, restricting hepatocyte proliferation even in uninjured liver. When 
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an adenoviral delivery strategy was employed to achieve hepatic expression of a TGFβ type 
II dummy receptor, hepatocyte proliferation increased even in the absence of an injurious 
stimulus.105 Importantly, targeting TGFβ activation, rather than TGFβ signalling directly, has 
also been shown to promote hepatocyte proliferation. Thrombospondin-1 has been shown to 
activate TGFβ in vivo.81,106 Following partial hepatectomy, thrombospondin-1 knockout mice 
demonstrated increased hepatocyte proliferation and accelerated liver regeneration compared 
to controls.107 
As with the inhibitory effect observed following the administration of exogenous TGFβ, 
the described effects on the promotion of hepatocyte proliferation were transient, suggesting 
that regulation of hepatocyte proliferation and liver regeneration relies on more than one 
factor or pathway. It is not surprising that such a key biological process has an element of 
redundancy, and this does not detract from the broad concept that targeting the TGFβ 
pathway to promote liver regeneration is an avenue worthy of ongoing exploration. 
Designing targeted anti-TGFβ therapies 
The importance and evident potency of TGFβ have resulted in it being widely studied as a 
potential therapeutic target in a range of cancers and fibrotic conditions.108 However, in 
developing effective therapies directed against the action of TGFβ, it is essential to remain 
mindful of the pleiotropic nature of this molecule and its myriad functions in homeostasis as 
well as in multiple disease processes. Blunt, ‘sledgehammer’ approaches, blocking TGFβ 
signalling globally, risk causing unacceptable side effects, such as significant autoimmunity 
or cancer development.76,88,89,108 For this reason, if TGFβ signalling is to be targeted 
successfully, nuanced approaches are required. These aim to limit excessive and harmful 
TGFβ activity whilst not completely abolishing the low levels of TGFβ signalling necessary 
for the success of core homeostatic processes. 
The importance of the activation of latent TGFβ has already been highlighted as a key 
regulatory checkpoint. Modulating TGFβ activation in the appropriate cellular niche therefore 
has the potential to limit the harmful effects resulting from localised, excess TGFβ activity. 
Several mechanisms by which TGFβ can be released from the LAP have been identified. 
Activation may be mediated by plasmin, thrombospondin and, as previously described, one 
or more αv integrins. The αv integrins are attractive in this respect because of their proven 
ability to activate TGFβ in vivo. Indeed, in some contexts, αv integrins appear to be the 
principle mediators of TGFβ activation.57 
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Hypothesis 
Consolidating the previous experimental evidence that αv integrins play a role in the 
progression of (fibrotic) liver disease and can activate TGFβ, which itself can inhibit 
hepatocyte proliferation, led to the following broad hypothesis, which is investigated through 
the body of work presented in subsequent chapters: 
Inhibition of αv integrin-mediated TGFβ activation results in increased 
hepatocyte proliferation and accelerated liver regeneration 
Aims and Goals 
Incorporating the hypothesis described above, the aims and goals of the investigations 
reported in this thesis were as follows: 
§ To investigate whether αv integrins play a role in the regulation of liver regeneration 
§ To examine whether any role for αv integrins in regulating liver regeneration is 
mediated via TGFβ 
§ To develop a novel model to study liver regeneration in mice, combining partial 
hepatectomy with intravital multiphoton microscopy 
§ To demonstrate how intravital multiphoton microscopy can be used to study dynamic 
processes occurring during liver regeneration, at a cellular level, in the living animal 
Tools to study liver regeneration 
Models of liver regeneration 
Liver regeneration is a co-ordinated, multi-cellular process, which makes it a challenge to 
study in vitro. This is despite recent advances in organoid technology and tissue slice culture 
systems.109,110 It is also a highly dynamic process, necessitating study at multiple time points 
as regeneration progresses. This feature, combined with the many practical and logistical 
challenges, limits the study that can be performed in human subjects. Therefore, rodent 
models still form the mainstay of research into liver regeneration. The regenerative process 
can be initiated at a defined point in time, in multiple, genetically identical subjects. The injury 
models are refined so as to produce a consistent, reproducible time course over which liver 
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regeneration occurs. The entire regenerative process is then complete in a relatively short time 
frame, within one week in the case of the mouse.11 
Although a number of liver injury models exist in rodents, two in particular are 
frequently used to study the regenerative response and are employed in the work that is 
described in the following chapters. Partial hepatectomy has been employed for the study of 
liver regeneration in mice for over 60 years.11 It is generally considered as the purest model of 
liver regeneration, since it does not trigger a marked inflammatory response. The most 
commonly performed procedure is described variously as a ‘two-thirds’ or ‘70%’ partial 
hepatectomy (Box 5). This degree of hepatectomy results in minimal morbidity and mortality, 
whilst driving significant hepatocyte proliferation and liver regeneration.111 Removing a lesser 
amount of liver tissue results in a response defined primarily by cellular hypertrophy rather 
than true regeneration.112 Conversely, although excision of up to 90% of the mass of the liver 
has been reported,113 often referred to as ‘massive’ hepatectomy, this leads to (unacceptably) 
high mortality rates without offering significant benefits with regards to the study of liver 
regeneration. 
The second model of liver injury and regeneration employed in this body of work is that 
of acetaminophen (paracetamol) overdose (Box 5).114 The liver is able to metabolise a certain 
amount of acetaminophen without toxic effects. However, overdose results in accumulation 
of the (toxic) metabolite NAPQI, in excess of that which can be safely processed by the 
glutathione pathway. This results in generation of reactive oxygen species, accompanied by 
hepatocyte necrosis in a centrilobular distribution. In mice, this initial injury phase is complete 
by 24 hours and the regenerative phase dominates from this point on.115 Experimentally, the 
dose of acetaminophen administered is titrated to achieve significant injury whilst minimising 
the incidence of total liver failure and death from multiple organ dysfunction.114 
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Box 5: Mouse models of liver regeneration 
The rodent partial hepatectomy model of liver regeneration was initially described in rats.116,117 
The first large study in mice was reported in the 1950s,11 and the model continues to be a 
mainstay of the study of liver regeneration to the present day, with only minor technical 
refinements.111 
The multi-lobar structure of the liver makes it possible to vary the degree of partial 
hepatectomy.118 However, the standard procedure comprises removal of the median and left 
lobes (Figure 1 - 7). 
There is a repeatable, coordinated response to partial hepatectomy. Hepatocytes are the first 
liver cells to proliferate, with DNA synthesis peaking at 36-48 hours.111,119,120 The majority of 
hepatocytes undergo one or two rounds of replication.121 Hepatocyte proliferation is followed 
by proliferation of HSCs and LSECs, with regeneration essentially complete by seven days.122 
 
Figure 1 - 7 Mouse liver lobe anatomy and partial hepatectomy. 
The multi-lobar mouse liver permits excision of lobes singly or in combination. In the standard ‘two-thirds’ 
partial hepatectomy, the left lateral and median lobes are excised. Labelled lines indicate ligating suture 
location for excision of the right median (a), left median (b), and left lateral (c) lobes. Adapted from Nature 



















Box 5 Continued: 
Acetaminophen-induced liver injury is a translatable model of injury and repair, as 
acetaminophen overdose is a major cause of acute liver failure in human patients.123 Whereas 
partial hepatectomy is ‘pure’ model of liver regeneration, with minimal inflammation, 
acetaminophen evokes a strong inflammatory response whilst also driving liver 
regeneration.114,115 
At low doses, the majority of acetaminophen is safely metabolised by glucuronidation and 
sulphation in the liver, before excretion in urine (Figure 1 - 8).114 However, a percentage is 
converted to the highly toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine) by the 
cytochrome P450 system. Even NAPQI can be processed by the liver without injury, through 
conjugation to glutathione. But once glutathione stores are depleted, NAPQI results in 
mitochondrial damage and massive hepatocyte necrosis. 
 
Figure 1 - 8 Routes of acetaminophen metabolism. 
At low doses, acetaminophen may be safely metabolised via glucuronidation, sulphation, or conjugation 






A further, huge advantage gained from using mice to study the process of liver regeneration 
derives from the major advances that have occurred in transgenic technology in this species 
over the preceding three decades. The advent of the Cre-lox system now permits cell-specific 
targeting of gene depletion and reporter protein expression.124-126 This has greatly enhanced 
the precision with which gene and cell function can be interrogated. In particular, the 
opportunities provided by Cre-lox enable the study of certain gene products, including the β8 
integrin subunit, for which global or constitutive knockout would be lethal.127 The resource is 
now so great that it can essentially be considered as a transgenic targeting ‘toolkit’.128 
The bacteriophage-derived enzyme Cre recombinase essentially functions as a pair of 
molecular scissors, targeted to cut genomic DNA by the insertion of ‘loxP’ sites at precise 
locations (Box 6).129 Preceding the Cre construct with a cell-specific promoter restricts 
expression to the cell type of interest, and its activity can then be temporally restricted by 
further transgenic modifications. Hundreds of Cre-expressing mouse lines have already been 
generated and the number continues to grow.128 Individual Cre lines can then be interbred 
with any one of numerous ‘floxed’ lines to achieve the desired genetic modification, be that 
inactivation of a gene of interest or switching on expression of a reporter protein (Box 6). 
In the liver, cell-specific expression of Cre recombinase is achievable in all of the principal 
cell types.129 Depletion of all αv integrins can be achieved by interbreeding the Cre line of 
choice with a line in which a section of the Itgav gene (encoding the αv integrin subunit) has 
been floxed.41 Similarly, a floxed Itgb8 allele (encoding the β8 integrin subunit) allows Cre-
mediation depletion of integrin αvβ8.130 
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Box 6: The Cre-lox system 
The Cre-lox system facilitates spatial and temporal control of gene expression in mice (Figure 
1 - 9).129 Cre (cyclization recombinase) catalyses DNA recombination. The site and nature of 
recombination is determined by the location and orientation of two loxP sites. Spatial control 
of gene expression results from combining the Cre construct with cell-specific promoter 
sequences, to restrict its expression to the cell type(s) of interest. Cre expression may be 
constitutive in the cell type of interest, although, once recombination has occurred in a cell, the 
genome modification is heritable and irreversible. Temporal control of recombination may be 
achieved through various means. These include driving Cre expression via the ‘Tet system’, or 
linking Cre to a modified oestrogen receptor (ERT2). This latter strategy retains Cre outside of 
the nucleus until tamoxifen (an ER ligand) is administered (Figure 1 - 9B). 
 
Figure 1 - 9 The Cre-lox system. 
Cell-specific expression of Cre, with subsequent recombination, may be used to produce gene 
inactivation or activation (A). Temporal control of Cre activity may be achieved using a modified version 
of Cre – CreERT2, which is unable to access the nucleus and drive recombination until tamoxifen (TAM) 
is administered (B). Reproduced from Hepatology,129 under CC BY 4.0. 
 
Alternatively, a floxed STOP codon may be inserted,
whereby transcription of the downstream sequence,
commonly a fluorescent reporter construct, only pro-
ceeds following Cre-mediated excision (Fig. 1A). Thus,
Cre-lox permits intrinsic cellular labeling through cell-
specific and, if required, temporally restricted, fluores-
cent protein expression. These manipulations require
at least two Tg modifications, inserting Cre and loxP
sites respectively, and are achieved by interbreeding
strains carrying a single transgene. Therefore, this per-
mits essentially any combination of Cre driver and
floxed allele.
“Conditional” Cre Expression
Cell-specific Cre expression is achieved using a cell-
specific promoter element. In constitutive systems, pro-
moter activation leads directly to Cre expression and
recombination. However, constitutive systems do not
permit a defined cohort of cells to be labeled at a spe-
cific point in time (temporal Cre expression), which
negates their use in true fate-mapping experiments.
Furthermore, constitutive Cre-driven ablation of devel-
opmentally important genes, even if cell specific, has
the potential for embryonic lethality. As such, use of
inducible Cre-lox systems, in which an exogenous
stimulus is required to permit Cre-mediated recombi-
nation, has increased in recent years. This temporal
regulation of Cre can be mediated through systems
including Cre fusion proteins or the tetracycline (Tet)
system.
The commonly used tamoxifen-inducible system
employs a Cre fusion protein, CreERT2, containing a
Fig. 1. Schematic diagram of cell-specific Cre recombinase-induced gene inactivation and fluorescent reporter expression systems. (A) Cell-
specific expression of Cre recombinase results in excision of loxP-flanked sequences leading to gene inactivation or fluorescent reporter expres-
sion. (B) Spatiotemporal regulation of Cre activity: tamoxifen (TAM) administration permits entry of the Cre-ERT2 complex into the nucleus, allow-
ing excision of loxP-flanked sequences.
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Box 6 Continued: 
The Cre-lox system can be utilised in a number of ways; for example: 
Gene inactivation: loxP sites are inserted to flank (‘flox’) an exon of the gene of interest; Cre-
mediated recombination results in exon excision and prevents transcription of a functional gene 
product (Figure 1 - 9A, upper). 
Gene activation: most commonly applied to switch on (fluorescent) reporter gene expression; 
a floxed STOP codon before the gene of interest prevents transcription except in cells (and/or 
until such time as) Cre-mediated excision occurs and permits gene expression (Figure 1 - 9B, 
lower). 
Since insertion of Cre and the loxP sites requires two separate transgenic modifications, in 
theory any Cre line can be interbred with any line with a floxed allele. One copy of any Cre or 
floxed reporter allele is generally sufficient for recombination and reporter protein expression, 
respectively. However, for maximal gene depletion, mice must be homozygous for the floxed 
allele. 
 
Assessing TGFβ activity 
As stated above, TGFβ is produced in an inactive form and secreted into the extracellular 
matrix. In liver homogenate, at least 90% of TGFβ is inactive.131 As such, demonstrating a role 
for TGFβ in a given biological process cannot be achieved merely by examining TGFβ gene or 
protein expression. Rather, it is necessary to assess the level of active TGFβ present at the 
biological site of interest, or alternatively examine downstream effects on TGFβ signalling 
pathways and transcription. 
A number of methods to measure active TGFβ have been reported.132 Of these, the mink 
lung epithelial cell (MLEC) system is frequently used to measure levels of active TGFβ.20-
24,29,55,68,70 Its principles are described in further detail in Chapter Four. Briefly, MLECs were 
modified to express firefly luciferase in response to active TGFβ.133 As well as being able to 
measure the amount of active TGFβ in a culture medium or cell supernatant, co-culture with 
MLECs allows the ability of a cell type of interest to activate latent TGFβ to be assessed. More 
recently, an alternative system, in which mouse fibroblasts secrete alkaline phosphatase in 
response to active TGFβ has been reported.134 The broad principles of both cell-based assays 
for active TGFβ are similar, although the newer assay claims a degree of increased sensitivity 
and specificity. 
Demonstrating TGFβ activity in tissue remains challenging.131 Whilst an ELISA approach 
has been utilised to measure both total and active TGFβ,29,38,74 its ability to detect low levels of 
	 21	
active TGFβ reliably is questionable.131 Therefore, an indirect assessment of TGFβ activity is 
often employed, such as detection of phosphorylated SMAD proteins or quantification of 
TGFβ-responsive gene expression.24,29,62,70,91,135,136 In addition to individual genes, such as 
Serpine1, that are known to be highly responsive to TGFβ, a hepatocyte TGFβ ‘signature’ has 
been published.137 This was defined by using microarray to identify 314 genes whose 
expression was significantly altered, positively or negatively, by the addition of recombinant 
TGFβ in vitro. 
Challenges to studying liver regeneration 
Although studying liver regeneration in mouse models offers several advantages in 
comparison to both in vitro systems and human subjects, there are still limitations. As well as 
the perennial question of translational relevance to human disease, experimental rodents have 
generally been considered to be ‘single use only’. Animals are humanely killed at relevant 
time points to allow tissue harvest. Not only does this drastically limit the amount of 
information that can be gleaned from each individual experimental animal, but only a 
snapshot of any disease or physiological process is ever obtainable. The temporal dimension 
of the process under study must therefore be reconstructed by averaging multiple snapshots 
at each time point before combining them in sequence. It is the scientific equivalent of 
producing a flick book by merging four (or more) artists’ illustrations on every page and 
always asking different artists to draw the next image in the sequence. Further challenges to 
biological relevance result from the fact that harvested tissue is, by definition, no longer part 
of a living organism. Dynamic processes such as blood flow and cell migration cannot be 
studied in this way. Fixation and other processing steps prior to analysis can also introduce 
artefacts or mask true biology. In summary, although harvesting tissue from rodent models 
has facilitated huge advances in our understanding of many biological processes, it can also 
be seen as costly, scientifically limiting, and restrictive to efforts to reduce experimental animal 
use. 
Intravital imaging 
It is for these reasons that, in recent years, rapid advances have been made with regard to 
imaging tissues or cells of interest in the living subject, be these patients or experimental 
animals. All such techniques fall broadly under the heading of intravital imaging. The key 
benefits of intravital imaging are the potential for the tissue of interest to be imaged on more 
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than one occasion, in situ, with limited or no disruption to cellular processes. External tissues 
and organs, such as the skin or eye, are readily accessible for imaging. Similarly, techniques 
such as radiography, ultrasound and magnetic resonance, have permitted intravital imaging 
of internally-located tissues for many years. However, intravital imaging of internal tissues at 
a cellular, or even subcellular, level does present a number of challenges. Primarily, light 
microscopy relies on there being minimal interference to the passage of the beam of light, with 
only a small distance (of the order of micrometres) between the cells of interest and the 
objective lens. 
To perform intravital microscopy of the liver, several investigators have surmounted 
these challenges by exteriorising the organ in the anaesthetised animal.138-143 Whilst this does 
at least allow dynamic processes to be studied, with the organ more or less in situ, it restricts 
the period over which imaging in the individual animal can be performed to a few hours at 
most, since such a procedure must always be performed under terminal anaesthesia. 
Therefore, repeated imaging in the same subject cannot be performed over a number of days. 
Repeat microscopy of internal tissues requires that the tissue of interest is made available 
for microscopy within a closed, sterile system that also allows the experimental animal to 
exhibit normal behaviour as far as possible between imaging sessions. Surgical implantation 
of an imaging ‘window’ facilitates this by removing the physical barriers to light provided by 
skin, muscle and bone, whilst maintaining the integrity of the body cavity in question. 
Typically, such implants consist of a medical-grade metal or alloy with a central aperture over 
which a glass coverslip is placed. Imaging windows have been used to image the brain, lung 
(in a non-recovery setting), and various abdominal organs.144-146 More than one type of 
window for intravital microscopy of the liver has been reported, illustrating the continuing 
evolution of such techniques.146,147 
Intravital microscopy presents its own set of challenges to investigators, as they strive to 
obtain repeatable, high-quality data at subcellular resolution. Unwanted movement, 
including respiratory excursion of the anaesthetised animal, is probably the single greatest 
barrier to obtaining the perfect image. A number of modifications to window implantation 
technique,146 immobilisation during imaging,147 acquisition protocols,148 and post-acquisition 
image processing149,150 can all assist in reducing movement artefact. The tissue of interest must 
also maintain close apposition to the coverslip. This can be achieved using synthetic adhesive, 
retaining implants, or simply gravity. The presence of dead space between coverslip and 
tissue not only directly hampers image quality and depth, but may also promote the 
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accumulation of biofilms and cellular infiltrates. Furthermore, glass is a biologically reactive 
material, so coating the coverslip in an inert polymer has been recommended.146 
Multiphoton microscopy 
Concurrent with the technical advances to provide the appropriate conditions in which 
intravital microscopy of internal tissues may be performed in experimental animals, there 
have been continuing developments in microscopic techniques. Repeated innovations have 
improved image resolution and depth, provided new modalities through which biological 
structures can be visualised, and permitted simultaneous detection and discrimination of 
multiple (sub-)cellular labels. Epifluorescence and confocal microscopy have both been 
utilised in intravital imaging.143,151 However, the greatest technological advance in the context 
of intravital microscopy came with the advent and application of multiphoton microscopy 
(Box 7). 
The advantages of two photon excitatory fluorescence (TPEF) microscopy, compared to 
using a single excitatory photon of half the wavelength, include increased depth penetration, 
reduced light scattering, and lower phototoxicity. Multiphoton microscopy also offers the 
opportunity of label-free imaging, using second harmonic generation (SHG) and coherent 
anti-Stokes Raman scattering (CARS). This information can be acquired contemporaneously 
with detection of more traditional fluorescent antibody labels or dyes, usually administered 
intravenously. In addition, transgenic technology can be co-opted to drive fluorescent protein 
expression in cells or structures of interest. This may be achieved through a number of 
techniques, including knock-in reporter genes and Cre-lox driven reporter expression, with 
subsequent inter-breeding allowing expression of multiple fluorophores in a single animal. In 
fact, the vast array of possible labels, combined with the huge amounts of data that can be 
generated following the intravital imaging of just a single experimental animal, have elevated 
this field into the world of ‘big data’, alongside the complementary spheres of whole-genome 
and RNA sequencing. 
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Box 7: Multiphoton microscopy 
Multiphoton microscopy is not actually a single technique. Rather, it offers several different 
modalities by which an image can be obtained from a biological specimen. The common feature 
is the use of multiple excitatory photons in combination (Figure 1 - 10). 
	
Figure 1 - 10 Example multiphoton microscope setup. 
The titanium-doped sapphire laser and optical parametric oscillator (OPO) allow production of two 
parallel laser beams for TPEF, SHG and CARS microscopy. DL, delay line; DM, dichroic mirror; L, lens; 
F, bandpass filter; PMT, photomultiplier tube. Reprinted from Biomedical Optics Express,152 ©2017, 
Optical Society of America. 
 
TPEF – two photon excitatory fluorescence microscopy was first described in 1990.153 
Conventional fluorescence microscopy relies on the excitation of a molecule by a single, higher 
energy, shorter wavelength photon, in order to achieve emission of a lower energy, longer 
wavelength photon for detection. TPEF generates the same emission signal from the 
simultaneous (within 10-18s) arrival at the focal point of two photons, themselves of lower 
energy and longer wavelength than the single emission photon they produce (Figure 1 - 11). 
SHG – second harmonic generation is a technique that allows label-free imaging of highly 
ordered structures, such as collagen. Essentially, two identical photons interact with the 
material, resulting in the generation of a single photon of half the wavelength (Figure 1 - 11). 
CARS – Coherent anti-Stokes Raman scattering is another label-free technique which exploits 
the differential vibrational properties of molecules within a sample. One light beam is used to 
provide ‘pump’ and ‘probe’ photons, in combination with a second Stokes beam. As the 
molecules relax from the virtual state to which they are excited, returning to the ground energy 
state, a detectable signal is produced (Figure 1 - 11). CARS can be used to provide an image of 
general cellular morphology (similar to that of standard brightfield microscopy), but is also well-
suited to imaging lipid molecules within a sample. 
 
	  
for 256 pixels × 256 pixels image. For each imaging session, the live, fast scanning imaging 
was performed at the speed of 3.25 seconds per frame to scan the whole sample surface to 
locate the region of interest. After acquisition, the raw data was processed to get color 
encoded images by a custom-built Matlab pr gram (Matlab R2015a, Mathworks, MA, USA). 
 
Fig. 1. Schematic of the TP/CARS combined microscopic system. The system uses 
Ti:Sapphire and OPO to produce 808 nm and 1049 nm beams as the pump and Stokes beams. 
Moxifloxacin signal and CARS signal are collected backward using objective lens and two 
photomultiplier tubes. SBS: beam splitter; OPO: optical parametric oscillator; DL1, DL2: 
delay lines; DM1, DM2, DM3: dichroic mirror; F1: 3nm narrow bandpass filter; F2, F3: 
detection bandpass filter; L1, L2, L3: lens; PMT: photomultiplier tube. 
Large FOV moxifloxacin based TP imaging of brain tumor tissues, containing DsRed 
cancer cells, was conducted by using a commercial TPM (TCS SP5 II MP, Leica, Wetzlar, 
German ) equipped with a Ti:Sapph re laser (Chameleon V sion II, Coherent, CA, USA). 
Excitation wavelength was selected at 830 nm to simultaneously excite both moxifloxacin 
and DsRed with deep tissue penetration. A 20x objective lens (HCX APO L20x 1.0NA, water 
immersion, Leica, Wetzlar, Ge many) was used with z stepwise increm nt of 2 μm for 3D 
imaging. By using a set of dichroic mirrors and band-pass filters, emission light was 
spectrally resolved to 2 channels, 495 nm - 560 nm for moxifloxacin and 560 nm - 620 nm for 
DsRed, and detected by photomultiplier tubes (R10467U-40, Hamamatsu Tokyo, Japan). 
Each image contains 1024 pixels × 1024 pixels with FOV of 775 μm × 775 μm. The imaging 
speed was 0.1 frame per second including 2 line averaging and 2 frame accumulation. In 
order to enable large-area imaging, nine images were taken using an x-y translational stage 
and carefully stitched toge her manu lly. 
2.2 Normal mouse brai  tissu  preparation 
This study was approved by the Institutional Animal Care and Use Committee board of the 
Pohang University of Science and Technology (POSTECH-2015-0030-C1). Mouse models 
were bred at the animal facility of POSTECH Biotech Center under specific pathogen-free 
(SPF) condition. Six-week-old, three C57BL/6 mice were used. The brain tissue was 
extract d from the skull ri ht after sacrifice. The brain tissue was sectioned in the coronal 
plane in 1 mm thickness with a surgical razor blade after 5 minutes of hardening in a freezer 
at − 20 °C. Moxifloxacin ophthalmic solution (0.5%, Vigamox, Alcon, TX, USA) was 
dropped over the sectioned brain tissue followed by incubation for 20 minutes at room 
temperature. After the incubation period, the remnant moxifloxacin was washed out with PBS 
1 × and then the tissue was imaged with TP/CARS microscope system. After locating the 
hippocampus and subcortical white matter areas by performing the live and fast scanning 
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Box 7 Continued: 
 
Figure 1 - 11 Multiple photons can be utilised to produce detectable emission signals from 
biological specimens. 
S0, ground energy state; S1, excited state; Sh, higher virtual state; ω, frequency. Reprinted from Journal 
of Biophotonics,154 ©2016, with permission from John Wiley & Sons Inc., and from Journal of 
Hepatology,155 ©2010, with permission from Elsevier. 
 
Multiphoton microscopy is well-suited to intra-vital imaging for a number of reasons: the image 
is generated from emitted rather than transmitted light; longer wavelength excitatory photons 
have increased depth penetration and result in decreased phototoxicity to live cells.154 Further, 
all three techniques described above can be performed simultaneously, maximising data 
acquisition relative to imaging time. In liver, TPEF permits simultaneous imaging of multiple 
fluorescent reporter proteins, exogenously administered fluorescent labels, and intrinsic 
autofluorescence (such as vitamin A in HSCs). SHG can be used to image the liver capsule and 
collagen deposition during fibrosis. CARS can be employed to assess hepatocyte lipid dynamics 
in health and disease. 
 
	
Although intravital multiphoton microscopy of the liver has been described, it has either been 
performed as a terminal procedure with the liver exteriorised, or has been applied to the study 
of biliary excretion or cancer.147,156 Liver regeneration has not previously been studied with 
this approach. In some respects, this is surprising. Liver regeneration is a coordinated, 
dynamic, multicellular process, which takes place, at least in mice, over a time frame short 
enough to be imaged regularly from start to finish, but enduring long enough that it is unable 
to be encapsulated by a single, non-recovery imaging session. 
The under-representation of liver regeneration within the intravital microscopy literature 
may be, in part, because of the challenges posed by combining the liver injury necessary to 
trigger regeneration with the implantation of an imaging window. Understandably, concerns 
might exist about the potential welfare impact of combining surgical implantation of an 
because the longer-wavelength and lower-energy
excitation light reduces photodamage and increases
penetration depth, allowing imaging of living speci-
mens [11]. Unlike confocal microscopes, MPM does
not contain pinhole apertures, allowing the detector
to be placed closer to the objective to optimize col-
lection of scattered light, and further enhancing the
imaging d pth.
2.2 Imaging modality of MPM
As shown in Figure 2b, MPM can excite and detect
nonlinear signals including two-photon excited fluo-
rescence (TPEF), second harmonic generation (SHG)
and coherent anti-Stokes Raman scattering (CARS)
[13]. The concept of TPEF is based on the idea men-
tioned above that two photons of lower energy can
excite an electron into a state with higher energy,
from which it can decay and emit a shorter-wave-
length light. Each photon carries approximately half
the energy necessary to excite the fluorophore [5].
The most commonly used fluorophores in MPM
have excitation spectra in the range of 400–500 nm,
whereas the laser used to excite the TPEF lies in the
700!1000 nm range. As shown in Table 1, a number
of endogenous molecules in the liver can generate
fluorescence, which is a hindrance of traditional
fluorescence microscopy, yet is used as an advantage
in TPEF imaging [14]. The metabolic coenzymes
nicotinamide adenine dinucleotide hydride (NADH)
is a respiratory substrate for complex I of the mito-
chondrial electron transport chain, which is an en-
dogenous fluorophore in the cytoplasm of hepato-
cytes. As the fluorescence excitation, emission, and
lifetime of NADH and NADPH overlap, these two
molecules are usually measured together by MPM
coupled with FLIM (MPM-FLIM) and referred to as
NAD(P)H [15]. TPEF images of NAD(P)H in the
liver can provide basic information of liver structure.
Because NAD+, the oxidized form of NAD(P)H, has
no fluorescence, changes in the fluorescence inten-
sity of NAD(P)H can provide valuable information
regarding cell metabolism. Flavin adenine dinucleo-
tide (FAD) is only fluorescent in the oxidative
states, and can provide further information of the
cellular redox state [14, 16]. The most common opti-
cal method for metabolic imaging is the “redox ra-
tio,” which is the ratio of the fluorescence intensity
Figure 2 Typical optical principle of multiphoton systems
and imaging modalities. (a) A typical MPM us s a raster
scanning system to control the beam and a dichroic is used
to separate TPEF from the excitation light and direct this
fluorescence to a single-element detector such as a photo-
multiplier tube (PMT). (b) Energy level diagrams of TPEF,
SHG and CARS imaging modalities. L: lens; SM: scan mir-
ror; O: objective; S0: the ground energy state; S1: the excited
state; Sh: the higher virtual state. Reproduced with permis-
sion [10, 12]. 2013, Nature Publishing Group. 2010, Else-
vier.










NAD(P)H Mouse and rat in vivo,
human ex vivo
740–800 350–490 0.3–0.7 (bound),
2.5–3.0 (free)
[21, 22, 31, 47]
FAD Rat in vivo,
human ex vivo
800 500–620 0.04–0.4 (bound),
2.3–2.8 (free)
[31, 47, 75]
Elastin Human ex vivo 850 500–550 1.96 [25, 43]
Vitamin A Mouse and rat in vivo 700–830 !500 1.7–2.2 [21]
Porphyrin/
biliverdin/bilirubin
Human ex vivo 1230 670 0.4–1 [32]
Collagen SHG Human and rat ex vivo 800–1230 1/2 laser
wavelength
No lifetime [25, 31, 32, 76]
* two-photon excitation
H. Wang et al.: Visualizing liver anatomy, physiology and pharmacology using multiphoton microscopy48
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biophotonics-journal.org
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imaging window, induction of liver injury, and repeated imaging sessions under general 
anaesthesia. Practically, the two-thirds partial hepatectomy model of liver regeneration 
excises all of the easily accessible liver lobes over which any imaging window might be 
implanted. 
Subsequent chapters describe how the combination of partial hepatectomy and 
implantation of an imaging window is technically feasible, without increasing the 
experimental severity limits in place under the terms of the project licence issued by the Home 
Office. The novel procedure is validated by comparison with the standard model of two-thirds 
partial hepatectomy. Intravital microscopy of liver regeneration in transgenic, fluorescent 
reporter mice allows visualisation of the hepatic regenerative niche in situ, three-dimensional 
imaging of individual cell morphology and movement, and measurement of sinusoidal blood 
flow and vasculature structure, throughout the entire time course of liver regeneration. 
Summary 
There is a pressing need to improve our understanding of how the liver is able to regenerate, 
not least because of the dearth of effective treatments available when this life-sustaining organ 
fails. This knowledge will facilitate the discovery of novel therapeutic targets which can then 
be pursued as a means to promote regeneration of a patient’s own liver following acute or 
chronic injury. The αv integrins have been shown to play a role in the progression of liver 
fibrosis, through their ability to activate latent TGFβ. Given that TGFβ is also a potent inhibitor 
of hepatocyte proliferation, the experiments described in the following chapters examine 
whether αv integrins may regulate hepatocyte proliferation and liver regeneration through 
the activation of TGFβ. In conjunction with the experiments exploring αv integrin-mediated 
regulation of liver regeneration, a novel experimental model is presented that allows intravital 
multiphoton microscopy to be performed repeatedly throughout the time course of liver 
regeneration. This will reduce and refine experimental animal use, maximising both the 
amount and physiological relevance of the data that can be obtained from each experimental 
animal. Equally important are the opportunities it provides to reveal previously invisible 
cellular and molecular mechanisms underpinning the remarkable process of liver 
regeneration. 
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Chapter 2 – Materials and Methods 
Experimental animal details 
Mice 
Alb-Cre mice157 were originally obtained from the Jackson Laboratory. Pdgfrb-Cre158 and Cdh5-
PAC-CreERT2 (Cdh5-Cre)159 mice were obtained from R. Adams. Itgb8flox/flox mice130 were obtained 
from L. Reichardt. Itgavflox/flox mice were obtained from A. Lacy-Hulbert.41 Ai14 (Rosa-CAG-
LSL-tdTomato-WPRE), mTmG (TdTomato-eGFP), and Confetti (R26R-Confetti) reporter 
mouse lines were obtained from the Jackson Laboratory.160-162 PBAG (Pdgfrb-BAC-eGFP) 
reporter mice were obtained from the Mutant Mouse Regional Resource Center, USA. 
MacGreen mice were obtained from D. Hume.163 Fucci (R26Fucci2aR) and CAG-Cre mice were 
obtained from R. Mort.164 Wild-type C57BL/6J mice were obtained from Charles River 
Laboratories. All mice were maintained on a C57BL/6J background and housed in specific 
pathogen-free conditions in the animal facilities at the University of Edinburgh. All 
procedures were carried out under licence from, and in accordance with, UK Home Office 
regulations. 
Age- and sex-matched littermate controls were used for all experiments. Experimental 
order was decided at random, with blinding to genotype or treatment group maintained until 
the time of data analysis. Minimum group sizes for each experiment were decided based on 
sample size calculations using data previously reported or generated within the group to 
provide estimates of mean and standard deviation, and to detect a previously agreed effect 
size with error thresholds for a and b of 0.05 and 0.2 respectively. Groups were then expanded 
by 1-2 mice per group to ensure that each experiment remained adequately powered, even in 
the event of surgical or post-surgical complications necessitating the early humane killing of 
an individual mouse or the exclusion of its data from analysis. 
Genotyping of transgenic mice 
For ‘in-house’ genotyping, ear notches were obtained and DNA extracted through addition of 
75µL of 1X NaOH-EDTA solution, heating at 95ºC for 30 minutes, cooling on ice for 5 minutes, 
followed by addition of 75µL of 1X Tris-HCl solution and vortexing. A 50X NaOH-EDTA 
stock solution (1.25M NaOH, 10mM EDTA, pH 12) was prepared by dissolving 2.5g NaOH 
(Sigma-Aldrich, S5881) in 40mL distilled water (dH2O), adding 1mL 0.5M EDTA (pH 8, Sigma-
Aldrich, E5134), and making up to 50mL with dH2O. A 50X Tris-HCl stock solution (2M Tris, 
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pH 5) was prepared by dissolving 12.114g Trizma base (Sigma-Aldrich, T6066) in 35mL dH2O, 
adjusted to pH 5 by the addition of HCl (Sigma-Aldrich, 435570) and made up to 50mL with 
dH2O. 
A PCR mastermix was prepared in the proportions shown in Table 2 - 1 using reagents 
from the Taq PCR Core Kit (Qiagen, 201225). Allele-specific primers (Integrated DNA 
Technologies, Table 2 - 2) were prepared as 100µM stock solutions in DNase-free/RNase-free 
dH2O (Thermo Fisher Scientific, 10977-035). Working solution concentration and volume 
added to individual mastermixes are shown in Table 2 - 2. For each reaction, 11.5µL of 
mastermix was used, with the addition of 1µL of extracted DNA. Amplification was 
performed using a T100 Thermal Cycler (Bio-Rad) and optimised cycle protocols (Table 2 - 3). 
PCR products were detected by DNA electrophoresis using the QIAxcel Advanced System 
(Qiagen) and QIAxcel DNA Fast Analysis Kit (Qiagen, 929008) according to the 
manufacturer’s instructions. The expected size of the amplified product for each allele is 
shown in Table 2 - 4. The Fucci allele was genotyped by Transnetyx using real time PCR with 
specific probes for monomeric red fluorescent protein (mRFP) and the wild-type ROSA allele. 
 





5X Q-solution 2.5 
10X PCR Buffer 1.25 
dNTP Mix 0.25 
Taq DNA Polymerase 0.1 
Primers variable 
H2O variable 
Final Volume 11.5 
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Table 2 - 2 Primer sequences for genotyping 







(µL) Primer sequence 
Ai14 wild-type for 25 0.2 AAG GGA GCT GCA GTG GAG TA 
 wild-type rev  	 GGC ATT AAA GCA GCG TAT CC 
 mutant for  	 CTG TTC CTG TAC GGC ATG G 
 mutant rev  	 CCG AAA ATC TGT GGG AAG TC 
Confetti* wild-type for 25 0.5 CTC CTG GCT TCT GAG GAC C 
 confetti for  	 GAA TTA ATT CCG GTA TAA CTT CG 
 common rev  	 CCA GAT GAC TAC CTA TCC TC 
Cre cre for 25 0.5 GCG GTC TGG CAG TAA AAA CTA TC 
 cre rev  	 GTG AAA CAG CAT TGC TGT CAC TT 
 control for  	 CTA GGC CAC AGA ATT GAA AGA TCT 
 control rev  	 GTA GGT GGA AAT TCT AGC ATC ATC C  
Itgav for 25 0.2 TTC AGG ACG GCA CAA AGA CCG 
 rev  	 CAC AAA TCA AGG ATG ACC AAA 
Itgb8 for 25 0.2 GAGATGCAAGAGTGTTTACC 
 rev  	 CACTTTAGTATGCTAATGATGG 
MacGreen eGFP for 10 0.3 GCA CGA CTT CTT CAA GTC CGC CAT GCC  
 eGFP rev  	 GCG GAT CTT GAA GTT CAC CTT GAT GCC 
 fabpi for  	 CCT CCG GAG AGC AGC GAT TAA AAG TGT CAG  
 fabpi rev  	 TAG AGC TTT GCC ACA TCA CAG GTC ATT CAG  
mTmG common for 20 0.6 CTC TGC TGC CTC CTG GCT TCT 
 wild-type rev  0.4 CGA GGC GGA TCA CAA GCA ATA 
 mutant rev  0.8 TCA ATG GGC GGG GGT CGT T 
PBAG eGFP for 25 0.2 CCT ACG GCG TGC AGT GCT TCA GC 
 eGFP rev  0.2 CGG CGA GCT GCA CGC TGC GTC CTC 
 actin for  0.4 GAT GAC GAT ATC GCT GCG CTG GTC G 
 actin rev  0.4 GCC TGT GGT ACG ACC AGA GGC ATA CAG 
	




Table 2 - 3 Thermal cycler settings 
Allele: Ai14 Confetti Cre Itgav 
Temp (ºC) / time (min:sec):             	
1. Initial denaturation 94 3:00 95 3:00 94 5:00 95 2:00 
2. Denaturation 94 0:20 95 0:30 94 0:30 94 0:30 
3. Annealing 61 0:30 58 0:30 57 0:45 64 0:45 
4. Extension 72 0:30 72 0:30 72 2:00 72 1:00 
5. Final extension 72 2:00 72 5:00 72 10:00 72 10:00 
Repeats of steps 2-4 35 35 29 35 
 	 	 	 	 	 	 	 	
Allele: Itgb8 MacGreen mTmG PBAG 
Temp (ºC) / time (min:sec):             	
1. Initial denaturation 94 5:00 94 3:30 94 3:00 94 3:00 
2. Denaturation 94 0:30 94 0:30 94 0:30 94 0:30 
3. Annealing 57 0:30 65 0:30 61 1:00 58 0:45 
4. Extension 72 0:45 72 1:00 72 1:00 72 0:45 
5. Final extension 72 10:00 72 7:00 72 2:00 72 10:00 
Repeats of steps 2-4 39 34 34 30 
	




Ai14 mutant 196 
 wild type 297 
Confetti mutant 300 
 wild type 270 
Cre control 324 
 cre 100 
Itgav floxed 400 
 wild type 250 
Itgb8 floxed 350 
 wild type 300 
MacGreen eGFP 280 
 fabpi 500 
mTmG mutant 250 
 wild type 330 
PBAG eGFP 360 
 actin 1000 
Surgical procedures 
Standard partial hepatectomy 
Two-thirds partial hepatectomy was performed as previously described111,165 with minor 
modifications, including performing the procedure via a ‘mini-laparotomy’ incision, through 
which the median and left liver lobes were exteriorised in preparation for excision. The two 
segments of the median lobe were ligated individually, either side of the gall bladder, prior to 
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excision. Lobe ligation was performed with 1.5M braided silk (SMI, 8015); closure of the linea 
alba was performed using a simple continuous suture of 1.5M polyglactin 910 (Ethicon, Vicryl, 
W9067). Skin closure was achieved with surgical clips (Biochrom, 9mm Autoclips, 52-3748). 
Mice were anaesthetised with isoflurane (Abbott) in 100% oxygen and kept on a heated 
mat during anaesthesia and recovery. Eye lubricant was applied (Viscotears® Liquid Gel, 
Alcon Laboratories (UK) Ltd). Warmed, sterile 0.9% saline (25mL/kg, Braun, Sodium Chloride 
0.9% w/v Intravenous Infusion BP) was administered subcutaneously at time of surgery. 
Analgesia was provided with local instillation of 2-4 drops of bupivacaine (Marcain 0.25%, 
AstraZeneca) at the midline at time of surgery, and buprenorphine (0.1mg/kg, Ceva, 
Vetergesic), diluted to 0.03mg/mL in sterile water for injection and administered 
subcutaneously pre-operatively and 8-12 hours post-operatively. Mice were assessed twice 
daily until the end of the experiment. Additional, ‘rescue’ analgesia (0.05-0.1mg/kg 
buprenorphine subcutaneously) was available for administration, but was not required.  
Mice were humanely killed by cervical dislocation (or exposure to a rising concentration 
of CO2 where blood sampling was required) at pre-specified time points for liver harvest. Mice 
were weighed at time of surgery and harvest. The weights of excised and harvested liver were 
also recorded; harvested liver was weighed intact prior to fixation. 
Standard Abdominal Imaging Window insertion 
Implantation of the abdominal imaging window (AIW) onto the uninjured liver was 
performed as described, with minor modifications.146 Mice were anaesthetised and provided 
with local and systemic analgesia as for standard partial hepatectomy above. Following 
clipping, additional hair removal was performed by application of depilatory cream (Veet® 
Hair Removal Cream – Legs & Body – Sensitive Skin, Reckitt Benckiser) for 1-2 minutes, 
followed by removal with a standard swab. The surgical site was then prepared in a routine 
manner with chlorhexidine. 
A small midline laparotomy incision was made, large enough to allow the left lateral lobe 
of the liver to be expressed. The falciform and hepatophrenic ligaments were carefully incised 
to the level of the vena cava using Castroviejo microsurgical scissors. A purse string suture 
was laid, through the skin and abdominal muscle layers to encompass the incision, using 
Mersilk 4-0 suture (Ethicon, W501). The free ends were left at the caudal end of the incision. 
The left lateral lobe was then expressed and positioned for application of the AIW. 
The AIW (and accompanying inlay) design is shown in Chapter Five. Cyanoacrylate 
(Loctite Powerflex Gel, Henkel) was applied to the underside rim of the AIW (8mm internal 
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aperture version) before it was gently pressed onto the lobe surface and allowed to adhere 
undisturbed for three minutes. The lobe was then returned to the abdominal cavity and the 
purse string suture was tightened to draw the body wall into the central groove of the AIW, 
and then tied to hold the AIW in place and contiguous with the body wall. The exposed liver 
in the centre of the AIW aperture was moistened with saline before the inlay and coverslip 
assembly were screwed into place. Gentle pressure was applied laterally and dorsally to the 
abdominal cavity to assist the liver in contacting the coverslip. The mouse was then allowed 
to recover and observed closely for signs of AIW displacement. 
Coverslip preparation 
The AIW coverslips were prepared in a similar manner to that previously described.146 
Circular coverslips (12mm diameter, 1.5H, CellPath, SAN-5012-03A) were adhered to the 
external surface of the AIW inlay with cyanoacrylate (Loctite Powerflex Gel, Henkel) and 
allowed to dry for a minimum of two hours. The assembly was then disinfected by immersion 
in 70% ethanol for a minimum of 30 minutes. In a sterile flow cabinet, the coverslips were 
allowed to dry prior to application of a poly(L-lysine)-graft-poly(ethylene glycol) (PLL[20]-
g[3.5]-PEG[2], SuSoS) solution to the underside. This was left in situ for one hour, before 
washing off with PBS and allowing to dry. A 1mg/mL stock solution of PLL-g-PEG was 
prepared by dissolving (by rolling) in 10mM HEPES buffer (pH 7.4, Sigma-Aldrich, H3375) 
and then filter sterilising. Shortly before use, this was diluted to the working concentration of 
0.1mg/mL, again using 10mM HEPES. 
Pilot experiment to compare standard partial hepatectomy with a reduced partial 
hepatectomy 
Standard partial hepatectomy was performed in C57BL/6J mice using the anaesthesia protocol 
and surgical approach described above. For reduced partial hepatectomy, mice had only the 
right median and left lobes excised; the left median lobe was not excised. 5-Bromo-2’-
deoxyuridine (BrdU) was administered as described below. At 48 hours post partial 
hepatectomy, mice were humanely killed by cervical dislocation. Mice were weighed at time 
of surgery and harvest. The weights of excised and harvested liver were recorded. 
Combining partial hepatectomy with AIW insertion 
The development of this technique is described in Chapter Five. Mice were anaesthetised and 
prepared for surgery as described above. A small (~10mm) midline laparotomy incision was 
made, starting from the tip of the xiphisternum. The xiphisternum itself was clamped with 
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haemostat forceps and then excised. The falciform and hepatophrenic ligaments were incised 
as described above. The median and left lateral lobes were exteriorised by moderate 
abdominal pressure. The right median and left lateral lobes were excised as for standard 
partial hepatectomy. Care was taken to avoid trauma to the left median lobe, and it was kept 
moist through intermittent application of sterile saline. Following excision of the first two 
hepatic lobes, the left median lobe was replaced within the abdominal cavity. 
The midline incision was then extended caudally by another 10-15mm. Miniature Gelpi 
retractors (InterFocus Ltd, 17017-10) were placed to hold open the abdominal incision. A 
duodenal manoeuvre was performed and the intestines exteriorised onto, and covered by, a 
moistened swab to the left-hand side of the mouse. This facilitated visualisation of, and access 
to, the caudal right lobe of the liver, which was then excised in a standard manner. Excision 
was assisted by incision of the serous membrane linking this lobe to the caudal body wall. 
Upon completion of the modified partial hepatectomy, a purse string suture was placed 
in an identical manner to that of the standard AIW insertion. Additional simple interrupted 
sutures were pre-placed in the abdominal muscle layer to allow subsequent closure of the 
caudal portion of the midline incision not included within the purse string. The left median 
lobe was drawn gently caudally and midline to permit AIW placement. The AIW (5.2mm 
internal aperture version) was placed onto the lobe as described above and secure within the 
body wall by the purse string suture. The pre-placed sutures in the abdominal wall were then 
tightened to complete closure of the abdominal cavity. Simple interrupted sutures were then 
placed caudally to the AIW to complete skin closure. The inlay (with attached coverslip) was 
placed as described above. 
Validation of the modified partial hepatectomy with AIW insertion procedure 
Wild-type mice were randomly allocated to receive one of three procedures: standard partial 
hepatectomy, modified partial hepatectomy (excising right median, left, and caudal right 
lobes) or modified partial hepatectomy with AIW insertion. All procedures were performed 
as described above. In the first series, livers were harvested at 48 hours, following BrdU 
administration as described below. Serum was also obtained. In the second series, livers were 
harvested at seven days. Mice were weighed at time of surgery and harvest. The weights of 





To induce recombination in Cdh5-Cre lines, tamoxifen (Sigma-Aldrich, T5648) was dissolved 
(37ºC, overnight, protected from light, with rolling) at 20mg/mL in corn oil (Sigma-Aldrich, 
C8267), sterile-filtered (Millex-GP 0.22µm filter unit, Merck Millipore, SLGP033RS, unless 
otherwise stated), and administered intra-peritoneally at 100mg/kg. The standard dosing 
schedule was once daily for five consecutive days. 
Acetaminophen-induced liver injury 
Acetaminophen (Sigma-Aldrich, A7085) was dissolved (37ºC, 30 mins, with shaking) in 0.9% 
sterile saline (Baxter, UKF7124) and sterile-filtered. For routine experiments, mice were fasted 
for 12 hours prior to intra-peritoneal administration of 300mg/kg acetaminophen (10mg/mL 
solution). For intravital imaging experiments, mice were fasted for 16 hours and a 20mg/mL 
acetaminophen solution administered at 350mg/kg. 
5-Bromo-2’-deoxyuridine administration 
5-Bromo-2’-deoxyuridine powder (BrdU, Sigma-Aldrich (Roche), 10280879001) was dissolved 
(55ºC, 30 mins) in sterile PBS (Thermo Fisher Scientific, 14190-094) at 20mg/mL, 1mL aliquots 
were prepared and stored at -20ºC. To label proliferating cells, warmed, re-suspended BrdU 
was injected intra-peritoneally at 100mg/kg, two hours prior to humane killing. 
In vivo administration of b8 integrin subunit blocking antibody 
The b8 integrin subunit blocking antibody60 and an isotope-matched, non-binding control 
antibody were diluted to a working concentration of 0.5mg/mL in sterile PBS. Wild-type mice 
received 3mg/kg of either control or blocking antibody via intra-peritoneal injection, 
immediately prior to two-thirds partial hepatectomy. 
Injection of fluorescently-labelled red blood cells 
Donor mice were humanely killed and whole blood obtained through cardiac puncture. Blood 
was anti-coagulated by placing immediately into collection tubes containing sodium citrate 
(Greiner, 9NC, 459075) and inverting gently. Following centrifugation (500g, 4ºC, 10 minutes) 
and removal of plasma, the red blood cells were re-suspended and centrifuged three times 
with PBS (Thermo Fisher Scientific, 14190-094) to wash, before re-suspending in PBS at 100 
times the cellular volume in preparation for labelling. Vybrant DiO cell-labelling solution 
(Thermo Fisher Scientific, V22886) was added at 5µL/mL for 20 minutes at room temperature, 
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before centrifugation and re-suspending in an equal volume of PBS. Mice were injected with 
200µL of labelled red blood cells via the tail vein. 
Intravital imaging 
Mice with a pre-implanted AIW were examined prior to anaesthesia for intravital imaging in 
order to ensure their fitness for the procedure. General anaesthesia was induced and 
maintained using isoflurane in 100% oxygen. Immediately following induction of anaesthesia, 
eye lubricant was applied and saline administered subcutaneously as described above. Mice 
were then placed in dorsal recumbency on a heated mat to allow examination of the AIW, 
coverslip and visible liver within the imaging aperture. In order to maximise the quality of the 
subsequent intravital images, it was usually necessary to remove and flush (with saline) or 
replace the coverslip and inlay assembly. This was performed in an aseptic manner, following 
preparation of the external surface of the AIW and surrounding skin with chlorhexidine. 
Accumulated biofilm on the surface of the liver was also removed with great care using sterile 
cotton buds or forceps. In terminal imaging experiments in which nuclear labelling was 
performed, Hoechst 33342 (Thermo Fisher Scientific, H1399) was prepared according to the 
manufacturer’s instructions and applied topically to the surface of the liver at a working 
concentration of 5µg/mL. 
Once prepared, the mouse was placed in sternal recumbency within the bespoke, heated 
imaging box. Anaesthesia was maintained through the provision of isoflurane (typically 0.8-
1.0%) in 100% oxygen (~0.5L/min) and depth of anaesthesia was carefully titrated to maintain 
the mouse in the lightest possible plane. The external rim of the AIW was seated precisely 
within the baseplate to minimise motion artefact during imaging. Total duration of 
anaesthesia was restricted to two hours for recovery procedures or six hours for terminal 
procedures. 
AIW and imaging baseplate design 
Original AIWs were obtained from J. van Rheenen. The design was modified, as described in 
Chapter Five, using Autodesk AutoCAD 2016, (version M.49.0.0). Prototypes were printed in 
Vero White using an Objet Connex 260 3D printer, before being manufactured in titanium by 
ZME Fijnmechanisch Atelier B.V. The imaging baseplate into which the new AIW was 
inserted during intravital microscopy was designed as above and produced in aluminium by 
Computer Numerical Control machining (Proto Labs Inc.). 
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Sample collection and processing 
Liver lobe weight measurements 
Five surplus C57BL/6J mice were humanely killed by cervical dislocation, weighed, and then 
the liver was excised whole and weighed. Livers were then dissected and the weight of each 
lobe measured. Separately, five surplus C57BL/6J mice were humanely killed and surgical 
excision of individual lobes was performed via laparotomy, as described above. Excised liver 
tissue was weighed, as was the remnant liver. 
Serum biochemistry 
Whole blood was collected immediately post mortem by cardiac puncture, allowed to clot, 
and serum obtained by centrifugation (9391g, 5 minutes, twice). Samples were frozen at -20ºC 
pending analysis. Serum albumin, total bilirubin, alanine transaminase (ALT), and alkaline 
phosphatase (ALP) measurements were determined using commercial kits (Alpha 
Laboratories Ltd [albumin, bilirubin, ALT]; Randox Laboratories [ALP]) adapted for use on a 
Cobas Fara centrifugal analyser (Roche Diagnostics). 
Primary hepatocyte isolation 
Mice were humanely killed and livers perfused in situ, via cannulation of the thoracic vena 
cava, for 4 minutes with Liver Perfusion Medium (Thermo Fisher Scientific, 17701-038) 
followed by Liver Digest Medium (Thermo Fisher Scientific, 17703-034, pre-filtered using a 
Millipore Stericup-GP, SCGPU05RE) for 7-8 minutes, before a further 2 minutes of Liver 
Perfusion Medium. Flow rate was maintained at 5 mL/min using a peristaltic pump (Minipuls 
2, Gilson) and media were maintained at 37ºC. The liver was then excised and placed in 
Hepatic Perfusion Medium (HPM) consisting of Dulbecco’s Modified Eagle Medium (Thermo 
Fisher Scientific, 21969-035), 5% heat-inactivated foetal bovine serum (Thermo Fisher 
Scientific, 10500-064), 2% L-Glutamine 200mM (Thermo Fisher Scientific, 25030-024), 1% 
Penicillin-Streptomycin 10,000U/mL (Thermo Fisher Scientific, 15140-122). 
The digested liver was minced and passed through a 100µm cell sieve (EASYstrainer, 
Greiner Bio-One, 542000), before pelleting (90g, 2 minutes, Heraeus Multifuge 1S-R, Thermo 
Fisher Scientific) and resuspending twice with HPM to wash. Hepatocytes were then purified 
by centrifugation (200g, 15 minutes) through 50% equilibrated Percoll. Equilibrated Percoll 
was prepared by combining Percoll (GE Healthcare, 17-0891-01) with sterile-filtered 10X 
Dulbecco’s Modified Eagle Medium (DMEM) in a 9:1 ratio. The 10X DMEM solution was 
prepared from DMEM powder (Thermo Fisher Scientific, 12800-082) and 0.037g/mL NaHCO3 
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(Sigma-Aldrich, S6297). The equilibrated Percoll was subsequently diluted 1:1 with HPM to 
produce 50% equilibrated Percoll solution. The purified hepatocyte pellet was then 
resuspended in HPM, before pelleting (90g, 2 minutes) and resuspending twice to wash out 
the Percoll. Total cell count and viability were calculated using a NucleoCounter NC-100 
(ChemoMetec) according to the manufacturer’s instructions.  
Primary liver sinusoidal endothelial cell isolation 
Mice were humanely killed and livers perfused in situ with ice-cold PBS (Thermo Fisher 
Scientific, 14190-094) via the right ventricle of the heart. Samples and reagents were kept at 
4ºC unless indicated. Liver was minced prior to digestion with Collagenase Type I (Thermo 
Fisher Scientific, 17100-017) and DNase I (Roche, 10104159001) in HBSS (with CaCl2/MgCl2, 
Thermo Fisher Scientific, 14025-050), shaking for 20 minutes at 37ºC. Samples were passed 
through a 70µm cell sieve EASYstrainer, Greiner Bio-One, 542070) and diluted in PEB buffer, 
containing PBS (Thermo Fisher Scientific, 14190-094), 2% Foetal Bovine Serum (Thermo Fisher 
Scientific, 10500-064), and 2mM EDTA (Sigma-Aldrich, E5134), before pelleting (400g for 7 
minutes at 4ºC, Heraeus Megafuge 40R, Thermo Fisher Scientific). Samples were resuspended 
in Red Cell Lysis buffer (BioLegend, 420301) for 5 minutes before washing, pelleting, 
resuspending, and filtering through a 35µm nylon mesh (Corning, 352235). 
Samples were pelleted and blocked with 1% CD16/32 (BioLegend, 101302) and 10% 
mouse serum (Sigma-Aldrich, M5905) for 10 minutes. Fluorescent conjugated antibodies 
(Table 2 - 7), either CD31-APC and CD45-PE/Cy7, or CD31-PE/Cy7 and CD45-PerCP/Cy5.5, 
were then applied and samples incubated for 15 minutes before washing, pelleting and re-
suspending. 
Flow cytometry and fluorescence-activated cell sorting 
For flow cytometry or fluorescence-activated cell sorting (FACS), cells were isolated and 
stained with antibody as described above. Lasers and bandpass filters for each fluorophore 
are shown in Table 2 - 5. Controls for compensation and gating included an unlabelled sample, 
beads (UltraComp eBeads, Thermo Fisher Scientific, 01-2222-42) stained with single 
antibodies, and ‘fluorescence-minus-one’ samples. A live/dead stain (DAPI, Invitrogen, 
D3571) was added immediately prior to cytometry or sorting. Compensation for the eGFP and 
tdTomato intrinsic fluorescent reporters was assessed using GFP beads (Clontech 
Laboratories, Inc., 632594) and cells isolated from a mouse expressing only tdTomato. 
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LSECs were analysed by flow cytometry using an LSRFortessa (BD Biosciences) and 
FlowJo 10.0.8r1, with the following gating strategy. The cell population was gated on forward 
(FSC-A) vs side (SSC-A) scatter, with single cells gated on FSC-A vs FSC-H. Live cells were 
selected based on negative DAPI staining. Endothelial cells were identified as CD31+, CD45-. 
Efficiency and specificity of recombination in the Cdh5-Cre;mTmG reporter mouse (following 
tamoxifen administration) was assessed by assessing the percentage of cells in the endothelial 
cell population that were GFP+ and the percentage of GFP+ cells that were CD31+, CD45-. 
LSECs were isolated by FACS using a FACSAria II (BD Biosciences) to sort single, live, 
CD31+, CD45- cells. 
 
Table 2 - 5 Laser and filter setup for flow cytometry and FACS 
Label Laser (wavelength, nm) Longpass filter Bandpass filter 
APC Red (640)  670/14 
DAPI UV (355)  450/50 
GFP Blue (488) 505 525/50 
PE/Cy7 Yellow-Green (561) 750 780/60 
PerCP/Cy5.5 Blue (488) 685 710/50 
tdTomato Yellow-Green (561) 582/15 
	
In vitro cell adhesion assay 
To confirm optimal plating density, the utility of poly-L-lysine as a positive adhesion control, 
and time to adhesion, primary hepatocytes were isolated from a single wild-type mouse, as 
described above. Hepatocytes were plated, in triplicate, at densities of 25,000, 50,000, and 
75,000 live cells per well onto tissue culture plastic (untreated), collagen-coated wells, or poly-
L-lysine-coated wells of a 96-well, flat-bottomed, tissue-culture plate (Costar, 3595). Collagen-
coating was achieved by preparing a sterile-filtered 50µg/mL solution of Type I Collagen 
(Millipore, 08-115) in 0.01N acetic acid (Sigma-Aldrich, A6283). The collagen-coated wells 
were coated with 64µL of the collagen solution, to achieve a coating of 10µg collagen per cm. 
Poly-L-lysine 0.01% (Sigma-Aldrich, P4832) was applied to relevant wells at 50µL/well. 
Collagen and poly-L-lysine solutions were left for two hours before washing twice with HBSS 
(Thermo Fisher Scientific, 14175-053). Wells were then allowed to dry for a further two hours 
prior to introduction of cells and medium. Cells were incubated at 37ºC in 5% CO2. Wells were 
then observed at 50X magnification (Axiovert 200, Zeiss) immediately post-plating and then 
every 30 minutes up to two hours. Images were obtained of wells pre and post washing with 
HBSS at 30 minutes and 120 minutes post plating. 
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To perform the in vitro adhesion assay, primary hepatocytes were isolated as paired 
samples from one Itgavflox/flox;Alb-Cre mice and a littermate control as described above. Order 
was decided at random and samples were blinded during hepatocyte isolation. An ECM Cell 
Adhesion Array Kit (Millipore, ECM540) was prepared and utilised according to the 
manufacturer’s instructions. Hepatocytes were plated in triplicate at 50,000 viable cells per 
well, and incubated for two hours at 37ºC in 5% CO2. Following washing, staining, and repeat 
washing to remove unbound stain, the cell-bound stain was solubilised and absorbance at 
570nm was determined by plate reader (Synergy HT, Biotek). In addition to absolute 
absorbance, relative absorbance to the Bovine Serum Albumin negative control was calculated 
to account for any background absorbance. Similarly, relative absorbance to that of Collagen 
Type I was calculated to account for any small differences in viable cell number between 
replicates and samples. 
In vitro TGFβ activation assays 
Cell line culture 
Cryopreserved Huh7, HepG2, and LX-2166 (obtained from S.L. Friedman) cell lines were 
resuscitated and cultured in 75cm2 culture flasks (Corning, 430641U) to 70% confluence using 
standard medium (DMEM, 10% foetal bovine serum, 1% penicillin and streptomycin, 1% L-
glutamine). Single-cell suspensions were prepared by removing culture medium, washing 
with PBS, adding 1.5mL trypsin (Thermo Fisher Scientific, 25300-054), incubating at 37ºC for 
5-10 minutes, inactivating trypsin with 4mL culture medium, then pelleting (300g, 5 minutes), 
and re-suspending in culture medium. 
Transgenic mink lung cell co-culture assay 
Transgenic mink lung cells (TMLCs, obtained from D. Rifkin) were cultured in standard 
medium (DMEM, 10% foetal bovine serum, 1% penicillin, 1% L-glutamine) with the addition 
of 0.25mg/mL Geneticin (G418 sulfate, Thermo Fisher Scientific, 10131035). Co-culture was 
performed as previously described,132,133 in an opaque, 96-well, tissue culture-treated plate 
(Corning, 3917). Cells were also cultured on a standard, tissue culture-treated plate to allow 
microscopy examination during the incubation period. TMLCs were seeded at a density of 
15,000 per well. For co-culture with cell lines, the test cells of interest were added immediately 
after. For co-culture with primary hepatocytes, TMLCs were allowed to attach for six hours at 
37ºC in 5% CO2, prior to addition of test cells. Primary hepatocytes were isolated as described 
above. Test cells were added at 25,000 per well, 50,000 per well, 75,000 per well, 100,000 per 
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well (not every density was used in every experiment). Control wells included: medium only, 
TMLCs only, test cells only, TMLCs with recombinant human TGFβ-1 (rhTGFβ), TMLCs with 
rhTGFβ and TGFβ antibody, TMLCs with test cells and TGFβ antibody. Test wells (TMLCs 
with test cells) were plated in triplicate. The final volume for each well was adjusted to 200µL. 
In the Huh7 co-culture experiment only, standard medium was replaced with serum-free 
medium after two hours. Plates were incubated for 16-20 hours at 37ºC in 5% CO2. Following 
incubation, cells were washed twice with PBS. Luciferase activity was assessed using the 
Luciferase Assay System (Promega, E1500) according to the manufacturer’s instructions. 
Following cell lysis and substrate addition, luminescence was immediately assessed by plate 
reader (Synergy HT, Biotek). Recombinant human TGFβ-1 (R&D, 240-B) was reconstituted to 
a stock concentration of 2µg/mL with 1mg/mL Bovine Serum Albumin (Sigma-Aldrich, 
A7906) in 4mM HCl (Sigma-Aldrich, 435570) and used at a working concentration of 2ng/mL. 
It was supplemented at 0.1ng/mL (4pM) unless otherwise stated. TGFβ antibody (R&D, 
MAB1835) was reconstituted at 0.5mg/mL in sterile PBS and supplemented at 0.05mg/mL. 
MFB-F11 co-culture assay 
MFB-F11 reporter cells were obtained from H. McSorley and cultured in standard medium 
with the addition of 15µg/mL Hygromycin B (Thermo Fisher Scientific, 10687-010). On 
reaching 90% confluence, a single-cell suspension was prepared as described above, with re-
suspension in a low-serum (2.5% foetal bovine serum) medium. Cells were seeded at a density 
of 40,000 per well in a 96-well flat-bottom plate (Corning, 3595) and allowed to attach (3-4 
hours, 37ºC, 5% CO2). Primary hepatocytes were isolated as described above and added to the 
test wells at either 50,000 or 100,000 per well. rhTGFβ and TGFβ antibody were used as 
controls, as described above. In addition, recombinant human latent TGFβ-1 (latent TGFβ, 
R&D, 299-LT-005) was added at 50 or 100 ng/mL. After 36 hours, 20µL of culture supernatant 
was added to 180µL of p-Nitrophenyl phosphate solution (pNPP, Sigma-Aldrich, N2770) in a 
new 96-well plate and incubated at room temperature, protected from light, for 24 hours. 
Absorbance at 405nm was measured using a plate reader (Synergy HT, Biotek). 
Primary hepatocyte culture with β8 integrin subunit blocking antibody 
Primary hepatocytes were isolated as described above, resuspended in low-serum medium 
(DMEM (Thermo Fisher Scientific, 11960-044), 2.5% heat-inactivated Foetal Bovine Serum 
(Thermo Fisher Scientific, 10500-064), 2% L-Glutamine (Thermo Fisher Scientific, 25030-024), 
1% Penicillin Streptomycin (Thermo Fisher Scientific, 15140-122)) and plated onto collagen-
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coated wells (Collagen Type I, Millipore) in a 6-well plate at a density of 5 x 105 cells/well. 
Either β8 integrin subunit blocking antibody60 or control antibody were added at 20µg/mL 
and samples were incubated for 24 hours at 37ºC in 5% CO2. Wells were then washed with 
PBS and cells lysed as described below. 
Gene expression analysis 
RNA was isolated from whole mouse liver, primary hepatocytes or LSECs using an RNeasy 
Mini Kit (whole liver, hepatocytes) or RNeasy Plus Micro Kit (LSECs) (Qiagen, 74034/74104) 
according to the manufacturer’s instructions. Cells were lysed with RLT buffer from the 
aforementioned kits, with the addition of 10µL/mL β-mercaptoethanol (Sigma-Aldrich, 
M7522). Homogenisation was performed using QIAShredder columns (Qiagen, 79656) and 
centrifugation (20238g, 2 minutes). RNA quantity and purity was assessed using the 
Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific). 
Reverse transcription to cDNA was performed using the QuantiTect Reverse 
Transcription Kit (Qiagen, 205311) according to the manufacturer’s instructions. Control 
samples with no template or with no reverse transcriptase were also prepared. 
Real-time quantitative PCR was performed using the QuantiTect SYBR Green PCR Kit 
(Qiagen, 204143) according to the manufacturer’s instructions. Reactions were set up in 
triplicate in a MicroAmp 96-well 0.1mL Reaction Plate (Applied Biosystems, 4346907), sealed 
with MicroAmp Optical Adhesive Film (Applied Biosystems, 4311971). Primers are listed in 
Appendix 1 and cycling conditions in Table 2 - 6. A ‘no-template control’ was run for each 
gene. Samples were amplified on an ABI 7900HT thermocycler (Applied Biosystems) and 
normalised to mean Actb and/or Gapdh expression. A dissociation curve was run for all 
analyses to assess reaction specificity and the presence of primer-dimers. 
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Table 2 - 6 qPCR thermal cycler settings 
	 Temp (ºC) 
Time 
(min:sec) 
1. Initial denaturation 95 15:00 
2. Denaturation 94 0:15 
3. Annealing 55 0:30 
4. Extension 72 0:30 
Repeats of steps 2-4 45 
  
TGFβ signalling qPCR array 
To assess TGFβ signalling, a custom RT2 Profiler PCR array (Qiagen, 330171) was designed 
containing the genes shown in Appendix 2. RNA was isolated following primary hepatocyte 
culture with β8 integrin subunit blocking, as described above, and reverse transcribed using 
the RT2 First Strand Kit (Qiagen, 330401). qPCR was performed using RT2 SYBR Green ROX 
qPCR Mastermix (Qiagen, 330522) on an ABI 7900HT thermocycler; gene expression was 
normalised to mean Actb and Gapdh expression. Standardisation and expression analysis is 
described below. 
Tissue fixation and preparation 
Mouse liver tissue 
Liver samples for DAB (3,3'-diaminobenzidine) immunohistochemistry were fixed overnight 
at room temperature in either methacarn (60% methanol, 30% chloroform, 10% acetic acid), 
for BrdU immunohistochemistry, or 10% neutral buffered formalin. Samples were then 
paraffin-embedded prior to sectioning. Standard section thickness was 4µm. 
Fixed-frozen tissue preparation was performed by placing in 4% paraformaldehyde at 
4ºC overnight, before washing with PBS and dehydrating through serial sucrose gradients 
(10% then 20% for 1 hour each at room temperature, followed by 30% overnight at 4ºC). Tissue 
was then placed in OCT embedding matrix (Thermo Fisher Scientific, 12678646) and frozen 
on dry ice. Samples were stored at -80ºC until sectioning at 10µm using a cryostat microtome 
(Bright Instruments, 5040). 
Human liver tissue 
De-identified sections of formalin-fixed, paraffin-embedded, uninjured and fibrotic human 
liver tissue were provided by the Lothian NRS Bioresource with approval from Tissue 
Governance. Samples of acetaminophen-injured human liver tissue were obtained as part of 
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the Pathophysiology of Acute Liver Injury Study. This study was approved by the Scotland A 
Research Ethics Committee and NHS Lothian Research and Development. 
Immunohistochemistry and histology 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue unless 
otherwise stated. At the start of each protocol, samples were de-waxed in xylene (2 x 5 
minutes) and rehydrated through decreasing alcohol concentrations (100%, 75%, 65%, 2 
minutes each). The wash buffer was PBS unless otherwise stated. Primary and secondary 
antibodies (Table 2 - 7) were diluted in blocking solution unless ready-to-use solutions or part 
of a kit. 
BrdU 
This protocol was performed on methacarn-fixed tissue. Endogenous peroxidases were 
quenched with 0.3% H2O2 (Sigma-Aldrich, H1009) in methanol (10 minutes), followed by 
consecutive 10-minute incubation steps with 0.1% trypsin (Sigma-Aldrich, T7168), warm 1.8M 
HCl and 0.1M sodium tetraborate decahydrate (Sigma-Aldrich, S9640). Blocking (1 hour) and 
subsequent incubation steps utilised the Mouse on Mouse Elite Peroxidase Kit (Vector 
Laboratories, PK2200). Primary antibody was applied for 30 minutes. A control section to 
which no primary antibody was applied was stained in parallel. Secondary antibody was 
Mouse on Mouse Biotinylated Anti-mouse IgG Reagent, applied for 10 minutes. Detection was 
performed using the Elite Vectastain ABC kit (Vector, PK7100) and DAB (Dako, K3648) before 
counterstaining with haematoxylin, dehydration and mounting. For each sample, twenty 
sequential fields were acquired at x20 magnification, excluding tissue edges, staining artefact, 
and large deficits. Approximately 3,000 hepatocytes were counted to calculate the percentage 
of proliferating hepatocytes. 
F4/80 / GR1 / PDGFRβ 
Antigen retrieval was performed with Tris-EDTA (PDGFRb only, 1.21g Trizma base, Sigma-
Aldrich, T6066, 0.37g EDTA, Sigma-Aldrich, E5134 in 1L dH2O, pH9, microwave 800W for 15 
minutes), endogenous peroxidases were quenched with 3% H2O2 (Sigma-Aldrich, H1009, 10 
minutes), Avidin / Biotin block (Vector, SP-2001) was applied, before blocking with 20% 
normal goat serum (Vector, S-1000) (PDGFRb, GR1) or 20% normal rabbit serum (Vector, S-
5000) (F4/80) for 30 minutes. Primary antibodies were applied for 2 hours at room temperature 
(PDGFRb) or overnight at 4ºC (F4/80, GR1). Control sections to which no primary antibody 
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was applied were stained in parallel. Secondary antibody (PDGFRb – biotinylated goat anti-
rabbit; GR1 – biotinylated goat anti-rat; F4/80 – biotinylated rabbit anti-rat) was applied for 30 
minutes at room temperature. Detection was performed using the Elite Vectastain ABC kit 
(Vector, PK7100) and DAB (Dako, K3468) before counterstaining with haematoxylin, 
dehydration and mounting. For each sample, ten sequential fields were acquired at x20 
magnification (excluding tissue edges, staining artefact, and large deficits) and percentage 
positive staining calculated using FIJI (Appendix 3).167 
For F4/80 immunofluorescence of fixed-frozen tissue, slides were air-dried for at least 60 
minutes, blocked with 20% normal goat serum (30 minutes) and primary antibody was 
applied for 2 hours. Secondary antibody was applied for 30 minutes. Slides were mounted 
with Vectashield HardSet Antifade Mounting Medium with DAPI (Vector, H-1500). 
Integrin β8 
Antigen retrieval was performed with Tris-EDTA (microwave 800W for 15 minutes), 
endogenous peroxidases were quenched with 3% H2O2 (Sigma-Aldrich, H1009, 10 minutes), 
before blocking with 20% normal horse serum (Vector, S-2000, 30 minutes). Primary antibody 
was applied overnight at 4ºC. Control sections, to which either no primary antibody or an 
isotype control were applied, were stained in parallel. Detection was performed using the 
ImmPRESS Polymerized Reporter Enzyme Staining System (Vector, MP7401) and DAB 
(Dako, K3468), before counterstaining with haematoxylin, dehydration and mounting. 
Desmin-Red Fluorescent Protein dual immunostaining 
Antigen retrieval was performed with Tris-EDTA (microwave 800W for 15 minutes), 
endogenous peroxidases were quenched with 3% H2O2 (10 minutes), before blocking with 10% 
normal goat serum (30 minutes). Primary antibody against desmin was applied for 2 hours, 
followed by goat anti-rabbit peroxidase for 30 minutes. TSA Plus Fluorescein (Perkin Elner, 
NEL741001KT – 1:50) was applied for 5 minutes. Slides were returned to Tris-EDTA 
(microwave 800W for 3 minutes, 400W for 4 minutes), followed by repeat blocking as above. 
Primary antibody against red fluorescent protein was applied for 2 hours, followed by repeat 
peroxidase as above. TSA Plus Cyanine 3 (Perkin Elner, NEL744001KT – 1:50) was applied for 
5 minutes. Nuclear counterstain was achieved with 6mM DAPI (Sigma-Aldrich, D9542) for 10 
minutes, before mounting (ProLong Gold, Thermo Fisher Scientific, P36930). 
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Phospho-SMAD3 
For DAB immunostaining, endogenous peroxidases were quenched with 3% H2O2 (10 
minutes). Permeabilisation was performed with 0.5% Triton X-100 (Sigma-Aldrich, T8787, 10 
minutes). Antigen retrieval was performed with Tris-EDTA (800W microwave, 20 minutes). 
Avidin / Biotin block was applied, before blocking with 20% normal goat serum (30 minutes). 
Primary antibody was applied overnight at 4ºC. A control section to which no primary 
antibody was applied was stained in parallel. Secondary antibody was biotinylated goat anti-
rabbit, applied for 30 minutes. Detection was performed using the Elite Vectastain ABC kit 
and DAB, before counterstaining with haematoxylin, dehydration and mounting. 
 For immunofluorescence, TBS-tween was used as the wash buffer. A 10X stock solution 
was prepared (0.5M Trizma base (Sigma-Aldrich, T6066), 9% NaCl (Sigma-Aldrich, 13423), 
0.5% Tween 20 (Sigma-Aldrich, P1379), pH 8.4) and then diluted 1:10 in dH2O prior to use. 
Serum blocking was performed with 20% normal horse serum (30 minutes). Detection was 
performed using the ImmPRESS Polymerized Reporter Enzyme Staining System, followed by 
TSA Plus Cyanine 3 (1:100 for 5 minutes). Nuclear counterstain was achieved with 1mM DAPI 
for 10 minutes, before mounting. 
Haematoxylin and eosin staining 
This was performed within the Histology, Immunodetection and Aquila-HistoPlex section of 
the Shared University Research Facilities within the Queen’s Medical Research Institute, 
according to a standard protocol. Briefly, sections were baked overnight at 55ºC overnight, 
before de-waxing and rehydration. Slides were then placed in Harris Haematoxylin (Thermo 
Fisher Scientific) for five minutes. After washing, slides were placed in 1% acid alcohol for 
five seconds, followed by Scott’s tap water substitute for two minutes. Slides were then 
transferred to Eosin Y solution (Thermo Fisher Scientific) for two minutes, followed by 
washing, dehydration, and mounting. 
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Table 2 - 7 List of antibodies 











A-11006  1:200 
Anti-BrdU IHC (1º) Dako M0744 1:40 
Anti-CD16/32 FC BioLegend 101302 1:100 
Anti-CD31-APC FC BioLegend 102410 1:100 
Anti-CD31-PE/Cy7 FC BioLegend 102417 1:100 
Anti-CD45-PE/Cy7 FC BioLegend 103114 1:100 
Anti-CD45-PerCP/Cy5.5 FC BD Biosciences 550994 1:100 
Anti-Desmin IF (1º) Abcam ab8592  1:500 
Anti-F4/80 IHC (1º) Abcam ab6640 1:200 
Anti-F4/80 IF (1º) Abcam ab6640 1:100 
Anti-GR1 IHC (1º) R&D MAB1037 1:750 
Anti-Itgb8 IHC (1º) Abcam ab80673 1:500 
Anti-Itgb8, isotype control IHC (1º) Abcam ab27472 1:1 
Anti-PDGFRβ IHC (1º) Abcam ab32570 1:500 




Anti-Smad3 (phospho S423 + 
S425) 




R&D MAB1835 0.05mg/mL 






























Biotinylated goat anti-rabbit  IHC (2º) Vector BA-1000 1:1000 
Biotinylated goat anti-rat  IHC (2º) Vector BA-9401 1:1000 
Biotinylated rabbit anti-rat IHC (2º) Vector BA-4001 1:200 
Goat anti-rabbit peroxidase  IF (2º) Vector P1-1000 1:800 
Mouse on Mouse Biotinylated 
Anti-mouse IgG Reagent 
IHC (2º) Vector PK-2200 1:250 
	
1º, primary; 2º, secondary; adminn, administration; concn, concentration; FC, flow cytometry; IF, 




Brightfield and epifluorescence microscopy 
Routine brightfield microscopy was performed on an Axiovert 200 microscope (Zeiss). Images 
were acquired using the Axiocam MRc Rev 3 (Zeiss) and AxioVision software (Release 4.6.3). 
White balance and exposure were optimised for each experiment then kept constant for all 
sections within an experiment. Images were saved as TIFF files. For epifluorescence, an HBO 
100 (Osram) mercury lamp was used with the same microscope setup and Zeiss filter sets 02 
(DAPI), 10 (for Fluorescein / Alexa Fluor 488) and 20 (red fluorescent protein). 
Confocal microscopy 
Confocal microscopy was performed using an LSM780 microscope system with 
405/458/488/514/561/633nm laser lines and Zen 2011 SP3 (black edition, version 8.1.0.484) 
software (Zeiss). Laser attenuation, pixel dwell time, gain and pinhole diameter were all 
optimised for each fluorophore within each experiment, then kept constant for all slides. 
Images were saved as CZI files. 
Multiphoton microscopy 
Multiphoton microscopy, encompassing TPEF, SHG and CARS,  was performed using the 
following, previously described,168 custom-built setup. The tunable pump laser (720-990nm, 
7ps, 80MHz repetition rate) and spatially and temporally overlapped Stokes laser (1064nm, 5-
6ps, 80MHz repetition rate) were generated by a picoEmerald laser (APE). Output beams were 
channelled into an Olympus FV1000MPE inverted microscope, incorporating an NA 1.05 
objective (Olympus, XLPL25XWMP). Backscattered emission signals from TPEF and CARS 
were separated from backscattered excitation light by means of a short-pass 690nm dichroic 
mirror and IR cut filter (Olympus). Emission signals were detected by 4 photo-multiplier 
tubes, having been deconvolved by a series of filters and dichroic mirrors. Images were 
recorded using FV10-ASW software (Olympus). Standard image size was 512x512 pixels. Pixel 
size was 0.99µm2 for standard resolution and 0.497µm2 for high resolution images. Z-depth 
was 2µm for standard resolution and 1µm for high resolution. Tiled images (3x3 or 4x4) at 
30µm depth were obtained for all mice, followed by one or more z-stacks from the liver surface 
to the limit of detectable signal. Repeated z-stacks of the same area were acquired every 10-15 
minutes for imaging of cycling hepatocytes. Continuous scanning was performed for blood 
flow imaging, with scan orientation matched to the direction of flow and pixel dwell time 
adjusted until streaks of (labelled) red blood cells were observed (~4µs). 
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Image processing and analysis 
Processing and analysis was performed using FIJI (ImageJ, version 2.0.0-re-59/1.51n)167 or 
Imaris 8.4.1 (Bitplane). Percentage positive DAB staining was calculated as described above. 
Quantification of phospho-SMAD3 nuclear staining was performed as follows on five high-
power images per sample. Nuclei were manually defined as regions of interest and mean grey 
value in the Cyanine 3 channel was calculated for those areas. Three-dimensional vascular 
analysis using Imaris was performed in Cdh5-Cre;Ai14 mice as follows. For each time point 
and mouse, a 30µm z-stack (z-depth 2µm) from immediately beneath the liver capsule was 
reconstructed in Imaris. A vascular surface was created from the Ai14 channel; total area and 
volume were calculated. For two-dimensional vascular analysis using Angiotool,169 the three 
central slices of the Ai14 channel from the previously assembled z-stack were used to produce 
a maximal intensity projection with FIJI. A red lookup table was applied and the images were 
saved as RGB TIFF files. Analysis was performed using optimised parameters, unchanged 
between images (threshold 15-255; vessel diameter 5-8, removing small particles (100) and 
filling holes (150)). Intracellular lipid analysis following partial hepatectomy was performed 
as follows. For each time point and mouse, a 30µm z-stack (z-depth 2µm) from immediately 
beneath the liver capsule was reconstructed in Imaris. In mice (Cdh5-Cre;Ai14) in which 
intrinsic endothelial labelling was present, a vascular surface was created from the Ai14 
channel, as described above, to enable this to be masked from the CARS channel. A lipid 
surface was created in the masked CARS channel to enable the total volume of lipid to be 
calculated. Algorithms for lipid surface creation are shown in Appendix 4. 
Calculation of sinusoidal red blood cell velocity was performed in a similar manner to 
that previously described.170 First, labelled red blood cell smear length was measured. Then 
the starting and finishing coordinates of the smear were used to calculated the total number 
of pixels scanned by the detector between the smear endpoints. This was multiplied by the 
pixel dwell time to give the elapsed time between the start and end of the smear. Distanced 
travelled divided by time taken provided velocity. 
No additional processing was performed prior to quantitative analysis of microscopy images. 
All images within an experiment were processed identically. Images presented in figures were 
contrast-enhanced by adjusting intensity minima and maxima. Noise was removed by use of 
background subtraction (using the pre-suggested filter width), baseline subtraction, and/or a 
median filter (either 3x3x3 or 3x3x1 as appropriate). 
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Statistics 
Data were analysed using Microsoft Excel for Mac (version 15.33) and GraphPad Prism 7 for 
Mac OS X (version 7.0c). Data are presented as individual values with mean where feasible, 
otherwise as mean with standard error of the mean. Data were assessed visually for normality. 
The statistical significance of differences between two groups was calculated with a 2-tailed, 
unpaired Student’s t test (for independent groups with equal variance) or Mann Whitney test 
(for independent groups with unequal variance). A paired t test was performed on hepatocyte 
adhesion data. For comparisons between more than two groups, an ordinary one-way 
ANOVA was performed, followed by Tukey’s multiple comparisons test. Multiplicity-
adjusted P values were calculated for each comparison. Differences with a P value of less than 
0.05 were considered statistically significant. To examine the relationship between excised 
liver weight or serum ALT and hepatocyte proliferation index, linear regression was 
performed. ALT values were log10-transformed prior to analysis. PCR array data were 
standardised as previously reported,171 to identify genes in test samples with a 95% confidence 
interval for standardised relative fold change that did not overlap 1 (the value assigned to the 
fold change for the same gene in control samples). 
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Chapter 3 – Cell-specific depletion of αv integrins in 
liver regeneration 
Introduction 
The αv integrins have been shown to have a key role in the progression of liver fibrosis, 
through activation of latent TGFβ.29 Because TGFβ is stored as a latent complex, its activation, 
through release from the LAP, is a key regulatory step. The role of αv integrins in liver 
regeneration has not previously been explored, despite evidence that, as well as being a major 
inflammatory cytokine, active TGFβ is a potent inhibitor of hepatocyte proliferation.93,98,105,172 
Thus it is possible that depletion of one or more αv integrins within the liver might promote 
hepatocyte proliferation and accelerate liver regeneration following liver injury. This is the 
hypothesis explored in this chapter. 
Although all five αv integrins have been shown to activate latent TGFβ,20-24 combined 
global knockout of integrins αvβ6 and αvβ8 alone is sufficient to recapitulate the 
developmental effects of loss of TGFβ-1 and -3.57 This suggests that these two αv integrins in 
particular play a major role in TGFβ activation. Expression of integrin αvβ6 in the liver 
appears to be relatively restricted, but has been shown in activated cholangiocytes, 
transitional hepatocytes, and oval cells during biliary and portal fibrosis.39,173 Expression of 
integrin αvβ8 within the liver has not been well-characterised, but this integrin has been 
shown to play an important role in TGFβ activation in many other cells and tissues, including 
the respiratory, nervous and immune systems.43,59-63 Specifically, integrin αvβ8 inhibits 
proliferation of lung epithelium through TGFβ activation.55 Therefore, as well as exploring the 
role in liver regeneration of cell-specific depletion of αv integrins in general, the expression 
and cell-specific depletion of integrin αvβ8 alone were also examined. 
This chapter presents data to show that depletion of hepatocyte integrin αvβ8 leads to 
increased hepatocyte proliferation and accelerated liver regeneration. Hepatocytes and 
integrin αvβ8 appear to be the key liver cell and integrin, respectively, since depletion of 
integrin αvβ8 or all αv integrins from HSCs or LSECs did not produce a pro-regenerative 
phenotype. Expression of integrin αvβ8 by hepatocytes in samples of human liver tissue was 
confirmed immunohistochemically. Taken together, the findings reported in this chapter 
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suggest that targeting hepatocyte integrin αvβ8 may represent a promising therapeutic 
strategy to promote regeneration of a patient’s own liver. 
Results 
Depletion of αv integrins from hepatic stellate cells does not affect hepatocyte 
proliferation following partial hepatectomy 
Given the previously confirmed role for HSC αv integrins in hepatic fibrosis,29 the effect on 
hepatocyte proliferation of αv integrin depletion from HSCs was examined in a mouse model 
of liver regeneration. The same transgenic approach as that used to demonstrate the role of 
HSC αv integrins in liver fibrosis was employed (Figure 3 - 1a). Depletion of αv integrins was 
targeted to HSCs through utilisation of double transgenic mice, homozygous for a floxed Itgav 
allele and heterozygous for Pdgfrb-Cre. As described in Chapter I, this strategy targets Cre 
recombination and subsequent gene inactivation in a cell-specific manner. HSCs are targeted 
in a highly efficient manner by Pdgfrb-Cre.29 
Partial hepatectomy was performed in Itgavflox/flox;Pdgfrb-Cre mice and littermate controls 
(Figure 3 - 1b). The thymidine analogue BrdU was injected two hours prior to liver harvest in 
order to label proliferating cells. Livers were harvested at the time of peak hepatocyte 
regeneration in this model, 48 hours following partial hepatectomy, and BrdU 
immunostaining was performed. No difference in hepatocyte proliferation or liver-to-body-
weight ratio could be detected between Itgavflox/flox;Pdgfrb-Cre mice and controls (Figure 3 - 
1c,d). This suggests that although HSC αv integrins play a key role in driving liver fibrosis in 
chronic injury, they do not play such an important role in the immediate regenerative 
response following acute liver injury. 
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Figure 3 - 1 Depletion of αv integrins from HSCs does not promote liver regeneration following 
partial hepatectomy. 
a) Creation of double transgenic ‘Cre-lox’ mice to facilitate cell-specific depletion of a target gene. This 
strategy also yields Cre-negative littermate controls. b) Schematic of partial hepatectomy model of liver 
regeneration; i.p., intra-peritoneal. Quantitation of BrdU+ hepatocyte nuclei (c) and liver-to-body-weight 
ratio (d) in control and Itgavflox/flox;Pdgfrb-Cre (αv-PdgfrbCre) mice at 48 hours post partial hepatectomy; 
line indicates mean. 
Depletion of hepatocyte integrin αvβ8 promotes hepatocyte proliferation and 
liver regeneration 
Whilst HSCs play a crucial role in coordinating the inflammatory response following chronic 
liver injury, it would be reasonable to consider hepatocytes as the dominant cell type in the 
hepatic regenerative response. Fate-mapping studies have provided strong evidence that, in 
the majority of murine models of liver injury, hepatic regeneration occurs through self-
duplication of the pre-existing hepatocyte population.16,17 Although the αv integrin subunit 
has five possible β subunit binding partners, individual αv integrins may be more important 
than others within the context of specific organs, cell types or biological processes. Integrin 
αvβ8 has been shown to have a key role in development, is expressed on epithelial cells in the 
lung, and has a growth inhibitory effect when transfected into tumour cells subsequently 
injected into mice.54,57 
Hepatocytes were isolated from wild-type mice and qPCR demonstrated expression of 
integrin αvβ8, albeit at a low level (Figure 3 - 2a). The same technique also showed that 
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integrin αvβ8 is depleted from hepatocytes in Itgb8flox/flox;Alb-Cre mice (Figure 3 - 2a). Following 
partial hepatectomy, hepatocyte proliferation is significantly increased at 36, 48 and 72 hours 
in Itgb8flox/flox;Alb-Cre mice compared to controls (Figure 3 - 2b,d). Concomitantly, liver-to-body-
weight ratio in Itgb8flox/flox;Alb-Cre mice was also increased at 72 and 96 hours following partial 
hepatectomy (Figure 3 - 2c), supporting the conclusion that the observed increase in 
hepatocyte proliferation drives restoration of liver mass following injury. 
 
Figure 3 - 2 Depletion of hepatocyte integrin αvβ8 promotes hepatocyte proliferation and liver 
regeneration following partial hepatectomy. 
a) qPCR of Itgb8 expression in hepatocytes isolated from control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) 
mice. Quantitation of BrdU+ hepatocyte nuclei (b) and liver-to-body-weight ratio (c) in control and β8-
AlbCre mice after partial hepatectomy (n=3-6). d) Representative images from BrdU immunostaining of 
liver sections from control and β8-AlbCre mice at 0 and 48 hours after partial hepatectomy. Horizontal 
line in (b) indicates mean; data in (c) is presented as mean, error bars show SEM. * P<0.05, ** P<0.01, 
**** P<0.0001. Scale bar 100µm.* 
Depletion of hepatocyte integrin αvβ8 does not alter hepatocyte proliferation, 
liver architecture or liver biochemistry in the uninjured liver  
Constitutive depletion of integrin αvβ8 from hepatocytes has the potential to produce a 
phenotype in the uninjured liver, which might explain or confound the increased hepatocyte 
proliferation observed following partial hepatectomy. No difference in hepatocyte 
proliferation or liver-to-body-weight ratio was observed in livers from Itgb8flox/flox;Alb-Cre mice 
																																																						
* Experiments performed by N.C. Henderson and K. Saeteurn. 
	 55	
and controls prior to partial hepatectomy (Figure 3 - 2b,c). To examine this further, serum and 
liver tissue were obtained from uninjured Itgb8flox/flox;Alb-Cre mice and littermate controls to 
assess for any obvious baseline differences in the tissue, or in circulating markers of liver 
injury and function. No difference in serum albumin, ALT, ALP, or total bilirubin was 
detected between Itgb8flox/flox;Alb-Cre mice and controls (Figure 3 - 3). Quantitation of positive 
immunostaining for markers of Kupffer cells (F4/80), neutrophils (GR1) and HSCs (PDGFRβ) 
in uninjured livers revealed no differences between Itgb8flox/flox;Alb-Cre mice and controls 
(Figure 3 - 4). Similarly, no morphological changes were observed on examination of sections 
stained with haematoxylin and eosin (Figure 3 - 5). These findings support the conclusion that 
depletion of hepatocyte integrin αvβ8 does not alter the form or function of the uninjured 
liver. 
 
Figure 3 - 3 Depletion of hepatocyte integrin αvβ8 does not alter liver biochemistry in the 
uninjured mouse. 
Serum biochemistry (albumin, total bilirubin, ALP, ALT) from uninjured control and Itgb8flox/flox;Alb-Cre 
(β8-AlbCre) mice. Horizontal line indicates mean. 
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Figure 3 - 4 Depletion of hepatocyte integrin αvβ8 does not alter immunostaining for Kupffer cells, 
neutrophils, or HSCs in the uninjured liver. 
Quantification and representative images from F4/80 (Kupffer cell, a), GR1 (neutrophil, b), and PDGFRβ 
(HSC, c) immunostaining of liver from uninjured control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice. 
Horizontal line indicates mean. Scale bar 100µm. 
 
Figure 3 - 5 Depletion of hepatocyte integrin αvβ8 does not alter liver architecture. 
Representative images of haematoxylin and eosin staining of liver tissue from uninjured control and 
Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice (n=6). Scale bars 250µm (upper) and 100µm (lower). 
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Depletion of hepatocyte integrin αvβ8 does not alter the degree of injury or 
inflammatory response following partial hepatectomy 
To investigate whether depletion of hepatocyte integrin αvβ8 alters the degree of injury 
following partial hepatectomy, serum was obtained from Itgb8flox/flox;Alb-Cre mice and controls 
at 48 hours following partial hepatectomy. No significant differences in serum albumin, ALT, 
ALP or total bilirubin were detected (Figure 3 - 6). Quantitation of positive immunostaining 
for markers of Kupffer cells (F4/80), neutrophils (GR1) and HSCs (PDGFRβ) in liver sections 
from Itgb8flox/flox;Alb-Cre mice and controls at 48 hours following partial hepatectomy also did 
not reveal any differences between groups (Figure 3 - 7). These findings suggest that depletion 
of hepatocyte integrin αvβ8 does not alter the degree of injury or inflammatory responses that 
occurs following partial hepatectomy. 
 
Figure 3 - 6 Depletion of hepatocyte integrin αvβ8 does not alter liver biochemistry following 
partial hepatectomy. 
Serum biochemistry (albumin, total bilirubin, ALP, ALT) from uninjured control and Itgb8flox/flox;Alb-Cre 
(β8-AlbCre) mice at 48 hours post partial hepatectomy. Horizontal line indicates mean. 
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Figure 3 - 7 Depletion of hepatocyte integrin αvβ8 does not alter immunostaining for Kupffer cells, 
neutrophils, or HSCs following partial hepatectomy. 
Quantification and representative images from F4/80 (Kupffer cell), GR1 (neutrophil) and PDGFRβ 
(HSC) immunostaining of liver from control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) mice at 48 hours post 
partial hepatectomy. Horizontal line indicates mean. Scale bar 100µm. 
Depletion of hepatocyte integrin αvβ8 has no detectable effect on hepatocyte 
proliferation and liver regeneration in acetaminophen-induced liver injury 
Given the pro-regenerative phenotype observed following depletion of hepatocyte integrin 
αvβ8 in the partial hepatectomy model of liver regeneration, an alternative murine model of 
liver injury was employed to assess whether a similar pro-regenerative phenotype could be 
recapitulated. Acetaminophen overdose is a clinically relevant model of liver injury that 
results in rapid hepatocyte injury and death, observed histologically as centrilobular 
necrosis.114 The dose of acetaminophen is titrated to produce sufficient injury and subsequent 
regeneration, without causing death from acute hepatic failure. Experimental design is shown 
in Figure 3 - 8a. Interestingly, Itgb8flox/flox;Alb-Cre mice had equivalent hepatocyte proliferation 
index compared to controls at 48 hours after acetaminophen administration (Figure 3 - 8b). 
Mean serum ALT levels were also equivalent (Figure 3 - 8c), suggesting that the degree of 
initial injury was consistent between the two groups. However, within both groups there was 
marked variation in serum ALT at 48 hours, consistent with a variable degree of hepatocyte 
injury (Figure 3 - 8d). Whilst not unexpected in this model of liver injury, it may well make 
	 59	
the detection of differences in hepatocyte proliferation more challenging. However, serum 
ALT at 48 hours post acetaminophen does not show any clear association with proliferation 
index (Figure 3 - 8d), so ‘correcting’ hepatocyte proliferation for the degree of injury ALT does 
not reduce the variability within the two groups (Figure 3 - 8e). 
 
Figure 3 - 8 Depletion of hepatocyte integrin αvβ8 has no detectable effect on hepatocyte 
proliferation in acetaminophen-induced liver injury. 
a) Schematic of experimental design; i.p., intraperitoneal. Quantitation of proliferation index (percentage 
of BrdU+ hepatocyte nuclei) (b), serum ALT (c), linear regression of log10(ALT) and proliferation index 
(d), and proliferation index expressed relative to serum ALT (e) in control and Itgb8flox/flox;Alb-Cre (β8-
AlbCre) mice at 48 hours post acetaminophen administration. Solid lines indicate mean, except for (d) 
where solid line is line of best fit, with dotted lines indicating 95% confidence bands. 
Injection of a β8 integrin subunit blocking antibody does not affect hepatocyte 
proliferation following partial hepatectomy 
To investigate whether pharmacological blockade of hepatocyte integrin αvβ8 could 
recapitulate the pro-regenerative phenotype observed following genetic depletion, a β8 
integrin subunit blocking antibody60 was administered to wild-type mice undergoing partial 
hepatectomy. When compared to mice who received a non-binding control antibody, it was 
not possible to detect a difference in either hepatocyte proliferation index or liver-to-body-
weight ratio at 48 hours following partial hepatectomy (Figure 3 - 9). This result suggests that 
a single dose of the β8 integrin subunit blocking antibody tested in this experiment is unlikely 




Figure 3 - 9 Administration of a β8 integrin subunit blocking antibody does not promote liver 
regeneration following partial hepatectomy. 
Quantitation of BrdU+ hepatocyte nuclei (a) and liver-to-body-weight ratio (b) at 48 hours post partial 
hepatectomy in mice receiving control or β8 integrin subunit blocking antibody; line indicates mean. 
Depletion of integrin αvβ8 on hepatic stellate cells does not affect hepatocyte 
proliferation following partial hepatectomy 
Hepatic stellate cells have been shown to express integrin αvβ8.29 It is possible that the failure 
to observe a pro-regenerative phenotype following partial hepatectomy in mice in which all 
αv integrins were depleted from HSCs (as reported above) could have occurred as a result of 
conflicting effects from the depletion of multiple integrins. Therefore, to determine whether 
depletion of integrin αvβ8 alone from HSCs might result in a similar pro-regenerative 
phenotype to that seen following its depletion from hepatocytes, Pdgfrb-Cre mice were crossed 
with Itgb8flox/flox mice to generate an Itgb8flox/flox;Pdgfrb-Cre line. Following partial hepatectomy, 
with tissue harvest at 48 hours, there was no difference in either hepatocyte proliferation index 
or liver-to-body-weight ratio between Itgb8flox/flox;Pdgfrb-Cre mice and littermate controls 
(Figure 3 - 10). This suggests that integrin αvβ8 depletion in HSCs alone does not alter 
hepatocyte proliferation following liver injury. 
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Figure 3 - 10 Depletion of HSC integrin αvβ8 does not promote liver regeneration following partial 
hepatectomy. 
Quantitation of BrdU+ hepatocyte nuclei (a) and liver-to-body-weight ratio (b) in control and 
Itgb8flox/flox;Pdgfrb-Cre (β8-PdgfrbCre) mice at 48 hours post partial hepatectomy; line indicates mean. 
Evaluation of a Cdh5-Cre to target liver sinusoidal endothelial cells 
Liver sinusoidal endothelial cells have been shown to play an important role in liver 
regeneration.47,174,175 Recently, a novel, inducible transgenic mouse, expressing Cre under 
control of the VE-Cadherin promoter, has been utilised to target LSECs.159,175 In order to 
characterise recombination in this Cdh5-PAC-CreERT2 mouse, it was crossed separately to two 
reporter lines to produce Cdh5-PAC-CreERT2;Ai14 (Cdh5-Cre;Ai14) and Cdh5-PAC-
CreERT2;mTmG (Cdh5-Cre;mTmG) mice. Following tamoxifen induction, multiphoton 
microscopy of excised whole liver and confocal microscopy of liver sections showed excellent 
labelling of cells lining the hepatic sinusoids, consistent with LSECs (Figure 3 - 11). No 
evidence of hepatocyte labelling was observed. 
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Figure 3 - 11 Cdh5-Cre effectively targets LSECs. 
Multiphoton microscopy of excised whole liver shows labelling of sinusoids in the Cdh5-Cre;Ai14 mouse 
(a) and Cdh5-Cre;mTmG mouse (b, cells in which recombination has occurred express GFP). c) 
Confocal microscopy of fixed-frozen section of Cdh5-Cre;Ai14 liver shows Ai14 reporter (red) is 
maintained after processing; DAPI (blue). d) 3D reconstruction of z-stack from excised whole Cdh5-
Cre;Ai14 liver (acquired using multiphoton microscopy) outlines the branching vascular tree. 
 
Immunofluorescence was then utilised to assess the specificity of recombination and labelling 
in Cdh5-Cre;Ai14 mice. This demonstrated that Cdh5-Cre does not target the F4/80+ Kupffer cell 
population within the liver (Figure 3 - 12a). Similarly, a dual immunostaining approach, to 
label Ai14+ cells and desmin+ HSCs, revealed two distinct populations, illustrating that 
recombination in the Cdh5-Cre;Ai14 mouse does not label HSCs (Figure 3 - 12b). 
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Figure 3 - 12 Cdh5-Cre does not target Kupffer cell or HSC populations within the liver. 
a) Immunostaining of Cdh5-Cre;Ai14 liver for F4/80 (green); Ai14 – red; DAPI – blue. b) Immunostaining 
of Cdh5-Cre;Ai14 liver for desmin (green) and red fluorescent protein (red); DAPI – blue. 
 
Analysis of the recombined population in Cdh5-Cre;mTmG mice, expressing membrane-
targeted GFP, was performed using flow cytometry. From this it was determined that at least 
95% of CD31+;CD45- endothelial cells expressed GFP following tamoxifen induction (Figure 3 
- 13a). Over 99% of GFP+ cells expressed CD31 (Figure 3 - 13b). Together these findings confirm 
that Cdh5-Cre targets LSECs in a highly efficient manner and with excellent specificity. 
 
Figure 3 - 13 Flow cytometry demonstrates that Cdh5-Cre targets LSECs in a highly efficient 
manner and with excellent specificity. 
Representative pseudocolour plots from flow cytometry of digested liver from Cdh5-Cre;mTmG mice 
(n=2) show >95% of singlet, live, CD31+;CD45- cells are GFP+ (a) and >99% of singlet, live, GFP+ cells 
are CD31+ (b). SSC-A, side scatter-area. 
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LSECs do not express integrin αvβ8 and depletion of all LSEC αv integrins 
does not affect hepatocyte proliferation following partial hepatectomy 
To assess whether integrin αvβ8 depletion from LSECs might promote liver regeneration 
following injury, in a similar manner to that seen with integrin αvβ8 depletion from 
hepatocytes, it was first necessary to investigate LSEC expression of integrin αvβ8. 
Fluorescence activated cell sorting was utilised to obtain CD31+;CD45- LSECs from the 
uninjured murine liver. Following cell lysis, RNA extraction and reverse transcription, it was 
not possible to detect expression of mRNA for the gene Itgb8, which encodes the β8 integrin 
subunit (Figure 3 - 14a). This finding suggests that LSECs do not express integrin αvβ8. LSECs 
have been shown to express αv integrins, namely αvβ3 and αvβ5.29,50,52 Therefore, 
Itgavflox/flox;Cdh5-Cre mice were generated through interbreeding in order to permit depletion 
of all αv integrins from LSECs upon tamoxifen administration. Following partial 
hepatectomy, there was no difference in hepatocyte proliferation index or liver-to-body-
weight ratio at 48 hours between Itgavflox/flox;Cdh5-Cre mice that received tamoxifen and Cre-
negative littermate controls (to which tamoxifen was also administered) (Figure 3 - 14b,c). This 
suggests that depletion of αv integrins from LSECs does not promote liver regeneration 
following partial hepatectomy. 
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Figure 3 - 14 LSECs do not express integrin αvβ8 and depletion of LSEC αv integrins does not 
promote liver regeneration following partial hepatectomy. 
a) qPCR failed to detect Itgb8 mRNA expression by freshly isolated LSECs (n=4); Itgb8 mRNA was 
detected in an HSC positive control (green lines). Quantitation of BrdU+ hepatocyte nuclei (b) and liver-
to-body-weight ratio (c) in control and Itgavflox/flox;Cdh5-Cre (αv-Cdh5Cre) mice at 48 hours post partial 
hepatectomy; line indicates mean. 
Human hepatocytes express integrin αvβ8 
For hepatocyte integrin αvβ8 to be a viable therapeutic target to promote liver regeneration, 
it must be expressed by human hepatocytes. Tissue samples were obtained from uninjured 
human liver, from patients with acute liver failure secondary to acetaminophen overdose, and 
from patients with cirrhosis. These samples were stained immunohistochemically for the β8 
integrin subunit and revealed widespread expression of integrin αvβ8 by hepatocytes (Figure 
3 - 15). The evidence that human hepatocytes express integrin αvβ8 in both health and disease 
suggests hepatocyte integrin αvβ8 may be a viable therapeutic target to promote hepatocyte 
proliferation and regeneration of a patient’s own liver. 
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Figure 3 - 15 Human hepatocytes express integrin αvβ8. 
Representative low- and high-magnification images of β8 integrin subunit immunostaining in uninjured 
human liver (n=5), following acetaminophen overdose (n=5), or in cirrhosis (n=6). Scale bars 250µm 
(upper) and 100µm (lower). 
Discussion 
The body of work contained within this chapter explores the role of αv integrins in liver 
regeneration. Whilst HSC αv integrins have been shown to have an important role in the 
development and progression of liver fibrosis,29 the depletion of αv integrins, or specifically 
integrin αvβ8, from HSCs does not promote hepatocyte proliferation. Conversely, depletion 
of integrin αvβ8 from hepatocytes does promote hepatocyte proliferation and accelerate liver 
regeneration following partial hepatectomy. LSECs do not express integrin αvβ8, at least in 
the uninjured liver, neither does depletion of all αv integrins from LSECs promote hepatocyte 
proliferation following partial hepatectomy. Human hepatocytes express integrin αvβ8 in 
uninjured liver, and this expression persists in both acute liver failure following 
acetaminophen overdose and in cirrhosis. 
Dissecting the roles of individual αv integrin subtypes 
Integrin αvβ8 has previously been shown to be expressed by epithelial cells in the lung and 
was shown to have a growth regulatory function.54 Although normal airway epithelial cells 
express integrin αvβ8, lung carcinoma cells do not. When lung and colon carcinoma cell lines 
were transfected to express integrin αvβ8, a reduction in proliferation was observed. The 
transfected lung carcinoma cells also formed fewer, smaller tumours when injected into mice. 
The data presented above fits with a role for integrin αvβ8 in epithelial cell growth regulation. 
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Whether any of the remaining four αv integrins also have a growth-inhibitory role in the 
liver is, as yet, unconfirmed. As previously noted, expression of integrin αvβ6 in the liver 
appears relatively restricted, but its expression may drive both fibrosis and hepatobiliary 
carcinoma.39,173 The expression and role of other αv integrins in the liver, namely αvβ1, αvβ3, 
and αvβ5, is gradually being elucidated, but a complete picture is yet to emerge. 
Recently, hepatocyte β1 integrin has been shown to be required for successful liver 
regeneration.176 However, the β1 integrin subunit is particularly promiscuous, having the 
potential to bind twelve of the eighteen alpha subunits.18 No attempt was made in the 
aforementioned study to determine which of the β1 integrin heterodimers was responsible for 
the observed phenotype, so whether integrin αvβ1 has a role in liver regeneration is uncertain. 
Investigating the role of integrin αvβ1 remains challenging because no specific genetic 
technique exists to deplete integrin αvβ1 alone, without simultaneously targeting other αv 
integrins or β1 subunit binding partners. A small molecule inhibitor of integrin αvβ1 has now 
been developed, which does not inhibit cell adhesion mediated by any of the other four αv 
integrins.24 The inhibitor was then used to ameliorate mouse models of fibrosis in lung and 
liver.24 If hepatocyte expression of integrin αvβ1 were confirmed, the effect of integrin αvβ1 
inhibition on liver regeneration following partial hepatectomy would be interesting to 
examine. 
Cell-specific depletion of the β3 integrin subunit through use of Cre-lox has been 
reported, albeit in platelets and myeloid cells.177 It should be eminently feasible to generate a 
mouse in which the gene encoding the β5 integrin subunit is floxed, allowing its cell-specific 
depletion. Using similar transgenic approaches to those employed here, this would facilitate 
investigation of the individual contribution of these αv integrins to the regulation of liver 
regeneration. Such investigations might also serve to highlight the benefits of targeting 
specific αv integrins to promote liver regeneration, in contrast to the anti-fibrotic effects seen 
with inhibition of all αv integrins. For example, inhibition of integrin αvβ3 has been suggested 
to reduce hepatocyte proliferation and suppress angiogenesis following liver injury.178,179 
Assessing hepatocyte proliferation 
BrdU is a thymidine analogue and acts a marker of proliferation by its incorporation and 
subsequent detection in cells in S phase of the cell cycle between the time of BrdU 
administration and tissue harvest and fixation. Other methods to detect cell proliferation, such 
as Ki67 immunostaining, can also be used. However, all these methods only serve to provide 
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a snapshot of which cells are progressing through the cell cycle, and it is likely that not every 
hepatocyte entering S phase and replicating its DNA continues on to complete cytokinesis. 
This is why hepatocyte proliferation data is augmented by measurement of liver-to-body-
weight ratio. Elevation of both above baseline, or relative to control, supports the conclusion 
that increased hepatocyte proliferation is occurring and leading to regeneration of functional 
hepatic mass. 
The αv integrins and hepatic non-parenchymal cells 
Depletion of HSC αv integrins, HSC integrin αvβ8 alone, or depletion of LSEC αv integrins 
all failed to increase hepatocyte proliferation or liver-to-body-weight ratio at 48 hours 
following partial hepatectomy. It is not possible to rule out a small effect, or one which occurs 
at a different time point following injury. The 48-hour time point was chosen for liver harvest 
because 36-48 hours is the time of peak hepatocyte proliferation following partial hepatectomy 
in the mouse.119,120 As such, this was considered the best single time point to be able to detect 
an effect on hepatocyte proliferation. Once no effect was demonstrated, consideration was 
given to harvesting at a range of time points following partial hepatectomy. However, the 
likelihood of detecting a difference in hepatocyte proliferation at other time points when no 
effect was apparent at 48 hours following partial hepatectomy was considered low. As such, 
the use of additional mice to confirm this would be hard to justify. 
Hepatocyte integrin αvβ8 in acetaminophen-induced liver injury 
The failure to observe an effect of hepatocyte integrin αvβ8 depletion on liver regeneration 
following acetaminophen overdose may have occurred for a number of reasons. It is possible 
that a subtle effect might be masked by other factors specific to the more inflammatory milieu 
in which hepatocyte injury and subsequent liver regeneration occurs in this model. 
Hepatocyte proliferation following acetaminophen overdose is both more localised and less 
pronounced than that which occurs following partial hepatectomy. Both these features could 
make detection of differences in proliferation more challenging. The degree of injury 
occurring following acetaminophen administration is also quite variable from mouse to 
mouse. The experiment was powered based on data previously obtained by Alexandra 
Thompson, anticipating a proliferation index of 8% in control mice and with an 80% power to 
detect an increase (or decrease) in proliferation index of 4%, considered to be an appropriate 
effect size (estimated SD 3%, α=0.05). Despite the wide variation in liver injury that was 
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observed, reflected in the serum ALT, the control group mean proliferation index and 
standard deviation were broadly as expected (mean 10.6%, SD 2.5%). Increased variation was 
seen in the proliferation index of Itgb8flox/flox;Alb-Cre mice (mean 12.2%, SD 5.0%), but this 
difference in variation was not statistically significant. The similar and overlapping 95% 
confidence intervals of both experimental groups (control 8.5-12.8%, Itgb8flox/flox;Alb-Cre 8.7-
15.8%) also support the conclusion that no large effect exists, rather than that the study failed 
to detect one. Thus, although mean proliferation index was marginally increased in 
Itgb8flox/flox;Alb-Cre mice compared to control,  it may well be that integrin αvβ8 plays a lesser 
or no role in regulating hepatocyte proliferation in this model of liver injury. 
The β8 integrin subunit blocking antibody 
Injection of a β8 integrin subunit blocking antibody at the time of partial hepatectomy also did 
not reveal a similar phenotype to genetic depletion. Whilst a detectable difference in 
hepatocyte proliferation between those mice administered blocking antibody and controls 
would have provided an elegant proof of the concept that pharmacological blockade of 
integrin αvβ8 could promote liver regeneration, there are many possible reasons for the failure 
to observe any effect. Despite being based on expert recommendation from the group who 
both produced and have extensive experience of using this blocking antibody, the dose, route 
and timing of injection may not have been optimal to achieve the desired promotion in 
hepatocyte proliferation following partial hepatectomy. Since the antibody was not 
specifically targeted to hepatocyte integrin αvβ8, it is possible that binding to integrin αvβ8 
on other cell types, or off-target binding, could have resulted in poor affinity to, or incomplete 
blockade of, hepatocyte integrin αvβ8. Further pharmacological blockade experiments could 
be performed, first to confirm binding to hepatocyte integrin αvβ8, and subsequently to assess 
alternative dosing regimens, including increased and repeated dosing, or an intravenous 
rather than intraperitoneal route of administration. Therefore, although this experiment did 
not demonstrate an effect on hepatocyte proliferation from administration of a β8 integrin 
subunit blocking antibody at the time of partial hepatectomy, this does not rule out the 
possibility that pharmacological targeting of the αvβ8 integrin could be of therapeutic benefit 
through promotion of hepatocyte proliferation. 
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LSECs and αv integrins 
Endothelial cells have been reported to express multiple αv integrins.45 However, LSEC 
expression of specific αv integrins may differ from, and be lower than, that of other 
endothelial cells.48,52 No expression of integrin αvβ8 by LSECs isolated from uninjured liver 
was detected. However, it is possible that LSECs might express Itgb8 following injury. This 
could be investigated further by attempting isolation of LSECs following partial hepatectomy, 
although the ability to obtain adequate numbers of cells for RNA extraction, reverse 
transcription and qPCR by routine methods would be hampered by the small size of the 
remnant liver. An alternative approach would be to attempt to detect β8 integrin subunit 
expression in situ, with co-localisation of a suitable LSEC marker such as CD31. Again, this is 
hampered by the current lack of a suitable antibody against the β8 integrin subunit which 
works well in murine tissue. At time of writing, there is also no well-validated antibody 
against the β8 integrin subunit for use in flow cytometry, which would otherwise be another 
potential modality through which to confirm whether LSECs ever express integrin αvβ8. 
Depletion of all αv integrins on LSECs did not reveal a positive or negative effect on 
hepatocyte proliferation following partial hepatectomy. However, it should be noted that 
successful depletion of αv integrins from LSECs in the Itgavflox/flox;Cdh5-Cre mouse was not 
confirmed either at the transcript or protein level. Although the Cdh5-Cre transgene encodes 
an inducible form of Cre recombinase, the validation experiments performed with Cdh5-
Cre;Ai14 and Cdh5-Cre;mTmG reporter mice demonstrated highly efficient recombination 
following tamoxifen administration, so there is no reason to suspect that LSEC αv integrin 
depletion would be any less efficient. Hepatocyte proliferation was only measured at 48 hours 
post partial hepatectomy in Itgavflox/flox;Cdh5-Cre mice and controls. Given that LSECs have been 
shown to express integrins αvβ3 and αvβ5,50,52 and, separately, inhibition of integrins αvβ3 
and αvβ5, using Cilengitide, has been shown to impair angiogenesis in mouse models of 
chronic liver disease,179 it would be of interest to assess both angiogenesis and hepatocyte 
proliferation at a later time point following partial hepatectomy. Following partial 
hepatectomy, the first round of hepatocyte division precedes LSEC proliferation, which 
principally occurs between three and six days post partial hepatectomy.180 If integrins αvβ3 
and αvβ5 are the predominant αv integrin heterodimers expressed by LSECs, their depletion 
might impair angiogenesis following partial hepatectomy, in a similar manner to that seen in 
models of chronic liver disease. Impaired angiogenesis might be expected to retard liver 
regeneration, either by a direct inhibitory effect on subsequent rounds of hepatocyte 
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proliferation, or more generally by slowing the rate at which the liver returns to its normal 
size. 
Kupffer cells and αv integrins 
Of the principal hepatic cell types, only the potential role of integrin αvβ8 expression by 
Kupffer cells was not explored in this body of work. Kupffer cells do express αv integrins,29,44 
but it has also been reported that macrophages express ‘very low or undetectable’ levels of 
Itgb8.43 It would be relatively straightforward to confirm whether Kupffer cells express 
integrin αvβ8 at the transcript level, using fluorescence assisted cell sorting to isolate Kupffer 
cells, followed by RNA extraction, reverse transcription and qPCR for Itgb8, in the same 
manner as was performed for LSECs. However, until very recently, cell-specific targeting of 
Kupffer cells has not been possible, so it would be difficult to use a transgenic approach to 
deplete integrin αvβ8 solely in Kupffer cells. The most commonly utilised ‘macrophage-
specific’ Cre drivers, LysM-Cre and Csf1-Cre, target the entire monocyte-derived cell 
population, and have also been shown to target neutrophils to a significant degree.129 Recently, 
the Clec4f gene has been identified as a means of selectively depleting Kupffer cells.181 A Clec4f-
Cre mouse has been generated, but it remains to be seen whether it is able to drive efficient 
and specific recombination in Kupffer cells. If successful, such a strategy could be used to 
investigate the role of Kupffer cell expression of specific proteins, including integrin αvβ8, on 
liver regeneration. 
Redundancy in regeneration regulation 
As one would expect for the regulation of such an important, coordinated process as liver 
regeneration, integrin αvβ8 is clearly not the only means of slowing or stopping hepatocyte 
proliferation.180,182 A diverse range of pathways, including liver metabolism, the immune 
response, and liver vasculature, have been shown to play important roles in liver 
regeneration.175,183,184 Redundancy is commonly observed in many biological processes and 
often acts as a protective mechanism to prevent severe physiological derangement in 
circumstances where a particular regulatory pathway is disrupted. In the context of integrin 
αvβ8, constitutive depletion of this integrin from hepatocytes did not lead to hepatomegaly, 
nor to uncontrolled proliferation following injury. However, targeting hepatocyte integrin 
αvβ8 does appear to tip the balance towards a pro-regenerative phenotype and it may 
therefore be possible to use this knowledge to therapeutic advantage. 
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Summary 
The results of the experiments described in this chapter show that depletion of hepatocyte 
integrin αvβ8 leads to increased hepatocyte proliferation and accelerated liver regeneration 
following partial hepatectomy in mice. Depletion of integrin αvβ8 from HSCs does not appear 
to affect hepatocyte proliferation following partial hepatectomy and LSECs do not express 
integrin αvβ8 in uninjured liver. Hepatocyte-specific depletion of integrin αvβ8 does not 
generate an obvious phenotype in uninjured liver, nor does it affect the degree of injury or 
inflammatory response following partial hepatectomy. The fact that human hepatocytes 
appear to express integrin αvβ8, in both health and disease, makes this integrin a potential 
therapeutic target to promote liver regeneration in patients with acute or chronic liver injury. 
Integrin αvβ8 has been shown to activate TGFβ in a number of other cell types and organs.43,59-
63 The following chapter will explore whether a similar mechanism underlies the apparent role 
for hepatocyte integrin αvβ8 as a brake on liver regeneration following partial hepatectomy. 
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Chapter 4 – Mechanistic studies of the role of integrin 
αvβ8 in liver regeneration 
Introduction 
Having confirmed that hepatocyte integrin αvβ8 depletion promotes hepatocyte proliferation 
and accelerates liver regeneration following partial hepatectomy in mice, attempts were made 
to dissect the mechanism underlying this phenotype. Integrin αvβ8 has been shown to have a 
key role in activating TGFβ in several different tissues and disease processes.43,59-63 In 
development, global knockout of integrins αvβ6 and αvβ8 is sufficient to recapitulate the 
TGFβ-null phenotype,57 suggesting that these two integrins in particular are critical to the 
process of TGFβ activation. In the partial hepatectomy model of liver regeneration, altered 
TGFβ  activation appeared to be the most likely mechanism through which depletion of 
hepatocyte integrin αvβ8 could promote liver regeneration, particularly given the well-
characterised ability of TGFβ to inhibit hepatocyte proliferation.93,98,105,172 As previously 
introduced, TGFβ is stored within the extracellular matrix, held in an inactive state by its 
seclusion within the LAP, which itself is anchored to the matrix by the LTBP. For this reason, 
assessing TGFβ transcription and protein levels within a cell or tissue is not particularly 
informative, as neither necessarily correlates with the extent of local TGFβ activity. 
Demonstrating alterations in TGFβ activation status in vivo is extremely challenging and, 
most commonly, in vitro assays are employed in a surrogate capacity.132 
An alternative approach to investigate a mechanistic role for TGFβ in a given scenario is 
to examine the downstream signalling pathway. Canonically, following binding of active 
TGFβ to the TGFβ receptor (II) and formation of the TGFβ receptor I-II complex, intracellular 
signalling occurs through sequential phosphorylation of SMAD proteins, ultimately leading 
to nuclear translocation of the SMAD2,3,4 complex and a change in transcription.84 As with 
TGFβ itself, it is not simply sufficient to detect and quantify the presence of the SMAD 
proteins, since it is their phosphorylation state that is altered during TGFβ signalling. 
Furthermore, as well as the classical TGFβ signalling pathway, TGFβ is also able to signal non-
canonically via several other pathways, including multiple mitogen-activated protein kinase 
(MAPK) pathways, the PI3K-Akt pathway, and the NF-κB pathway.85 As such, a failure to 
detect a change in canonical signalling does not necessarily rule out a role for TGFβ. 
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The αv integrins are also known to interact with the extracellular matrix. The principal 
binding partner for integrin αvβ8 is vitronectin, but it has also been reported to act as a ligand 
for collagen IV, laminin and fibronectin.185,186 It is therefore possible that depletion of 
hepatocyte integrin αvβ8 could change the interaction between hepatocytes and the 
surrounding extracellular matrix, in such a way as to facilitate cellular proliferation. 
In this chapter the time course of integrin αvβ8 expression in the liver following partial 
hepatectomy is presented, which supports the postulated role for integrin αvβ8 as a regulator 
of hepatocyte proliferation. The effect of hepatocyte integrin αvβ8 depletion on hepatocyte 
adhesion is also examined. Finally, a range of techniques are employed to investigate whether 
depletion of hepatocyte integrin αvβ8 alters TGFβ signalling and how this might promote 
hepatocyte proliferation and liver regeneration. 
Results 
Whole liver expression of the β8 integrin subunit following partial 
hepatectomy 
Partial hepatectomy was performed in wild-type mice and livers harvested at multiple time 
points following surgery for quantification of whole liver β8 integrin subunit expression by 
qPCR.† This revealed a marked downregulation of expression immediately following partial 
hepatectomy, which reached a nadir at 12 hours after injury (Figure 4 - 1). Thereafter, β8 
integrin subunit expression increased, peaking at around 10 times baseline expression by 120 
hours post partial hepatectomy. Expression then returned to baseline levels by 168 hours 
(seven days). This time course supports the hypothesis that integrin αvβ8 acts a brake on 
hepatocyte proliferation. In the normal liver, the immediate downregulation of expression 
following injury appears to be permissive for the initiation of hepatocyte proliferation. Once 
liver regeneration is nearing completion and the liver is close to its pre-injury functional mass, 
the observed increase in β8 integrin subunit expression is consistent with a role in suppressing 
ongoing hepatocyte proliferation. 
																																																						
† Experiment performed by N.C. Henderson and K. Saeteurn. 
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Figure 4 - 1 Whole liver expression of integrin αvβ8 following partial hepatectomy. 
qPCR for Itgb8, n=3-6 per time point. Data presented as mean; error bars – SEM. 
Depletion of integrin αvβ8 on hepatocytes does not alter adhesion to multiple 
matrix proteins 
To examine whether depletion of integrin αvβ8 on hepatocytes would alter their ability to 
adhere to the extracellular matrix, an in vitro extracellular matrix adhesion assay was 
performed. Primary hepatocytes were isolated from Itgb8flox/flox;Alb-Cre mice and controls, and 
plated separately onto seven different extracellular matrix proteins or bovine serum albumin 
(as a negative control).‡ Following incubation and washing, a cell stain was applied to detect 
the degree of cellular adhesion in each well by means of a colorimetric technique. 
In four independent experiments comparing adhesion between primary hepatocytes 
from an Itgb8flox/flox;Alb-Cre mouse and a Cre-negative control, no difference in adhesion to any 
of the extracellular matrix proteins tested was detected (Figure 4 - 2). In addition to measuring 
absolute absorbance for each well (Figure 4 - 2a), relative absorbance was calculated to the 
bovine serum albumin negative control (Figure 4 - 2b) and also to collagen I, to reduce any 
variation arising from differences in the number of viable cells plated per column (Figure 4 - 
2c). 
																																																						
‡ Poly-L-lysine is often used as a positive control in adhesion assays due to its highly 
adhesive properties. However, during assay optimisation, it was observed that hepatocyte 
adhesion to type I collagen was greater than adhesion to 0.01% poly-L-lysine, negating the 
benefit of this additional step. 
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Figure 4 - 2 Depletion of hepatocyte integrin αvβ8 does not alter adhesion to extracellular matrix 
proteins. 
Isolated hepatocytes from control and Itgb8flox/flox;Alb-Cre (β8-AlbCre) tested in a colorimetric 
extracellular matrix adhesion assay. Line indicates mean; BSA, bovine serum albumin; Col, collagen. 
In vitro assays to detect TGFβ activation by hepatocytes 
Because of the challenges posed by detecting TGFβ activation status in vivo and in situ, a 
commonly used method to measure active TGFβ is an in vitro assay employing transgenic 
mink lung epithelial cells (MLECs).133 These cells express firefly luciferase under control of the 
promoter for PAI-1 (plasminogen activator inhibitor-1), a protein whose expression is 
upregulated by TGFβ signalling. As such, TGFβ signalling leads to increased production of 
firefly luciferase, which results in an increase in luminescence when the substrates luciferin 
and ATP are added to the MLEC lysate. A cell’s ability to activate latent TGFβ can therefore 
be assessed by co-culture with MLECs (Figure 4 - 3).132 
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Figure 4 - 3 Schematic to illustrate the principal of the MLEC TGFβ activation assay. 
Test cells are co-cultured with MLECs and facilitate release of active TGFβ from the LAP. Active TGFβ 
drives luciferase expression by MLECs. Following cell lysis, luciferase production is assessed by addition 
of the substrates ATP and luciferin, followed by measurement of light production. 
 
An initial attempt to optimise the assay for detection of TGFβ activation by hepatocytes was 
made using the Huh7 hepatoma cell line. MLECs (15,000 per well) and Huh7 cells (25,000-
75,000 per well) were co-cultured in serum-free medium for 16 hours. Following washing and 
cell lysis, the luciferase substrates luciferin and ATP were added, and luciferase activity 
measured with a luminometer. 
The results from this experiment were unable to demonstrate activation of TGFβ by the 
Huh7 cell line, above the low level of background luminescence from MLECs cultured alone 
(Figure 4 - 4a). Indeed, the decreasing luciferase activity noted with increasing Huh7 cell 
number, albeit non-significant, suggests that they might even act as a sink for active TGFβ and 
reduce the amount of active TGFβ signalling in MLECs. The MLECs are clearly responsive to 
active TGFβ, as evidenced by the increasing luminescence associated with increasing 
concentrations of recombinant human TGFβ-1 (rhTGFβ) provided as positive control (Figure 
4 - 4b). This effect is blocked by the addition of anti-TGFβ antibody. 
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Figure 4 - 4 The MLEC TGFβ activation assay is unable to detect activation of TGFβ by the Huh7 
cell line. 
a) Relative luminescence following 16-hour incubation of Huh7 cells, MLECs and MLEC-Huh7 co-
cultures. b) MLECs respond in a dose-dependent fashion to the addition of recombinant human TGFβ 
(rhTGFβ); this response is abolished by addition of TGFβ antibody (TGFβ Ab). All conditions tested in 
triplicate and expressed relative to mean luminescence of MLEC culture alone; solid line indicates mean. 
 
To investigate whether the failure to detect TGFβ activation was specific to the Huh7 cell line, 
the co-culture experiment was repeated, this time comparing the Huh7 line with another 
hepatocyte cell line (HepG2), and the LX-2 hepatic stellate cell line. Two small modifications 
in the experimental design were also made. Firstly, the period of co-culture was extended to 
20 hours, in the hope that this would result in increased, and more easily detectable, luciferase 
production by the MLECs in co-culture. Secondly, foetal bovine serum was added to the co-
culture medium to try to ensure that a source of TGFβ was present. Once again, despite a 
marked response of MLEC cells to rhTGFβ, an increase in the amount of active TGFβ in the 
co-culture system was not demonstrated with Huh7, HepG2 or LX-2 cell lines (50,000 test cells 
per well) (Figure 4 - 5). Furthermore, luciferase activity was decreased from that of MLECs 
cultured alone when MLECs were co-cultured with Huh7, HepG2 or LX-2 cells, suggesting 
that these cells lines may all decrease the amount of active TGFβ signalling in MLECs. 
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Figure 4 - 5 The MLEC TGFβ activation assay is unable to detect activation of TGFβ by the Huh7, 
HepG2 or LX2 cell lines. 
Relative luminescence following 20-hour MLEC co-culture with a) Huh7, b) HepG2, and c) LX-2 cell lines. 
d) MLECs respond to the addition of rhTGFβ; this response is abolished by addition of TGFβ antibody 
(TGFβ Ab). All conditions tested in triplicate and expressed relative to mean luminescence of MLEC 
culture alone; solid line indicates mean. 
 
Despite the possibility, raised by the above experiments, that it might not be possible to detect 
TGFβ activation by hepatocytes using the MLEC co-culture assay, it was decided to proceed 
with isolating primary hepatocytes, since these were the cells of interest. Although 
immortalised cell lines are frequently used for in vitro studies of cell functions, their 
phenotype and protein expression can vary markedly from primary cells.187 Primary 
hepatocytes were isolated from control mice from the Itgb8flox/flox;Alb-Cre line, added to wells 
pre-plated with 15,000 MLECs, and incubated for 20 hours. Brightfield microscopy of 
duplicate test wells confirmed that both MLECs and primary hepatocytes had plated down as 
expected and did not show evidence of marked cell death. Once again, following 
measurement of luminescence, it was observed that the presence of hepatocytes did not result 
in increased TGFβ signalling in MLECs (Figure 4 - 6). Further, it again appeared that the 
presence of hepatocytes in co-culture with MLECs reduced TGFβ signalling in MLECs below 
that of MLECs alone. The only difference from the cell line co-culture experiments was that 
increasing numbers of hepatocytes did not show the trend of decreased TGFβ signalling; 
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rather a mild increase in luminescence was observed, never exceeding that seen in MLECs 
alone. 
 
Figure 4 - 6 The MLEC TGFβ activation assay is unable to detect activation of TGFβ by primary 
mouse hepatocytes. 
a) Relative luminescence following 20-hour MLEC co-culture with primary murine hepatocytes plated at 
various densities. b) MLEC response to the addition of rhTGFβ was confirmed for each MLEC sample; 
this response is abolished by addition of TGFβ antibody (TGFβ Ab). Each data point indicates one mouse 
or cell sample. Each sample tested in triplicate and expressed relative to mean luminescence of MLEC 
culture alone; solid line indicates mean. 
 
An alternative in vitro TGFβ activation assay has been reported, which is able to detect as little 
as 1pg/mL of active TGFβ.134 This sensitivity is somewhat improved on that reported for the 
MLEC co-culture assay.133 The broad principles of the two assays are similar, but in the newer 
one, murine fibroblasts (MFB-F11) were transfected to express a secreted alkaline phosphatase 
in response to TGFβ. Reporter enzyme activity is then assessed by the addition of p-
Nitrophenyl phosphate as substrate followed by measurement of absorbance at 405nm 
(Figure 4 - 7). 
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Figure 4 - 7 Schematic to illustrate the principle of the MFB-F11 TGFβ activation assay. 
Test cells are co-cultured with MFB-F11 cells and facilitate release of active TGFβ from the LAP. Active 
TGFβ drives expression of secreted alkaline phosphatase by MLECs. Enzyme activity is assessed by 
incubation with the substrate p-Nitrophenyl Phosphate, followed by measurement of absorbance at 
405nm. 
 
Primary hepatocytes from control mice were obtained, as previously, and co-cultured with 
the pre-plated MFB-F11 cells. As additional refinements to the prior co-culture experiments, 
a lower serum medium containing only 2.5% foetal bovine serum was used during the co-
culture, since serum itself contains some active TGFβ and therefore high concentrations can 
reduce the sensitivity of the assay. Also, a source of latent TGFβ was provided to some wells, 
through the addition of recombinant human latent TGFβ1. The assay appeared technically 
successful in that increased enzyme activity, above the baseline activity of MFB-F11 cells in 
culture medium, was observed when rhTGFβ was added to the culture medium (Figure 4 - 
8a). This increase was abolished by the addition of anti-TGFβ antibody. Hepatocyte 
monoculture alone revealed increased absorbance above baseline (Figure 4 - 8b). As with the 
MLEC assay, co-culture of hepatocytes with MFB-F11 reporter cells was unable to detect TGFβ 
activation above the background signal present in wells containing only hepatocytes (Figure 
4 - 8b). A dose-dependent response was seen when latent TGFβ was added to the co-culture, 
but an even greater response was seen when latent TGFβ was added to wells containing only 
MFB-F11 reporter cells (Figure 4 - 8c). Therefore, either MFB-F11 cells are able to activate latent 
TGFβ independently, or the recombinant human latent TGFβ1 product contains active TGFβ. 
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The results of the assay as a whole suggest that, despite being sensitive to low levels of rhTGFβ 
(4pM), even this reportedly more sensitive TGFβ activation assay is unable to detect any 
ability of hepatocytes to activate TGFβ in vitro. 
 
Figure 4 - 8 The MFB-F11 TGFβ activation assay is unable to detect activation of TGFβ by primary 
mouse hepatocytes. 
a) MFB-F11 response to the addition of rhTGFβ was confirmed; this response is abolished by addition 
of TGFβ antibody (TGFβ Ab). b) Relative absorbance following 20-hour MFB-F11 co-culture with primary 
murine hepatocytes. c) Addition of latent TGFβ (L-TGFβ) to culture medium increases absorbance in 
both MFB-F11-hepatocyte co-culture and MFB-F11 monoculture. Each sample tested in triplicate and 
expressed relative to mean absorbance of MFB-F11 culture alone; solid line indicates mean. 
Immunohistochemical detection of TGFβ signalling in hepatocytes following 
partial hepatectomy 
The activation of the canonical TGFβ signalling pathway can be examined ex vivo through 
detection of phosphorylated SMAD proteins in the nuclei of the cells of interest. An antibody 
against a phosphorylated form of SMAD3, specifically detecting the amino acid 
phosphorylation (Serine 423 and Serine 425) that occurs as a result of TGFβ signalling, was 
used to assess for the presence of active TGFβ signalling following partial hepatectomy. The 
presence of hepatocyte nuclear pSMAD3 is detectable immunohistochemically in liver 
harvested from mice at 48 hours post partial hepatectomy (Figure 4 - 9a). As expected, the 
number of hepatocyte nuclei in which pSMAD3 is detectable, and the strength of the detected 
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signal, is lower than is present in liver tissue harvested seven days following bile duct ligation, 
a far more inflammatory liver injury (Figure 4 - 9b). 
 
Figure 4 - 9 TGFβ signalling can be detected in hepatocyte nuclei following liver injury. 
Representative images from pSMAD3 immunostaining of murine liver tissue at 48 hours post partial 
hepatectomy (a) and 7 days post bile duct ligation (b). Brown staining indicates pSMAD3 positivity; scale 
bar 50µm. 
 
The immunohistochemistry protocol was then optimised to use a fluorescent readout of 
pSMAD3 immunostaining and thus permit quantification of fluorescent intensity as a 
measure of the amount of nuclear pSMAD3 present. Immunostaining was performed in liver 
sections harvested from Itgb8flox/flox;Alb-Cre mice and controls at 48 hours post partial 
hepatectomy. Mean fluorescence intensity for hepatocyte nuclear pSMAD3 was not different 
between the two groups (Figure 4 - 10), leading to the conclusion that any reduction in 
canonical TGFβ signalling in hepatocytes in Itgb8flox/flox;Alb-Cre mice, if indeed present, was not 
detectable using this methodology. 
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Figure 4 - 10 Quantification of pSMAD3 immunostaining in hepatocyte nuclei following partial 
hepatectomy. 
a) Representative image of pSMAD3 immunostaining of murine liver at 48 hours post partial 
hepatectomy; pSMAD3 – red, DAPI – blue, scale bar 100µm. b) Mean fluorescence intensity of 
hepatocyte nuclei following pSMAD3 immunostaining of liver tissue from control and Itgb8flox/flox;Alb-Cre 
(β8-AlbCre) mice at 48 hours post partial hepatectomy; line indicates mean. 
Inhibition of integrin αvβ8 modulates TGFβ-responsive genes in hepatocytes 
Because of the challenges in detecting changes in TGFβ signalling in or ex vivo, an in vitro 
experiment was designed to examine the effect of β8 integrin subunit blockade on hepatocyte 
TGFβ signalling (Figure 4 - 11a). Freshly isolated hepatocytes were plated onto collagen and 
treated with either β8 integrin subunit blocking antibody or non-binding control antibody. 
Following a 24-hour incubation, the cells were lysed and RNA extracted. A custom qPCR 
array was designed and performed to examine the effects of β8 integrin subunit blocking 
antibody on the transcription of known TGFβ-responsive genes in hepatocytes.137 
Transcription of αv and β8 integrin subunits, and of canonical TGFβ signalling pathway 
components, was also assessed (Appendix 2 and 5). Following standardisation, to account for 
the effect of biological variation between mice, 20 of 87 genes assessed (23%) had a consistent, 
detectable fold change in expression relative to control, comprising 8 upregulated and 12 
downregulated genes (Figure 4 - 11b). Many of these changes were relatively small, but of the 
12 genes in which greater than 10% up- or downregulation was detected when compared to 
control, 10 genes (83%) responded as predicted. Of particular note, the gene most 
downregulated was Hmox1 (mean fold regulation -1.4), whilst the most upregulated gene was 
Plat (mean fold regulation 3.3). 
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Figure 4 - 11 Inhibition of integrin αvβ8 modulates TGFβ-responsive genes in hepatocytes. 
a) Schematic of experimental design to assess the effect of integrin αvβ8 inhibition on hepatocyte 
expression of TGFβ-responsive genes. b) Genes from the qPCR array with a detectable change in 
hepatocyte expression following integrin αvβ8 inhibition. Fold regulation >1 indicates upregulation, <-1 
indicates downregulation relative to control. c) qPCR of plasminogen activator system genes. All data 
n=3, presented as mean, error bars – SEM. 
 
Hmox1 encodes heme oxygenase 1 (HO-1), which has been shown to be induced by TGFβ in 
human lung epithelial cells.188 Plat encodes tissue plasminogen activator (tPA), which is 
principally known for its role in coagulation, through conversion of plasminogen to plasmin. 
However, tPA has also been shown to convert inactive hepatocyte growth factor (pro-HGF) 
to its active form,189 and thus an increase in tPA production could potentially drive liver 
regeneration by increasing the activation of HGF. Initial attempts to demonstrate differences 
in hepatocyte expression of HO-1 and tPA via an immunohistochemical approach were 
hampered by the large amount of apparently non-specific binding of both antibodies when 
compared with isotype controls (Appendix 6). 
The effect of αvβ8 inhibition on the plasminogen activator system in 
hepatocytes 
Tissue plasminogen activator has a homologue, the urokinase plasminogen activator (uPA), 
and both have been shown to activate HGF.189 The regulation of tPA activity by hepatocytes 
has also been demonstrated. The majority of exogenously administered tPA is cleared by 
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hepatocytes in the rat liver,190 following binding to the low-density lipoprotein receptor-
related protein (LRP1).191 Endocytosis can be inhibited by binding of the low-density 
lipoprotein receptor-related protein associated protein (RAP) to LRP1.192 As such, the 
increased expression of Plat by hepatocytes treated with β8 integrin subunit blocking antibody 
was confirmed, and also expression of the genes encoding uPA, the uPA receptor (uPAR), 
LRP1, and RAP was examined. Since tPA and uPA convert plasminogen to plasmin (itself able 
to activate HGF), but are inhibited by plasminogen activator inhibitor-1 (PAI-1), expression of 
the genes encoding plasminogen and PAI-1 was also assessed. Finally, hepatocyte expression 
of the genes encoding HGF and its receptor, c-Met, was measured. 
Standard qPCR for the aforementioned genes was performed on the RNA obtained from 
the freshly isolated hepatocytes treated with either β8 integrin subunit blocking antibody or 
non-binding control antibody. This confirmed the upregulation of Plat, but failed to show any 
significant changes in any of the other plasminogen activator-related genes (Figure 4 - 11c), 
suggesting that hepatocyte integrin αvβ8 may have a regulatory role in tPA expression, but 
does not act elsewhere in the plasminogen activator system. 
Discussion 
The goal of this body was work was to try to establish the mechanism through which depletion 
of integrin αvβ8 leads to increased hepatocyte proliferation and accelerated liver regeneration 
following partial hepatectomy in mice. The previously reported role of integrin αvβ8 as a 
ligand for various matrix proteins and its well-documented ability to activate latent TGFβ 
were both investigated. Depletion of integrin αvβ8 does not appear to have a significant effect 
on hepatocyte adhesion. Demonstrating the ability of hepatocyte integrin αvβ8 to activate 
TGFβ proved extremely challenging, but evidence did emerge that blocking this integrin can 
lead to upregulation of tPA expression, although whether this occurs through a decrease in 
TGFβ signalling remains unconfirmed. An increase in tPA expression could explain the pro-
regenerative phenotype observed in mice depleted of hepatocyte integrin αvβ8, since tPA has 
been shown to activate HGF, a potent stimulator of hepatocyte proliferation. 
Hepatic expression of β8 integrin following partial hepatectomy 
A regulatory role for integrin αvβ8 in hepatocyte proliferation was supported by the β8 
integrin subunit expression time course following partial hepatectomy. The initial 
downregulation during the first 24 hours following liver injury may be permissive for the 
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initiation of hepatocyte proliferation. Subsequently, the peak of expression, reaching 10 times 
that of baseline, occurred at five days post partial hepatectomy, as the liver is approaching its 
pre-injury weight, and may therefore assist in terminating the regenerative process. However, 
it should be noted that β8 integrin subunit expression was assessed in whole liver, due to the 
challenges associated with isolating hepatocytes immediately following partial hepatectomy. 
As such, the changes observed following partial hepatectomy could be due to altered 
expression in non-parenchymal cells in addition to, or instead of, transcriptional alterations in 
hepatocytes themselves. One way in which the contribution of hepatocytes to whole liver 
αvβ8 integrin expression could be investigated further would be to repeat the expression time 
course experiments in Itgb8flox/flox;Alb-Cre mice. By comparing the whole liver expression results 
from wild-type mice and those in which integrin αvβ8 is depleted from hepatocytes, it would 
indirectly be possible to characterise the contribution of hepatocyte Itgb8 expression at each 
time point. 
Hepatocytes and TGFβ activation assays – is no result a result in itself? 
The inability to detect hepatocyte activation of TGFβ in vitro, using hepatocyte cell lines or 
freshly isolated primary hepatocytes, may have occurred for a variety of reasons. Clearly, it is 
possible that hepatocytes are unable to activate significant quantities of TGFβ even in vivo 
and the in vitro findings were an accurate reflection of this. However, several other possible 
explanations may be advanced for the failure to detect experimentally a process which 
functions well in vivo. 
The failure to detect TGFβ activation by the Huh7 or HepG2 cell lines in the early MLEC 
TGFβ activation assays was not overly surprising. However, the inability to detect TGFβ 
activation by the LX-2 line was unexpected, since HSCs have previously been shown to 
activate TGFβ.29 HSCs are usually activated for five days on tissue culture plastic prior to 
experimental use, but in the MLEC TGFβ activation assay LX-2 cells were used shortly after 
resuscitation. This may have affected their ability to activate TGFβ. Furthermore, it has been 
shown that protein expression in immortal cell lines can differ substantially from the primary 
cells whose phenotype they attempt to mimic.187 Indeed, this proteomic study by Pan et al., 
albeit in an alternative hepatic cell line (Hepa1-6) to those used in the experiments presented 
above, observed upregulation of TGFβ signalling pathways amongst other changes in the 
proteome. A similar change might explain the observed tendency for decreasing activation 
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signal with increasing Huh7 cell number, if the Huh7 cells were, in effect, sweeping up TGFβ 
from the co-culture medium. 
Addition of even small amounts of rhTGFβ resulted in detectable signal from the MLECs, 
so it appears that the reporter cells were responding as expected and problems with the assay 
setup itself do not explain the lack of detectable TGFβ activation. Expression of αv integrins, 
repeatedly shown to be capable of activating latent TGFβ, was not confirmed in any of the cell 
lines tested. To investigate this further, αv integrin subunit, and relevant beta subunit, 
expression by these cell types could have been assessed, at both the mRNA and, where 
possible, protein level. However, this would not necessarily have contributed greatly to the 
overall body of work investigating the ability of murine hepatocytes to activate TGFβ, since 
these were all human cell lines. Consideration was also given to testing the assay with a mouse 
hepatocyte cell line. No such line was readily available and, in any case, a cell line’s ability or 
otherwise to activate TGFβ would not have furthered the key question of whether depletion 
of integrin αvβ8 on primary mouse hepatocytes reduces their ability to activate TGFβ. 
Given the previous evidence that TGFβ activation by activated HSCs can be detected in 
the MLEC TGFβ activation assay,29 primary HSCs could have been isolated 
contemporaneously with hepatocytes from the same animal. This would have served as a 
cellular positive control, in addition to the pharmacological positive control provided by 
rhTGFβ. However, not only would this have added complexity to the isolation protocol, 
potentially compromising the number and viability of hepatocytes that could be obtained, but 
it would also have introduced certain temporal challenges which would have been difficult to 
surmount. Whilst HSCs are usually activated by five days of culture on plastic, primary 
hepatocytes are more challenging to maintain in culture and may undergo significant 
phenotypic changes during such periods. It was therefore desirable that the hepatocyte co-
culture assay should be set up immediately following isolation. Hence the possibility of 
simultaneously assaying hepatocytes and HSCs from the same mouse was not pursued 
further. 
Unfortunately, the MLEC TGFβ activation assay did not detect TGFβ activation by wild-
type murine hepatocytes, which therefore precluded demonstration of any reduction in TGFβ 
activation following depletion or inhibition of integrin αvβ8. With no good antibody available 
to detect murine integrin αvβ8 through immunohistochemistry, immunocytochemistry, flow 
cytometry or Western blot, it was not possible to confirm that isolated murine hepatocytes 
continue to express integrin αvβ8 at the cell surface following isolation. Almost certainly, the 
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attempts to detect hepatocyte activation of TGFβ were hampered by the fact that, particularly 
in uninjured liver, expression of integrin αvβ8 is low, as supported by the hepatocyte Itgb8 
mRNA expression data presented in Chapter Three (Figure 3 - 2a). Consideration was given 
to the possibility of transfecting either primary hepatocytes or a hepatocyte cell line to cause 
overexpression of integrin αvβ8. However, although this would likely make confirmation of 
the ability of integrin αvβ8 to activate TGFβ easier, something that is already well-
documented in the current literature, it would be open to the obvious criticism that such a 
mechanism might not be occurring in vivo. 
Another method which would increase hepatocyte expression of integrin αvβ8, and also 
provide a more relevant setting in which to examine the hepatocyte’s ability to activate TGFβ 
in the context of liver regeneration, would be to perform partial hepatectomy with subsequent 
hepatocyte isolation. However, the obvious sequela in the immediate aftermath of partial 
hepatectomy is a drastic reduction in the number of hepatocytes. As such, it was considered 
that it would be difficult to isolate sufficient numbers for in vitro experimental purposes until 
at least 72 hours following partial hepatectomy. Had hepatocytes been isolated post partial 
hepatectomy, at peak integrin αvβ8 expression, this may well have facilitated detection of 
their ability to activate TGFβ, and demonstrate a difference in hepatocytes depleted of integrin 
αvβ8. However, given that significantly increased hepatocyte proliferation was recorded 
earlier in the regenerative phase, any findings regarding TGFβ activation later in liver 
regeneration would again be open to the criticism that a different mechanism might exist to 
explain the earlier effects. 
It is also feasible that the presence of hepatocytes in co-culture with the reporter cells 
impacted on the survival of the latter, or their ability to respond to the presence of active TGFβ. 
Although there was no evidence of this when wells containing either one or both cell types 
were examined microscopically, this possibility could have been examined in more detail, and 
potentially circumvented through prior culture of isolated hepatocytes alone, with subsequent 
culture of the reporter cells in the hepatocyte culture medium. However, this approach would 
not have prevented any autocrine TGFβ uptake by hepatocytes from occurring, nor increased 
the amount of active TGFβ available to bind receptors on reporter cells. 
Missing links may thwart TGFβ activation 
The liberation of active TGFβ from the LAP is a process for which the presence of αv integrins 
alone is probably not sufficient. Recent studies have demonstrated how integrin αvβ6 is able 
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to liberate active TGFβ through binding to the RGD domains of the LAP and inducing a 
conformational change in the latter which permits escape of the active TGFβ homodimer.66,68 
This mechanotransduction also requires that the small latent complex, comprising TGFβ and 
the LAP, is anchored by the LTBP to the extracellular matrix. Insufficient extracellular matrix 
in the in vitro TGFβ activation assay could have resulted in a failure to activate latent TGFβ 
even if binding of the LAP to hepatocyte integrin αvβ8 had occurred. 
Potential modifications to the assay to optimise the provision of a suitable extracellular 
matrix could have included pre-plating the MLEC or MFB-F11 reporter cell lines for a longer 
period, prior to the addition of the test hepatocytes. However, this may have resulted in 
increased variability were different rates of reporter cell proliferation to occur across wells 
during the lengthened test period. When plated in isolation, hepatocytes are usually plated 
onto collagen. Pilot experiments showed that freshly isolated hepatocytes appeared to adhere 
well to plates containing previously plated MLECs, so additional coating of plates with 
collagen was not performed. However, the addition of collagen may have assisted the 
deposition of a suitable extracellular matrix to which stores of latent TGFβ could anchor. 
In contrast to a mechanotransduction mechanism of TGFβ activation, the first study to 
show that integrin αvβ8 activates TGFβ concluded that the presence of MT1-MMP (also 
known as MMP14) was required for activation to occur.21 This implies that an alternative, 
protease-mediated mechanism, rather than mechanical activation through stretching of the 
LAP, occurs in the case of integrin αvβ8-mediated TGFβ activation. The gene encoding 
MMP14 was assessed as part of the qPCR array that was performed on primary hepatocytes 
treated with β8 integrin subunit blocking antibody or control, and the results confirmed that 
hepatocytes reliably express this gene (Appendix 5). Hence, a lack of MMP14 would not 
appear to be the cause of the failure to detect TGFβ activation by integrin αvβ8 on hepatocytes. 
However, protein expression was not confirmed, so it is possible that insufficient surface 
expression, cleavage during the hepatocyte isolation process, or even a failure of co-
localisation might have prevented successful TGFβ activation. 
An alternative TGFβ activation assay 
Following the inability to detect hepatocyte activation of TGFβ using the MLEC assay, an 
alternative in vitro co-culture TGFβ activation assay was trialled. This more recently 
developed assay is reported to be able to detect concentrations of active TGFβ as low as 
1pg/mL, and is highly specific for TGFβ signalling because of the design of the promoter 
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element preceding the reporter gene, which only responds to SMAD-mediated signalling.134 
In comparison, the MLEC assay is reported to be able to detect TGFβ concentrations of 0.2pM 
(º5pg/mL) or greater. Unfortunately, despite this increased sensitivity, it was still not possible 
to detect convincing hepatocyte activation of TGFβ. One potentially complicating factor is that 
the MFB-F11 assay employs a secreted alkaline phosphatase as its reporter gene. There is a 
long-standing acceptance that alkaline phosphatase is expressed by hepatocytes,193 so this may 
have reduced the sensitivity of the assay to detect TGFβ activation, by increasing the amount 
of background signal. It could also explain why the detectable absorbance of hepatocytes 
cultured alone was similar (in fact, slightly higher) than MFB-F11 cells cultured alone, whereas 
one would normally not expect to be able to detect any reporter activity in the test cells 
themselves. Surprisingly, a more recent study has suggested that ALP is not expressed in 
mouse liver, so the MFB-F11 assay may indeed be suitable for use with hepatocytes or other 
liver cells.194 
Is there TGFβ to activate? 
A further challenge in these in vitro activation assays relates to the provision of a suitable 
source of latent TGFβ. Although hepatocytes can produce TGFβ, there is evidence that, 
particularly in uninjured liver, their expression of TGFβ is low (Appendix 5).101 Thus, the 
failure to detect hepatocyte activation of TGFβ may have resulted from there being insufficient 
stores of latent TGFβ to activate. An attempt was made to supply a latent source of TGFβ, but 
its ability to stimulate MFB-F11 reporter cells directly suggests that either MFB-F11 cells are 
able to activate latent TGFβ independently or, more likely, the product contained an amount 
of active TGFβ, which blunted the sensitivity of the assay. Foetal bovine serum can also 
provide a source of TGFβ, but the presence of active TGFβ in this fraction of the culture 
medium will also reduce the sensitivity of these assays to detect small degrees of TGFβ 
activation. During assay optimisation, no obvious benefit was noted when either low-serum 
or serum-free media were used for co-culture. 
Combined with the pre-existing knowledge that hepatocytes are highly responsive to 
TGFβ signalling,137 it is possible that the small amount of TGFβ they may be able to activate 
via integrin αvβ8 acts primarily in an autocrine fashion, binding TGFβ receptors on the 
hepatocytes themselves, rather than becoming available to signal to reporter cells in co-
culture. The concept of hepatocytes as net consumers of, rather than contributors to, the 
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extracellular pool of active TGFβ would fit the results of the TGFβ activation assays performed 
on freshly isolated primary murine hepatocytes. 
Assessing TGFβ signalling in hepatocytes 
As well as the inability to detect hepatocyte activation of TGFβ, immunostaining for pSMAD3 
failed to detect a difference in canonical TGFβ signalling between the hepatocyte nuclei of 
control and Itgb8flox/flox;Alb-Cre mice at 48 hours post partial hepatectomy. As with the 
consideration of the findings from the in vitro TGFβ activation assays, this may well support 
the conclusion that canonical TGFβ signalling is not altered by loss of hepatocyte integrin 
αvβ8 at this time point following partial hepatectomy. However, alternative explanations for 
the observed findings can again be offered. For example, because of the relatively weak 
nuclear pSMAD3 signal in hepatocytes following partial hepatectomy, when compared with 
that occurring in a more florid inflammatory process such as bile duct ligation, significant 
signal amplification was necessary to enable fluorescent detection in post partial hepatectomy 
liver tissue. This may have had the unwanted consequence of masking any small differences 
in signal between test and control tissues. Further, the absence of detectable change at one 
particular time point does not preclude a role for canonical TGFβ signalling at an alternative 
stage in the time course of liver regeneration. The multitude of signalling pathways through 
which TGFβ is able to exert its effects means that a failure to detect an effect in the canonical 
signalling pathway also does not rule out a role for TGFβ signalling through an alternative 
pathway, such as MAPK, PI3K-Akt, or NF-κB.195 
Is persisting with TGFβ detrimentally dogmatic? 
The continued emphasis on attempting to demonstrate a role for TGFβ in mediating the 
positive effects on hepatocyte proliferation that were observed following depletion of 
hepatocyte integrin αvβ8 might seem misguided. However, in over twenty years since the 
discovery of integrin αvβ8, this is the principle mechanism through which integrin αvβ8 
effects have been demonstrated to be mediated. There is an increasingly large body of 
literature showing that integrin αvβ8 is able to activate latent TGFβ in a wide range of cell 
types and tissues.43,59-63 Although all αv integrins have been shown to be able to bind latent 
TGFβ, these studies demonstrate that targeting integrin αvβ8 alone is sufficient to alter a 
disease phenotype, through a change in TGFβ activation. Integrin αvβ8 is also able to bind to 
proteins in the extracellular matrix, principally vitronectin, fibronectin, laminin, and collagen 
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IV.185,186 In contrast to the integrin αvβ8-mediated effects on TGFβ signalling, sufficient 
redundancy within the αv integrin family as a whole appears to exist such that depletion or 
inhibition of integrin αvβ8, or mutation of its intracellular domain, does not alter a cell’s ability 
to bind to the extracellular matrix.185,196 The lack of effect of integrin αvβ8 manipulation on cell 
adhesion is supported by the current work, which showed no difference in hepatocyte binding 
to vitronectin, fibronectin, laminin, or collagen IV when integrin αvβ8 was depleted. Although 
this lack of effect was demonstrated using hepatocytes from control and Itgb8flox/flox;Alb-Cre 
mice, one would anticipate that similar findings would also have resulted had wild-type 
hepatocytes, with or without the addition of β8 integrin subunit blocking antibody, been used 
instead. 
From assays to arrays 
Rather than exhaustively dissect multiple possible TGFβ signalling mechanisms in sequence, 
and following the failure to detect any alteration in canonical signalling, it was decided to 
pursue a broader approach to examining potential integrin αvβ8-mediated effects on TGFβ 
signalling. This led to the experiments in which primary murine hepatocytes were isolated 
and treated with β8 integrin subunit blocking antibody, followed by RNA isolation, to 
examine the effects on multiple potential readouts of TGFβ signalling in hepatocytes. A 
blocking antibody approach was utilised instead of comparing control hepatocytes with those 
from Itgb8flox/flox;Alb-Cre mice with the aim of reducing biological variation through use of 
paired samples from the same mouse. It was also thought that more prominent transcriptional 
changes would be more likely to occur in hepatocytes subjected to sudden blockade, rather 
than those with constitutive integrin αvβ8 depletion, in which the transcriptome has been 
afforded the time to adapt and return to a state of equilibrium. 
Overall, consistent changes were observed in over a quarter of the downstream signalling 
genes surveyed. Although the majority of these were only small in magnitude, this is perhaps 
not surprising given that the isolated hepatocytes came from uninjured liver and were 
unstimulated. Twelve genes showed a fold regulation of greater than 10% when compared to 
controls, with ten of these responding as predicted. Furthermore, the array principally 
incorporated hepatocyte TGFβ ‘signature’ genes, shown to be significantly up- or 
downregulated in response to the provision of active TGFβ, rather than genes responsive to a 
reduction in the amount of tonic TGFβ signalling activity, hypothesised to occur when 
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integrin αvβ8 is blocked. The magnitude of change occurring when tonic activity is inhibited 
is unlikely ever to match that seen when a system is actively stimulated. 
The gene most upregulated by inhibition of integrin αvβ8 on hepatocytes was Plat, 
encoding tPA. As a plasminogen activator, tPA has a well-established role in the context of 
coagulation. However, both tPA and its homologue uPA are also able to activate HGF.189 tPA 
has been shown to have an anti-fibrotic effect in murine bile duct ligation, or following carbon 
tetrachloride administration, with reduced hepatocyte proliferation in tPA-null mice in the 
bile duct ligation model.197-199 Liver regeneration following partial hepatectomy was shown to 
be transiently impaired in uPA-deficient mice.200 Deficiency in uPA was also shown to retard 
liver regeneration following administration of the pro-apoptotic ligand Fas.201 uPA and tPA 
were demonstrated to have a synergistic role in resolution of acute liver injury following 
carbon tetrachloride administration.202 Whilst hepatocyte expression of uPA has not been 
confirmed, hepatocytes have been shown to express uPAR.203 Increased uPAR expression 
correlates with increased uPA activity, and both were shown to occur immediately following 
partial hepatectomy in rats. 
Interestingly, several studies have also linked plasminogen activators with αv integrins. 
Both uPA and uPAR have been shown to associate and interact with multiple αv integrins.204-
207 Specifically, αv integrin interaction with vitronectin has been suggested to localise uPA to 
focal areas on the cell surface and, in ovarian cancer cells, decreased uPA and uPAR 
expression.208,209 In breast cancer cells, inhibition of αv integrins reduced p38 MAPK signalling 
and uPA expression.210 
The evidence that plasminogen activators have a role in liver fibrosis, combined with 
tantalising glimpses of a possible role in liver regeneration, links to αv integrins, and the 
finding of upregulation following hepatocyte integrin αvβ8 inhibition, prompted the 
assessment of expression of a number plasminogen activator-associated genes in control 
hepatocytes and those treated with β8 integrin subunit blocking antibody. This confirmed the 
upregulation of Plat expression following inhibition of integrin αvβ8 on hepatocytes, but did 
not show any other transcriptional changes in the genes encoding uPA, plasmin, HGF, and 
their associated receptors or regulatory molecules. The upregulation of Plat is encouraging, 
but arises from transcriptional analysis only, so remains to be validated through the 
demonstration of changes in tPA protein levels or activity. Similarly, although transcriptional 
changes were not observed elsewhere in the plasminogen activator pathway, this does not 
preclude a role in integrin αvβ8-mediated regulation of liver regeneration by means of, for 
	 95	
example, changes in cellular location or activation state. There are a number of ways in which 
integrin might impact plasminogen activator pathways, either downstream or independent of 
TGFβ signalling, to regulate hepatocyte proliferation and liver regeneration. These are 
presented visually in Figure 4 - 12. 
	
Figure 4 - 12 Plasminogen activators and hepatocyte proliferation: possible mechanisms. 
Hepatocyte integrin αvβ8 regulates tPA expression, either via direct intracellular signalling, or through 
activation of latent TGFβ. tPA and uPA can activate matrix-bound HGF, either directly or via increased 
plasmin production. HGF signals via the c-Met receptor to drive hepatocyte proliferation. tPA and uPA 
activity is inhibited by PAI-1. tPA clearance can occur through LRP1 association and endocytosis, but is 
inhibited by RAP. uPA may complex with uPAR and vitronectin-binding αv integrins. 
 
Should integrin αvβ8 be confirmed to regulate hepatocyte proliferation via tPA, there would 
remain the question of whether the effect on tPA occurs secondary to integrin-mediated TGFβ 
activation. Recently, evidence has emerged that integrin αvβ8 has intracellular signalling 
capability, in addition to its well-characterised extracellular roles in TGFβ activation and 
matrix adhesion. Integrin αvβ8 was shown to associate with Rho-GDP dissociation inhibitor 
1 and thereby regulate activation of Rho GTPases, that in turn promote cell motility and 
invasiveness in a model of glioblastoma.211 Signalling was abolished by mutation of the 
cytoplasmic tail of integrin αvβ8. Thus, it is also feasible that direct intracellular signalling by 




This chapter describes the body of work performed to explore the mechanism through which 
depletion of hepatocyte integrin αvβ8 promotes hepatocyte proliferation and accelerates liver 
regeneration. The time course of β8 integrin subunit expression in the liver, following partial 
hepatectomy, supports a role for integrin αvβ8 as a brake on hepatocyte proliferation. This 
regulation does not appear to occur through anchorage to the extracellular matrix, since 
depletion of hepatocyte integrin αvβ8 does not alter cellular adhesion to extracellular matrix 
proteins. 
The most frequently reported role for integrin αvβ8 is its ability to activate TGFβ, a potent 
suppressor of hepatocyte proliferation. However, confirming that targeting hepatocyte 
integrin αvβ8 was able to modulate TGFβ activation proved extremely challenging, not least 
because of the inability to detect activation of TGFβ by isolated primary hepatocytes from 
uninjured liver. Canonical TGFβ signalling does occur in hepatocytes following partial 
hepatectomy, as evidenced by the detection of nuclear pSMAD3. However, it was not possible 
to demonstrate a reduction in this signalling in Itgb8flox/flox;Alb-Cre mice. A qPCR array to assess 
a number of genes shown to be modulated by TGFβ did provide evidence that inhibition of 
hepatocyte integrin αvβ8 leads to changes consistent with a reduction in active TGFβ and 
downstream signalling. Most prominently, inhibition of hepatocyte integrin αvβ8 resulted in 
increased expression of Plat, the gene encoding tPA. Further work is required to confirm this 
finding, and clarify its implications, but tPA is known to activate HGF. As such, it is feasible 
that hepatocyte integrin αvβ8 may regulate hepatocyte proliferation through TGFβ activation 
and a reduction in tPA expression. Targeting hepatocyte integrin αvβ8 appears to increase 
tPA expression, which may drive HGF activation and hence promote hepatocyte proliferation 
and liver regeneration following injury. 
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Chapter 5 – Developing intravital microscopy of liver 
regeneration 
Introduction 
Reductionist approaches, such as in vitro cell culture experiments, can be particularly helpful 
in investigating the effect of specific molecules on intracellular signalling pathways and cell 
phenotypes. However, they are unable to reflect accurately the complex, multicellular 
environment in mammalian tissues. Harvesting tissue for ex vivo analysis, whilst permitting 
examination of entire tissue, can only provide a snapshot of the physiological process of injury 
and healing at a single time point, particularly when tissue harvest necessitates culling of the 
animal in question on either practical or humane grounds. In order to understand better how 
tissues respond to injury, and the cellular interactions that drive regeneration and repair, it is 
desirable to be able to observe these processes in situ in the living organism. The challenges 
of actually doing so in mammals are numerous and varied, and may depend on the tissue of 
interest, the study species, the nature of the injury, and timeline of the tissue response to the 
injurious stimulus. 
Many of the imaging modalities utilised in medical diagnostics, such as computed 
tomography, positron emission tomography, ultrasound and magnetic resonance, are of great 
utility in observing healthy tissue and the response to injury or disease at a macroscopic level. 
However, they lack the resolution necessary to observe individual cells. Traditional 
epifluorescence or confocal microscopy techniques provide the required resolution,143,151 but 
the practical implementation of these techniques, when applied to whole tissues, results in 
them being of limited utility, primarily because of restricted depth penetration (<100µm). 
Photobleaching and phototoxicity are also negative, and potentially limiting, consequences of 
intravital confocal microscopy.143 The development of multiphoton microscopy, with its 
enhanced depth penetration into the tissue of interest, enhances the ability to perform in vivo 
imaging of mammalian tissues in situ. However, a further challenge lies in accessing the tissue 
of interest, if one wishes to study structures that are not external like the skin or eye. One 
approach is simply to exteriorise the tissue of interest and this has previously been performed 
in the liver.212,213 Although facilitating in vivo imaging, the principal limitation of such a 
technique is the restriction to a single imaging session during terminal anaesthesia of the 
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animal under study. An alternative approach is to implant a device that maintains the 
integrity of the body cavity in which the tissue of interest is located, whilst also providing an 
optical conduit through which imaging can be performed. Such a technique was first utilised 
to image the liver a decade ago.147 Subsequently, Ritsma et al. described the implantation of 
an abdominal imaging window (AIW) that could be used to facilitate multiphoton microscopy 
of a range of abdominal organs, including liver, kidney, spleen, and the gastrointestinal 
tract.146 
In principle, AIW implantation provides an excellent means by which to study the 
process of liver injury and regeneration with cellular resolution. It facilitates repeated, 
sequential imaging of the same liver throughout the time course of injury and repair, and also 
permits detailed study of key waypoints with continuous imaging over an extended period. 
In order to achieve this, current experimental models of liver injury and regeneration need to 
be combined with AIW implantation and validated. AIW implantation has previously been 
combined with acetaminophen-induced liver injury within our group, with initial validation 
comparing this new technique with standard acetaminophen-induced liver injury.214 This 
chapter describes the development of a new model, allowing partial hepatectomy and AIW 
implantation, alongside ongoing refinements to both models. Through an iterative process of 
optimisation, of both the models themselves and subsequent multiphoton imaging, it is now 
possible to study the process of liver injury and regeneration following AIW implantation, 
using intravital multiphoton microscopy, in two separate murine models. The opportunity to 
study liver injury and regeneration in this way, for the first time, has the potential to offer 
exciting, novel insights into the processes and cellular coordination underpinning successful 
liver regeneration. This improved understanding will then offer refined and clinically relevant 
targets for intervention to drive liver regeneration in patients with liver disease. 
Results 
Exploring the combination of partial hepatectomy with AIW implantation 
Partial hepatectomy in mice has been used to study liver regeneration for over half a century 
and remains widely used to this day.11,111 The most commonly performed technique is often 
referred to as ‘two-thirds’ partial hepatectomy and involves excision of the left lateral 
(hereafter referred to as ‘left’) lobe and both limbs of the median lobe (Figure 5 - 1). This degree 
of hepatectomy drives a strong regenerative response, with hepatocyte proliferation in the 
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remnant lobes peaking at 36-48 hours,119,120 whilst still allowing the animal to survive. A 
greater degree of hepatectomy is associated with increased mortality,113 whilst excision of 
smaller amounts of liver tissue results in hypertrophy rather than true regeneration through 
hepatocyte proliferation.112 Fortuitously, the liver lobes excised during the standard two-
thirds partial hepatectomy are those most easily accessible following a midline laparotomy 
with the animal in dorsal recumbency.215 
 
Figure 5 - 1 Mouse liver lobe anatomy as relating to partial hepatectomy. 
In the standard ‘two-thirds’ partial hepatectomy, the left lateral and median lobes are excised. Labelled 
lines indicate ligating suture location for excision of the right median (a), left median (b), and left lateral 
(c) lobes. Adapted from Nature Protocols,111 ©2008, with permission from Macmillan Publishers Ltd. 
 
In desiring to combine AIW implantation with the two-thirds partial hepatectomy model of 
liver regeneration in mice, the greatest challenge lay in reconciling the two standalone 
procedures. For routine AIW implantation onto the liver surface, the implant is adhered to the 
largest, most superficial, left liver lobe. The option of implanting the AIW onto a lobe that 
does not usually have contact with the ventral body wall was immediately discounted, since 
this would make anchoring the AIW within the ventral body wall extremely challenging. 
Therefore, the standard partial hepatectomy technique needed modification to permit AIW 
implantation onto one of the three liver lobes normally excised in the standard procedure. 
Liver lobe weights and options for partial hepatectomy 
Five wild-type mice were culled, their livers removed, and the weights of individual lobes 
were measured (Figure 5 - 2a). This confirmed that the right median and left lobes together 
comprise the majority (54%) of total liver weight and, by extension, account for the majority 
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of the liver tissue that is excised during a standard partial hepatectomy (Figure 5 - 2b). The 
left median lobe, in contrast, comprised only 10% of total liver weight, and accounted for only 
16% of the total weight of the three lobes that are excised during a standard partial 
hepatectomy. In a separate cadaveric study, in which lobes were excised in the same manner 
as would occur during surgical excision in the anaesthetised animal, standard partial 
hepatectomy was compared with two possible variants, which would spare either the left 
median or left lobe for subsequent AIW implantation. In addition to weighing each of the 
excised lobes, the remnant liver was weighed to allow calculation of percentage hepatectomy 
for each procedure. Comparing standard partial hepatectomy with excision of just the right 
median and left lobes did not reveal a significant difference in percentage partial hepatectomy 
(mean difference -6.5%, P = 0.11) (Figure 5 - 2c). Conversely, excising both median and both 
right lobes, in order to spare the large left lobe, did significantly reduce the degree of partial 
hepatectomy performed (mean difference -8.3%, P = 0.04). 
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Figure 5 - 2 Mouse liver lobe weights and their contribution to partial hepatectomy. 
Individual lobe weights (a) and mean percentage of total liver weight (b) for C57BL/6J mice (each colour 
in (a) represents one mouse). c) Comparison of percentage hepatectomy achieved in standard and two 
alternative partial hepatectomies, excising the listed lobes. d) Quantitation of BrdU+ hepatocyte nuclei at 
48 hours after standard and reduced (right median and left lobes only) partial hepatectomy. e) Linear 
regression of excised liver weight and proliferation index for the experiment shown in (d); solid line of 
best fit, dotted lines indicate 95% confidence bands. f) Percentage partial hepatectomy achieved by 
performing standard partial hepatectomy in C57BL/6J mouse cadavers; dotted line indicates two-thirds 
hepatectomy. Horizontal lines indicate mean throughout. 
Reduced partial hepatectomy leads to decreased hepatocyte proliferation 
Following the liver lobe weight measurements, a pilot experiment was performed to compare 
the standard ‘two-thirds’ partial hepatectomy with a partial hepatectomy procedure in which 
only the right median and left lobes were excised. When assessing hepatocyte proliferation 
index at 48 hours, a marked decrease was observed in those mice that had received the 
reduced hepatectomy (Figure 5 - 2d). Although the power of the study meant that this finding 
did not reach statistical significance (P = 0.07), it strongly suggested that combining a reduced 
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partial hepatectomy with AIW insertion on the left median lobe might not result in sufficient 
injury to drive an adequate regenerative response for subsequent study. Linear regression of 
excised liver weight and hepatocyte proliferation index confirmed that there is a strong 
association between the two (R2 = 0.73) (Figure 5 - 2e). Targeting excision of >0.5g of liver (>2% 
body weight) is necessary to achieve the expected hepatocyte proliferation index of 15-20% at 
48 hours post partial hepatectomy. 
Standard partial hepatectomy does not result in two-thirds hepatectomy in the 
C57BL/6J mouse 
A further interesting discovery from the cadaveric experiments examining liver lobe weights 
of C57BL/6J mice was that the long-held belief that excising the left and median lobes equates 
to a two-thirds partial hepatectomy may be a small, but significant, over-estimate. It appears 
that, at least in C57BL/6J mice, the combined weights of the entire left and median lobes 
comprise, at most, 63% of the total liver mass (calculated from data presented in Figure 5 - 2a). 
Indeed, in the cadaveric study in which lobe excision was performed as if in vivo, mean 
percentage hepatectomy achieved was only 46% (Figure 5 - 2f). 
A modified partial hepatectomy equivalent to standard partial hepatectomy 
The investigations into combining AIW implantation and partial hepatectomy had, at this 
point, identified the left median lobe as the most suitable accessible lobe on which to implant 
the AIW, due to its relatively small contribution to the total mass of excised liver in a standard 
partial hepatectomy. Of the other superficial lobes, the left lobe alone constitutes around one-
third of the total liver mass, so retaining it for AIW insertion, in addition to the non-resectable 
portion of the liver hilus, would not be compatible with the goal of achieving close to two-
thirds partial hepatectomy. Similarly, the option of retaining the right median lobe was 
discounted because this would necessitate excision of the cranial right lobe as a comparable 
alternative, something which would be technically demanding given its cranial and dorsal 
location within the abdominal cavity, close to the diaphragm and lying directly underneath 
the right median lobe. The pilot experiment comparing standard partial hepatectomy with a 
reduced partial hepatectomy, excising right median and left lobes alone, suggested a reduced 
hepatectomy would not drive adequate hepatocyte proliferation. As such, excision of 
additional liver tissue was required. The measurement of individual lobe weights identified 
the right caudal lobe as similar in mass to the left median lobe (Figure 5 - 2a,b), so the 
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combined excision of right median, left, and caudal right lobes had the potential to match the 
degree of partial hepatectomy achieved by the standard technique. 
To confirm the feasibility of this modified partial hepatectomy, it was performed in four 
mice in order to obtain post partial hepatectomy liver tissue for optimisation of multiphoton 
imaging protocols. Despite the lack of a control group, and recognising that the cohort was 
relatively aged and consisted of females and males, this experiment demonstrated that the 
technique was technically feasible, and excision of an adequate weight of liver tissue was 
achieved in three of the four mice (Table 5 - 1). One mouse (ID23) had evidence of 
compromised hepatic blood supply (most likely resultant from stenosis of the suprahepatic 
vena cava) on post mortem examination, but all survived until the predetermined time of liver 
harvest. 
	















body weight) Notes 
25 f 26 23.9 0.44 1.84 Harvest at 48hrs 
24 f 26 25.1 0.76 3.03 Harvest at 72hrs 
23 f 26 23.5 0.51 2.17 Harvest at 24hrs 
16 m 28 38.8 1.22 3.14 Harvest at 72hrs 
 
f, female; m, male 
Modified partial hepatectomy with AIW implantation 
A series of cadaveric surgeries were performed to explore the feasibility of combining the 
modified partial hepatectomy with AIW insertion (Figure 5 - 3a). The final, complete 
procedure is described in detail in Chapter Two. Briefly, a standard midline ‘mini-laparotomy’ 
incision was initially performed and the right median and left lobes were excised in the same 
manner as for a standard partial hepatectomy (Figure 5 - 3b – 1,2). The midline excision was 
then extended caudally to facilitate access to the caudal right lobe (Figure 5 - 3b – 3). This was 
further aided by placement of abdominal retractors and a duodenal manoeuvre to displace 
the intestines lying superficial to this lobe. The caudal right lobe was then excised in a standard 
manner. The AIW was adhered to the left median lobe and secured within the ventral body 
wall by a purse string suture (Figure 5 - 3b – 4,5,6). The remaining section of the laparotomy 
incision was closed in a routine manner. 
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Figure 5 - 3 Modified partial hepatectomy with AIW implantation. 
a) Mouse liver lobe anatomy, with lobes excised in the modified partial hepatectomy highlighted 
(magenta) and indicating site of AIW implantation. Annotation of an original drawing in The Anatomy of 
the Laboratory Mouse,216 ©1965, reproduced by permission from Elsevier. b) Photo series illustrating 
modified partial hepatectomy and AIW implantation, as described in the accompanying text. 
Validating modified partial hepatectomy and AIW implantation in mice as a 
model of liver regeneration 
Having developed a novel procedure to combine partial hepatectomy with AIW insertion, it 
was necessary to examine whether either the modified partial hepatectomy or the presence of 
the AIW might significantly alter the hepatocyte proliferation and liver regeneration seen 
following a standard partial hepatectomy. As such, two experiments were designed to 
compare the standard partial hepatectomy with the modified partial hepatectomy and the 
modified partial hepatectomy with AIW implantation. The first experiment examined 
hepatocyte proliferation and liver regeneration at 48 hours post partial hepatectomy, whilst 
the second examined liver regeneration at one week post surgery. 
Excised liver weight does not differ between standard and modified partial 
hepatectomy 
In both experiments the weight of excised liver for each mouse was recorded as a primary 
measure of whether removal of a comparable mass of liver tissue was achievable in mice 
receiving either modified partial hepatectomy or modified partial hepatectomy and AIW 
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insertion, when compared to standard partial hepatectomy. No significant difference in the 
weight of excised liver tissue was observed between groups, and the data also showed that 
excision of at least 0.5g was achievable in the vast majority of cases (Figure 5 - 4a,b). 
 
Figure 5 - 4 The effect of modified partial hepatectomy and AIW implantation on excised liver 
weight and 48-hour hepatocyte proliferation index. 
Weight of excised liver in two experiments (48-hour harvest (a), 7-day harvest (b)) to compare standard 
partial hepatectomy (‘Standard’) with modified partial hepatectomy (‘Modified’) and with modified partial 
hepatectomy and AIW implantation (‘Modified + AIW’). Quantitation of BrdU+ hepatocyte nuclei at 48 
hours post partial hepatectomy in the cranial right lobe (c) and left median or caudal right lobe (AIW lobe, 
d). *Left median lobe for Modified and Modified + AIW groups, caudal right for Standard group. Orange 
dot highlights mouse ID135 in (c) and (d). Representative BrdU immunostaining from cranial right (e) 
and AIW (f) lobes of mouse ID135; positive nuclei are brown; scale bar 100µm. Solid horizontal lines 
indicate mean. 
The effect of modified partial hepatectomy and AIW implantation on hepatocyte 
proliferation 
The 48-hour time point is of key importance because this is the time of peak hepatocyte 
proliferation following partial hepatectomy. Immunostaining for BrdU, which was 
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administered two hours prior to liver harvest, was performed to allow quantification of the 
hepatocyte proliferation index. This revealed no significant difference between the amount of 
hepatocyte proliferation in mice receiving standard partial hepatectomy, modified partial 
hepatectomy alone, or modified partial hepatectomy with AIW implantation (Figure 5 - 4c). 
The initial comparison was performed on the cranial right liver lobe, which was retained in 
all three groups. However, it was also important to assess hepatocyte proliferation in the left 
median lobe, to which the AIW was adhered; this lobe is excised in the standard partial 
hepatectomy procedure. Overall, no significant difference in hepatocyte proliferation was 
observed between mice receiving the modified partial hepatectomy alone, or modified partial 
hepatectomy with AIW implantation, nor did these values differ significantly from the 
hepatocyte proliferation index in the caudal right lobe in mice in which standard partial 
hepatectomy was performed (Figure 5 - 4d). 
Although overall hepatocyte proliferation indices did not differ significantly between 
groups, there was an increased variation within the group receiving modified partial 
hepatectomy and AIW implantation. Two mice showed a failure of hepatocyte regeneration, 
manifested as a hepatocyte proliferation index ≤5% in both lobes in which hepatocyte 
proliferation was assessed. This is most likely due to a failure to excise sufficient liver mass, 
since these mice had less than 0.5g liver (<2% of bodyweight) excised. One other mouse 
(ID135) exhibited a failure of appropriate hepatocyte proliferation in the left median (AIW) 
lobe alone. This is likely due to surgical or AIW-related compromise of vascular flow to this 
lobe; post mortem examination identified a pale left median lobe even prior to 
immunohistochemical confirmation of drastically reduced hepatocyte proliferation (Figure 5 
- 4e). Interestingly, hepatocyte proliferation index in the cranial right lobe in this mouse was 
double that of the mean for this group, highlighting the remarkable regenerative capacity of 
the murine liver (Figure 5 - 4f). Reassuringly, in the remaining mice receiving modified partial 
hepatectomy with AIW implantation, where sufficient liver mass was excised and lobar blood 
flow was not compromised, hepatocyte proliferation at 48 hours was at an expected level and 
in fact slightly above that seen in mice receiving standard partial hepatectomy. This confirms 
that this novel, combined procedure can be used to study liver regeneration in mice. 
Inter-lobe comparison of hepatocyte proliferation 
Analysis of hepatocyte proliferation in two lobes from each mouse enabled a side-by-side 
comparison to be made to examine whether differences in the calculated proliferation index 
are present between lobes following partial hepatectomy (Figure 5 - 5). Although small shifts 
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in the calculated proliferation index were observed among the paired samples, there was no 
consistent trend or overall statistical difference in proliferation index between lobes in any of 
the three experimental groups. This suggests that the presence of an AIW does not have a 
localised lobar effect on hepatocyte proliferation index (except in the case of the previously 
reported mouse in which a marked reduction in hepatocyte proliferation was observed). It 
also suggests that liver regeneration following partial hepatectomy occurs equally among all 
remnant lobes. 
 
Figure 5 - 5 Inter-lobe comparison of hepatocyte proliferation following partial hepatectomy. 
Quantitation of BrdU+ hepatocyte nuclei at 48 hours post partial hepatectomy in each of two lobes per 
mouse following standard (a) or modified (b) partial hepatectomy, or modified partial hepatectomy with 
AIW implantation (c). Solid lines connect proliferation indices from the same mouse.  
The effect of modified partial hepatectomy and AIW implantation on the cellular 
inflammatory response 
Immunostaining to label HSCs (PDGFRβ), Kupffer cells (F4/80) and neutrophils (GR1) was 
performed on liver tissue harvested at 48 hours post surgery.  Partial hepatectomy is a model 
of liver regeneration that is characterised by minimal inflammatory response. However, it was 
reasonable to suspect that the increased manipulation required to access and excise the caudal 
right lobe, or the presence of an AIW might lead to an augmented inflammatory response, 
particularly neutrophil infiltration, which might then alter the dynamics of liver regeneration 
following injury. 
In fact, no difference in percentage positive staining for neutrophils was noted between 
any of the three surgical groups (Figure 5 - 6a,b), nor between the two lobes assessed for each 
mouse (Figure 5 - 6d-f). Although no comparison was made with uninjured liver, negligible 
neutrophil staining (<0.01%) was observed in all samples. Not only does this confirm that 
partial hepatectomy alone does not promote neutrophil recruitment to the liver, but also that 
the presence of the AIW does not drive significant additional neutrophil infiltration. 
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Figure 5 - 6 The effect of modified partial hepatectomy and AIW implantation on neutrophil 
immunostaining in the liver. 
Quantitation of GR1+ immunostaining at 48 hours post partial hepatectomy in the cranial right lobe (a) 
and left median or caudal right lobe (AIW lobe, b). *Left median lobe for Modified and Modified + AIW 
groups, caudal right for Standard group. c) Representative image illustrates rare GR1+ neutrophils 
(brown) within the hepatic parenchyma (arrow); scale bar 100µm. Inter-lobe comparison of GR1+ 
immunostaining at 48 hours post partial hepatectomy in each of two lobes per mouse following standard 
(d) or modified (e) partial hepatectomy, or modified partial hepatectomy with AIW implantation (f). Solid 
lines connect values from the same mouse. 
 
Similarly, no significant changes were detected in percentage positive staining for HSCs, 
either between surgical cohorts or the lobes in individual mice (Figure 5 - 7). This suggests 
that the modified partial hepatectomy and AIW implantation do not drive a change in HSC 
size or number in the first two days following surgery. 
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Figure 5 - 7 The effect of modified partial hepatectomy and AIW implantation on HSC 
immunostaining in the liver. 
Quantitation of PDGFRβ+ immunostaining at 48 hours post partial hepatectomy in the cranial right lobe 
(a) and left median or caudal right lobe (AIW lobe, b). *Left median lobe for Modified and Modified + AIW 
groups, caudal right for Standard group. c) Representative image of PDGFRβ+ staining (brown); scale 
bar 100µm. Inter-lobe comparison of PDGFRβ+ immunostaining at 48 hours post partial hepatectomy in 
each of two lobes per mouse following standard (d) or modified (e) partial hepatectomy, or modified 
partial hepatectomy with AIW implantation (f). Solid lines connect values from the same mouse. 
 
Lastly, F4/80 immunostaining was performed to label Kupffer cells in the liver tissue 
harvested at 48 hours post surgery. Again, no significant difference was detected in 
percentage positive staining between groups (Figure 5 - 8a,b), although a slight upward trend 
was observed when comparing the caudal right lobe in standard partial hepatectomy with the 
left median lobe in modified partial hepatectomy, with a further slight increase when AIW 
implantation was performed (Figure 5 - 8b). Further, although there was no difference in 
staining between the two lobes examined in mice receiving either standard or modified partial 
hepatectomy alone (Figure 5 - 8d,e), a small but statistically significant increase in percentage 
positive staining for F4/80 (mean increase 0.9%, 95% CI 0.01-1.8%) was observed when the left 
median (AIW) lobe was compared with the cranial right lobe in mice receiving modified 
partial hepatectomy and AIW implantation (Figure 5 - 8f). These findings suggest that the 
combination of the modified partial hepatectomy procedure and the presence of the AIW may 




Figure 5 - 8 The effect of modified partial hepatectomy and AIW implantation on Kupffer 
immunostaining in the liver. 
Quantitation of F4/80 immunostaining at 48 hours post partial hepatectomy in the cranial right lobe (a) 
and left median or caudal right lobe (AIW lobe, b). *Left median lobe for Modified and Modified + AIW 
groups, caudal right for Standard group. c) Representative image of F4/80 staining (brown); scale bar 
100µm. Inter-lobe comparison of F4/80 immunostaining at 48 hours post partial hepatectomy in each of 
two lobes per mouse following standard (d) or modified (e) partial hepatectomy, or modified partial 
hepatectomy with AIW implantation (f). Solid lines connect values from the same mouse. 
The effect of modified partial hepatectomy and AIW implantation on liver biochemistry 
Serum was also obtained at the 48-hour time point to allow assessment of biochemical markers 
related to hepatic injury and function. This aimed to assess whether a different degree of liver 
injury might occur in the different surgical groups. Although there was some increased 
variability in the mice receiving modified partial hepatectomy (with or without AIW 
implantation), the mean value for each parameter did not differ significantly between surgical 
groups (Figure 5 - 9). This supports the conclusion that the modified partial hepatectomy 
technique, either alone or in combination with AIW implantation, leads to a similar degree of 
liver injury when compared to standard partial hepatectomy. 
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Figure 5 - 9 The effect of modified partial hepatectomy and AIW implantation on liver 
biochemistry. 
Serum biochemistry (albumin, total bilirubin, ALP, ALT) at 48 hours following standard or modified partial 
hepatectomy, or modified partial hepatectomy with AIW implantation. Horizontal line indicates mean. 
The effect of modified partial hepatectomy and AIW implantation on seven-day liver 
and body weights 
In a second experiment comparing standard partial hepatectomy, modified partial 
hepatectomy, and modified partial hepatectomy with AIW implantation, mice were culled at 
seven days post surgery. This enabled calculation of liver to body weight ratio at the time 
point that marks the end of liver regeneration in the standard partial hepatectomy model. 
Although liver to body weight ratio did not differ significantly between surgical groups 
(Figure 5 - 10a), this ‘headline’ measure does not reflect certain underlying changes of interest. 
Seven-day liver weight was slightly, but significantly, decreased in mice receiving modified 
partial hepatectomy and AIW implantation in comparison to mice receiving standard partial 
hepatectomy (mean difference 198mg, 95% CI: 19 - 377mg) (Figure 5 - 10b). It is possible that 
the observed difference at seven days was due to a pre-existing difference in uninjured liver 
weight. However, given that mice were randomly allocated to surgical group, and neither 
body weight at time of surgery (Figure 5 - 10c) nor excised liver weight (Figure 5 - 4b) differed 
between surgical groups, there is no reason to suspect this. There was a slight decrease in 
seven-day liver weight in mice receiving modified partial hepatectomy compared to mice 
receiving standard partial hepatectomy, but this difference was non-significant (mean 
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difference 58mg, 95% CI: -11 - 228mg) (Figure 5 - 10b). No significant difference was observed 
when harvest liver weight in mice receiving modified partial hepatectomy was compared with 
mice receiving both modified partial hepatectomy and AIW implantation (mean difference 
141mg, 95% CI: -38 - 320mg). These findings suggest that the combination of modified partial 
hepatectomy and AIW implantation results in a slight retardation or inhibition of liver 
regeneration in mice. 
	
Figure 5 - 10 The effect of modified partial hepatectomy and AIW implantation on liver and body 
weights at seven days. 
Harvest liver to body weight ratio (a), harvest liver weight (b), mouse weight at surgery (c), and seven-
day weight change (d) for mice receiving standard or modified partial hepatectomy, or modified partial 
hepatectomy with AIW implantation. Horizontal line indicates mean. 
 
The apparent equivalence in seven-day liver to body weight ratio among surgical groups, 
despite the small differences in liver harvest weight, results from the finding that body weight 
at harvest also differed between the groups. Both the mice receiving modified partial 
hepatectomy alone and those receiving modified partial hepatectomy and AIW implantation 
showed increased and moderate weight loss compared to mice receiving standard partial 
hepatectomy (Figure 5 - 10d). Mice undergoing standard partial hepatectomy showed, on 
average, no weight change at seven days when compared to their pre-surgery weight. 
Modified partial hepatectomy resulted in mean weight loss of 1.7g (95% CI: 0.2-3.2g), 
equivalent to a 6% mean decrease from weight at time of surgery. Modified partial 
hepatectomy with AIW implantation resulted in mean weight loss of 2.9g (95% CI: 1.7-4.0g) 
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at seven days post surgery, equivalent to a 10% mean decrease from weight at time of surgery. 
Whilst this degree of weight loss may not impact significantly on the process of liver 
regeneration, it may serve as a surrogate indicator that the modified partial hepatectomy, with 
or without AIW implantation, is a slightly more invasive procedure and both increased 
monitoring of weight and additional husbandry measures to promote food intake and post-
surgical recovery may be indicated. 
Anaesthetic and peri-operative considerations associated with modified 
partial hepatectomy and AIW implantation 
As expected, the time required to perform partial hepatectomy and AIW insertion is roughly 
twice that needed for either procedure alone. Perhaps naively, this was not anticipated to be 
a significant issue, given that total surgical time would still only be around one hour, and 
anaesthetic and perioperative management protocols already incorporated measures to 
maintain body temperature, provide fluid support, and minimise the risk of hypoxia. Despite 
this, a number of adverse effects were seen in the first cohort of mice in which modified partial 
hepatectomy was performed, with or without AIW insertion. Specifically, 2/4 mice receiving 
modified partial hepatectomy with AIW implantation, and 1/2 mice receiving modified partial 
hepatectomy alone, manifested prolonged recovery from general anaesthesia, continued 
obtundation, and hindlimb paresis. These mice were therefore culled on welfare grounds. Post 
mortem examination revealed no evidence of surgical complications nor were these signs seen 
in mice receiving standard partial hepatectomy. Given this, and the fact that insertion of the 
AIW per se is minimally invasive and relatively atraumatic, it seemed likely that the adverse 
effects observed were most likely related to peri-operative factors, such as an issue with 
thermal support provided intra-operatively by the heat mat, and exacerbated by the increased 
surgical time and prolonged general anaesthesia. Figure 5 - 11 illustrates that surgical time, 
and as a result time under general anaesthesia, is slightly increased by performing the 
modified instead of standard partial hepatectomy; mean increase in time under anaesthesia 
versus standard partial hepatectomy was 9 minutes (95% CI: -2 – 21 minutes). Implantation of 
the AIW in addition to modified partial hepatectomy increased duration of general 
anaesthesia still further when compared to standard partial hepatectomy (mean increase 40 
minutes, 95% CI: 28-51 minutes). 
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Figure 5 - 11 The effect of modified partial hepatectomy and AIW implantation on surgical and 
anaesthesia time. 
Surgical time (a) and total time under general anaesthesia (b) for standard or modified partial 
hepatectomy, or modified partial hepatectomy with AIW implantation. Horizontal line indicates mean. 
 
Thereafter, a raft of further optimisations to the anaesthetic protocol and perioperative 
management were introduced. This included close titration of anaesthetic depth, additional 
administration of subcutaneous fluids at the start and end of the procedure, tighter control of 
thermal support until full recovery to minimise the risk of either overheating or hypothermia, 
and adjustments to limb immobilisation to reduce the risk of inadvertent neurological or 
vascular compromise. Following the introduction of these improvements, no further 
perioperative adverse effects of a similar nature were observed in any subsequent experiments 
involving partial hepatectomy and AIW implantation. 
It is important to note that the presence of the AIW itself can lead to adverse events. In 
the experiment in which livers were harvested seven days after partial hepatectomy, with or 
without AIW implantation, one mouse was culled after the AIW displaced during recovery. 
A second mouse was culled at 44 hours post surgery after becoming obtunded. Post mortem 
examination revealed that a section of jejunum had become entrapped between the liver lobe 
and the AIW, leading to intestinal obstruction. 
Optimising AIW design and imaging setup 
Previous AIW iterations 
In addition to developing a novel experimental model combining partial hepatectomy with 
AIW insertion, it was also necessary to redevelop both the AIW implant itself and the 
baseplate into which it sits, in order to optimise the quality of the images acquired during 
multiphoton microscopy. The design of the original AIW implant used by Ritsma et al.146 
(Figure 5 - 12a) had already been updated on two occasions, once to make the glass coverslip 
replaceable (by using a removable circlip rather than glue to anchor it in place) (Figure 5 - 
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12b), and subsequently to introduce a two-part design in which the glass coverslip is adhered 
to a circular titanium inlay which is then screwed into the body of the AIW (Figure 5 - 12c). 
Whilst this latter iteration facilitates coverslip replacement, and thereby helps maximise 
optical resolution, the complete range of the modifications introduced by the van Rheenen 
group in Utrecht also posed some additional challenges to obtaining high-quality multiphoton 
images. Principally, the coverslip now sits on top of the inlay, which screws into the upper 
surface of the AIW body; in contrast, in the previous iteration the coverslip was placed within 
the body of the AIW, facilitating contact with the liver surface. To maximise image quality 
and imaging depth during multiphoton microscopy, it is essential that the liver surface makes 
intimate contact with the coverslip; dead space is a potent foe for the photon! 
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Figure 5 - 12 AIW iterations. 
Design (a) and in situ photograph (b) of the original AIW. Adapted from Nature Protocols,146 ©2013, with 
permission from Macmillan Publishers Ltd. Design (c) and in situ photograph (d) of the first modification 
in AIW, with the coverslip held in place by a circlip. Graphical representation (e) and in situ photograph 
(f) of the third AIW iteration, with removable inlay to which the coverslip is adhered. Images in (e) used 
with permission of J. van Rheenen. All measurements in mm. 
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Modified AIW design 
Two new versions of the AIW were designed to suit better the specific requirements of 
intravital microscopy of the murine liver, with and without partial hepatectomy. These 
alterations are illustrated in the following figure and comprised three major modifications 
(Figure 5 - 13). The circumference of the external rim of the AIW was enlarged to enable four 
deeper notches (1.5mm versus 1.1mm) to be cut into the rim, improving the ability to 
immobilise the AIW when placed onto the imaging baseplate (Figure 5 - 13a,b blue arrows). 
The depth of the groove into which the purse string suture is placed was reduced from 1.3mm 
to 1.1mm, to reduce the overall depth of the AIW and facilitate contact between the liver and 
the coverslip (Figure 5 - 13a,b red rectangles). Thirdly, the inner wall of the AIW was slanted 
in an attempt to fit the natural contour of the liver, assisting its ability to enter into the inner 
aperture of the AIW and thus again bringing it closer to the coverslip (Figure 5 - 13a,b green 
ovals). The only difference between the two new versions was in the diameter of the internal 
aperture. One had a larger (8mm diameter) internal aperture to maximise the amount of liver 
available for imaging when the AIW was implanted, without partial hepatectomy, onto the 
large left lobe (Figure 5 - 13a). The second new version had a reduced (5.2mm diameter) 
internal aperture for use when the AIW was implanted onto the smaller left median lobe, 
following modified partial hepatectomy (Figure 5 - 13b). Having decided on the above 
modifications, prototypes were printed in plastic and suitability assessed on mouse cadavers 
prior to manufacture in titanium (Figure 5 - 13c). 
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Figure 5 - 13 Modified AIW design. 
Design of large aperture AIW (a) for standard implantation on left lobe and small aperture AIW (b) for 
implantation on left median lobe following partial hepatectomy. c) Plastic prototypes of the modified AIW 
design assessed in situ in a mouse cadaver. All length measurements in mm; ø, diameter. 
Imaging baseplate modification 
In order to accommodate the new AIW design, it was also necessary to re-design the baseplate 
into which the AIW sits to allow intravital microscopy to be performed. The original imaging 
baseplate had been manufactured to permit imaging of mammary tumours (Figure 5 - 14), so 
both the position of the imaging aperture and its simple, circular design were not optimised 
for the requirements of an AIW overlying the liver. 
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Figure 5 - 14 Imaging box including original baseplate. 
 
The accompany figure (Figure 5 - 15) shows the new baseplate design with an enlarged, central 
aperture to accommodate the AIW whilst also allowing the anaesthetised mouse to lie 
centrally within the heated imaging box. The addition of four nubbins, which interlock with 
the grooves of the AIW, facilitates stabilisation of the AIW and ensures identical orientation 
is maintained throughout repeated imaging sessions. 
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Figure 5 - 15 New imaging baseplate design. 
All length measurements in mm; ø, diameter. 
Further optimisations to the intravital imaging protocol 
In parallel to the improvements made to the design of the AIW and imaging baseplate, 
changes to other aspects of the intravital imaging protocol were necessary to obtain high-
quality, stable multiphoton images of the liver. Marked respiratory excursion is one reason 
why the liver may move during scan acquisition, even when the AIW is fitted correctly within 
the baseplate, and is easily recognised by its impact on the acquired image (Figure 5 - 16a). It 
was ascertained that this pattern of respiration was occurring due to mice being in a deep 
plane of anaesthesia. Previously, maintaining a deep plane of anaesthesia had been considered 
preferable, because it was thought that a lower respiratory rate would improve image quality. 
However, since there was no system for aligning image acquisition with the expiratory pause, 
whether a scan was completed during a period without respiratory excursion was entirely 
arbitrary. Conversely, during a light plane of anaesthesia, despite a relatively rapid 
respiratory rate (60-100 breaths per minute), the concomitant reduction in the degree of 
respiratory excursion meant that the liver was no longer displaced by respiration and 
therefore high-quality images could be acquired (Figure 5 - 16b). This required careful titration 
of anaesthetic depth, with isoflurane vaporiser settings routinely in the range 0.5-1%, despite 
the minimum alveolar anaesthetic concentration of isoflurane in the C57BL/6J reported to be 
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1.3%.217 Such an example illustrates how simple, practical refinements in experimental 
technique can benefit both the experimental animal and the quality of the data obtained. 
	
Figure 5 - 16 Respiratory movement can greatly affect image quality in intravital microscopy. 
a) Marked respiratory artefact during intravital multiphoton microscopy of Cdh5-Cre;Ai14 mouse liver 
(Ai14, red, LSECs). b) In the absence of excessive respiratory movement, images from intravital 
multiphoton microscopy, such as this image of Cdh5-Cre;mTmG liver, are indistinguishable from those 
obtained ex vivo (eGFP, green, LSECs; tdTomato, red, all cell membranes). Scale bar 50µm. 
Acetaminophen-induced liver injury in the context of intravital microscopy 
The effects of anaesthesia on experimental models frequently risk being neglected, with 
anaesthesia often viewed as a benign means to an end, rather than an integral part of any 
experimental study. The effects of general anaesthesia have already been observed in this 
body of work in relation to the extended surgical time required to combine modified partial 
hepatectomy with AIW implantation, and also in the quality of images obtained during 
intravital microscopy. A further example in which factors relating to anaesthesia may have 
altered the experimental model was observed when acetaminophen-induced liver injury was 
combined with AIW implantation and, crucially, subsequent intravital imaging. 
The standard protocol used to induce liver injury with acetaminophen (as described in 
Chapters II and III and recommended in the literature114) comprises administration of 
300mg/kg acetaminophen intra-peritoneally, following a 12-hour fast to deplete liver 
glutathione levels. The work of Alexandra Thompson validated that prior implantation of the 
AIW did not alter the degree of injury (serum ALT), centrilobular necrosis, or inflammatory 
response (neutrophil infiltration) observed in response to acetaminophen.214 However, when 
the same dose of acetaminophen was administered to mice with an implanted AIW at the end 
of baseline intravital imaging, which typically lasts 1-2 hours, we noted that the degree of 
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centrilobular injury appeared to be reduced, despite both the fast period and acetaminophen 
dose remaining unchanged. Measurement of serum ALT, albeit in a limited number of 
animals, also suggested that lower levels of injury than expected were occurring in most 
(Figure 5 - 17a). A number of possible explanations remained once issues with product, 
preparation or administration had been ruled out. Considered most likely was the possibility 
that pre-conditioning from the isoflurane anaesthetic, or other physiological response to 
prolonged anaesthesia, was causing the liver to become more resistant to the toxic effects of 
acetaminophen. 
Teasing apart the precise reason for the observed effects, although of personal interest 
and scientific merit, was considered beyond the scope of the current body of work. Instead, 
small, empirical adjustments were made to the injury protocol: the fast was extended to 16 
hours, the dose of acetaminophen administered was increased to 350mg/kg, and the saline 
volume in which the acetaminophen was administered was factored into the total peri-
anaesthetic fluid calculations. This resulted in a consistent and expected level of liver injury, 
evidenced by visible and quantifiable centrilobular necrosis during intravital imaging and on 
histology at 24 hours post-injury (Figure 5 - 17b-e). 
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Figure 5 - 17 Intravital microscopy affects acetaminophen-induced liver injury. 
a) The standard acetaminophen administration protocol (300mg/kg i.p. after 12-hour fast), leads to little 
or no liver injury in the majority of mice, as assessed by serum ALT. b) Administration of 350mg/kg 
acetaminophen after 16-hour fast leads to expected levels of hepatic necrosis in mice undergoing 
intravital imaging. c) Representative image, demonstrating acetaminophen-induced liver injury, following 
haematoxylin and eosin staining of liver harvested immediately after intravital microscopy at 24 hours 
post acetaminophen (higher dose). d,e) Appropriate hepatocyte injury is evident on intravital multiphoton 
microscopy at 24 hours after acetaminophen administration (higher dose) in Cdh5-Cre;mTmG mice 
(eGFP, green, LSECs; tdTomato, red, all cell membranes). APAP, acetaminophen. Scale bars 200µm 
(c), 50µm (d,e). 
Discussion 
The primary aim of this body of work was to develop the ability to visualise liver regeneration 
in vivo, at a cellular level, following partial hepatectomy in mice. The standard partial 
hepatectomy technique was successfully modified to facilitate AIW implantation. Not only 
was this combined procedure demonstrated to be technically feasible, but comparison with 
standard partial hepatectomy validated it as a viable model of liver regeneration. The amount 
of liver excised, and the degree of injury and percentage hepatocyte proliferation at 48 hours 
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post hepatectomy were not significantly different. Immunostaining of the HSC, Kupffer cell 
and neutrophil populations also did not reveal significant differences from a standard partial 
hepatectomy, although a small increase in Kupffer cell staining was noted when the AIW lobe 
was compared to a non-window lobe from the same mouse. Although liver to body weight 
ratio at seven days post hepatectomy was no different between groups, liver weight itself was, 
on average, 15% less in mice receiving modified partial hepatectomy with AIW implantation 
compared to standard partial hepatectomy, suggesting that the presence of the AIW may 
retard the return to baseline liver weight to some extent. As well as developing this new means 
through which to study liver regeneration in vivo, significant optimisations were made to 
facilitate the intravital imaging process itself. Both the AIW and imaging baseplate were 
redesigned to improve the quality of the multiphoton images that can be acquired. The 
surgical and imaging anaesthesia protocols were also improved, to the benefit of both 
experimental animal and data acquisition. Finally, further modifications were made to the 
second model of liver regeneration, acetaminophen-induced liver injury, to produce reliable 
injury following AIW implantation and intravital imaging. As such, two validated 
experimental models for the study of liver regeneration in vivo using multiphoton microscopy 
are now at the forefront of the toolkit available to the research community. They will enable 
us to further our understanding of this remarkable organ and hopefully to reveal new insights 
into the cellular processes and interactions that are necessary for successful liver regeneration 
to occur. 
The partiality of hepatectomy in mice 
It has previously been shown that removal of adequate liver mass is required to drive true 
liver regeneration, rather than merely inducing cellular hypertrophy.112 This likely explains 
why a marked reduction in hepatocyte proliferation was observed following a reduced partial 
hepatectomy, sparing the left median lobe for AIW implantation. The data from this 
experiment also confirmed the strong association between weight of excised liver and 
subsequent hepatocyte proliferation index at 48 hours post hepatectomy. Excision of at least 
0.5g of liver, or 2% of body weight, should be targeted in order to achieve a hepatocyte 
proliferation index of 15-20% at 48 hours. Weighing the excised liver at the time of partial 
hepatectomy should be mandatory, as it is both easy to do and offers an objective measure of 
the success of the procedure, potentially providing an explanation should insufficient 
regeneration subsequently be observed. 
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Having ruled out the option of simply sparing the left median lobe for AIW implantation, 
whilst excising the right median and left lobes as per a standard partial hepatectomy, the 
weights of each of the lobes in the C57BL/6J mouse were assessed in order to determine the 
most effective means of arriving at a degree of partial hepatectomy comparable to the 
standard procedure, whilst leaving an accessible lobe to facilitate placement of the AIW. The 
ideal lobe for AIW implantation is the left, for reasons of size, accessibility and distance from 
the motion artefact-inducing diaphragm. However, achieving an effective degree of 
hepatectomy without its excision is simply not feasible. Similarly, leaving the right median 
lobe would have challenging consequences, as it would necessitate excision of the relatively 
inaccessible cranial right lobe lying directly underneath it. Conversely, the caudal right lobe 
was confirmed to be approximately the same size as the left median lobe, enabling it to be 
substituted for the left median and thus become part of a modified partial hepatectomy 
procedure in which the right median, left and cranial right lobes are excised, leaving the left 
median lobe for AIW placement. 
These investigations into liver lobe weights in the C57BL/6J mouse also challenged the 
long-held assumption that the standard partial hepatectomy procedure (removing both 
median lobes and the left lobe) leads to excision of two-thirds of liver mass (or even 70% as is 
sometimes stated). Although the measured lobe weights generally matched those recorded in 
other studies,113,215 there were some small but important differences. In the study by Greene et 
al., the left median lobe contributed 15% of total liver weight in seven male C57BL/6J mice, in 
comparison to the figure of 10% reported above.215 This allowed the authors to conclude that 
68% hepatectomy could be achieved following a standard partial hepatectomy. Although 
from the same strain, the mice in that study were younger (7-8 weeks old) than those used 
here, both for assessment of liver lobe weight and for partial hepatectomy and AIW 
implantation (routinely males of 12-20 weeks). Hori et al. studied male mice from the 
C57BL/6NHsd strain.113 In these mice, assessed at 10-20 weeks of age, the relative 
contributions of the median and left lobes (21% right median, 12% left median, 32% left) more 
closely matched those reported here (20% right median, 10% left median, 34% left). As such, 
in this study too, the contribution to total liver weight (65%) from the entire weights of these 
three lobes did not quite reach the target value of 67%. 
Crucially, whilst the left lobe can, and should, be excised in its entirety by ligating at the 
hilus, it is not recommended to excise the two limbs of the median lobe in a similar fashion, 
for fear of causing stenosis of the suprahepatic vena cava.111 In the first report of partial 
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hepatectomy in mice (‘white mice of strain A’),11 65% hepatectomy was achieved through 
excision of the three lobes in their entirety. However, the number of adverse outcomes is not 
reported, and the authors did note focal necrosis and sinusoidal thrombi to be common, which 
suggests a degree of vascular compromise. If the recommendation of Mitchell and Willenbring 
is followed, the median lobe ligature(s) should be ‘no closer than 2mm from the suprahepatic 
vena cava’,111 and therefore the maximum achievable partial hepatectomy may be no more 
than 55-60%. This is supported by a review of rodent models of partial hepatectomies, in 
which the difference between rat and mouse livers are highlighted.118,218 Indeed, when partial 
hepatectomy was performed in cadavers, as described above, mean percentage hepatectomy 
was as low as 46%. Such a low figure is unlikely to arise purely from poor technique, given 
that the cadaveric nature of the surgeries meant that there were no additional challenges 
posed by respiratory movement, subconscious concerns about ligating lobes too proximally, 
or time pressure. 
It could be argued that, even if the base of the lobe is not completely excised, and 
therefore does not contribute to the recorded weight of excised tissue, the process of ligation, 
with the resulting tissue trauma and localised stagnation of blood flow, renders any remnant 
liver tissue non-functional. However, this has not been demonstrated conclusively and, 
anecdotally, enlargement of liver tissue immediately proximal to the location of the ligating 
suture is observed, in addition to regeneration in those lobes that are not excised. The 
differences in lobar weights and degree of achievable hepatectomy may also derive from the 
manner in which liver weights are measured. Some may weigh only the lobar parenchyma 
after each lobe has been dissected individually, whereas in this work the entire liver weight, 
including hilus, was always used as the denominator for the calculations of percentage 
hepatectomy. This was considered to be the truest measure of total liver mass, unaffected by 
differences in dissection technique. 
The overall goal of the ‘two-thirds’ partial hepatectomy model is to drive adequate liver 
regeneration for further study. As such, the precise amount of liver excised is of less 
importance than both the level of consistency within and across experiments, and the ability 
to drive an acceptable level of hepatocyte proliferation for further study. However, the 
possibility that the standard partial hepatectomy achieves less than the desired excision of 
two-thirds of liver mass, and the potential for variation between different strains or ages of 
mice, must be borne in mind, above all when attempting to compare findings when 
differences in surgical technique or strain are present. Recording and presenting the amount 
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of liver excised can act as a useful validation of any stated technique, particularly if whole 
liver and uninjured lobe weights from control mice are reported in conjunction. 
The modified partial hepatectomy facilitates AIW implantation 
Having proposed a modified technique which would be equivalent to standard partial 
hepatectomy, its practicality was first explored in a pilot experiment, which showed that 
sufficient liver (>2% body weight) could be excised in the majority of cases without obvious 
adverse effects. Cadaveric surgeries were then performed to confirm the exact sequence of 
modified partial hepatectomy with AIW implantation. Key features of this new procedure 
that should be emphasised are that it is easiest and quickest to excise the right median and left 
lobes via a mini-laparotomy excision, as for a standard partial hepatectomy, prior to extending 
the excision to excise the caudal right lobe. However, great care must be taken to keep the left 
median lobe moist and undamaged in preparation for later AIW implantation. 
Excising the caudal right lobe is made much more straightforward through the use of 
mini-Gelpi retractors to keep the abdominal incision open, facilitating visualisation and lobe 
manipulation. However, care must be taken with the position of the retractor tips in the body 
wall, and it is also necessary to ensure that the weight of the retractor itself does not restrict 
respiration. Visualisation and access to the caudal right lobe is enhanced further by 
performing a duodenal manoeuvre and carefully exteriorising the intestines to the left-hand 
side of the mouse. Careful draping should be in place to maintain asepsis and the intestines 
should be placed onto, and covered by, a moistened swab. 
Once the modified partial hepatectomy is complete, AIW implantation proceeds 
essentially as for a standard implantation. However, as well as paying particular attention to 
the placement of the purse string suture, and ensuring it is correctly seated within the groove 
of the AIW, it is usually necessary to close the caudal portion of the extended laparotomy 
incision separately. This is made easier by pre-placement of simple interrupted sutures in the 
muscle layer of the abdominal wall, prior to tightening of the purse string suture around the 
AIW. 
Validating modified partial hepatectomy and AIW implantation 
In the initial experiments in which the modified partial hepatectomy technique was combined 
with AIW implantation, several features were assessed to determine whether this novel 
procedure was broadly comparable to the standard partial hepatectomy model and therefore 
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provided an appropriate means through which to study the process of liver regeneration. 
Most importantly, the new technique was shown to drive appropriate levels of hepatocyte 
proliferation at 48 hours post surgery, as long as sufficient liver tissue is excised. More than 
0.5g of liver was excised in the majority of cases (8/13) in the first validation experiment. This 
rose to all cases in the second experiment, suggesting that experience improves the amount of 
liver tissue that can be excised, which should ensure that appropriate hepatocyte proliferation 
occurs. Proliferation index did not change significantly between AIW and non-AIW lobes in 
the same mouse, except in one case in which a failure of appropriate regeneration in the AIW 
lobe was accompanied by compensatory proliferation in the non-window lobe. This suggests 
that the presence of the AIW itself has minimal, if any, effect on hepatocyte proliferation. 
Immunostaining for HSCs, Kupffer cells and neutrophils suggested that no major 
changes in these populations occur following modified partial hepatectomy and AIW 
implantation. Partial hepatectomy is considered to be a relatively non-inflammatory model of 
liver regeneration, so it is reassuring that neither the slightly more invasive hepatectomy 
procedure nor the presence of the AIW triggers neutrophil infiltration. Immunostaining for 
Kupffer cells did reveal a slight increase in positive staining in the AIW lobe, when compared 
to a non-AIW lobe in the same mouse. A trend for difference between the same two lobes was 
also observed when modified partial hepatectomy was performed without AIW implantation. 
This suggests that the combination of increased handling and the presence of the AIW itself 
may promote a small increase (of <1% positive staining area) in number or size of Kupffer cells 
in the left median lobe. Such an increase is not particularly surprising, and its significance is 
uncertain. It could be explored further by, for example, flow cytometry phenotyping of 
Kupffer cells isolated from the AIW lobe compared with those isolated from a non-AIW lobe 
in the same mouse. 
Measuring percentage positive staining provides a relatively crude assessment of cell 
populations, although it does permit detection of both changes in number and size of cells in 
the population under consideration. For example, the lack of detectable change in HSC 
staining does not preclude changes in activation status. Furthermore, immunostaining was 
only performed on tissue obtained at 48 hours after hepatectomy and AIW implantation, so 
the potential for more chronic changes in these populations was not assessed. Additional 
immunostaining at later time points and for cell-specific phenotypic markers, or flow 
cytometric analysis, could be employed to examine these aspects in more detail. 
	 129	
Serum biochemical analysis also revealed no major differences between standard and 
modified partial hepatectomy, with or without AIW implantation. This suggests that the 
degree of injury is comparable across the different procedures. Some increased variation in 
the assessed liver enzymes (ALP and ALT) was observed in the modified partial hepatectomy 
with AIW group. This likely reflects the increased tissue handling and reduced experience 
with this procedure. It would be expected that the degree of variation would reduce with 
increasing familiarity with the new technique. 
The seven-day liver and body weights of mice receiving modified partial hepatectomy 
and AIW implantation revealed the greatest difference from standard partial hepatectomy of 
all the variables assessed, with both liver and body weights significantly decreased at this time 
point. A less pronounced effect was also observed with modified partial hepatectomy alone, 
suggesting that both the more invasive hepatectomy and the presence of the AIW contribute 
to the changes seen. The cause and relationship between these two findings is not entirely 
clear. It is possible that the more invasive nature of these procedures, and the longer duration 
of general anaesthesia, led to a catabolic state which was not sufficiently reversed in the post-
operative period. As well as manifesting as weight loss, this alone could delay the return to 
baseline liver weight. Something as simple as post-operative ileus, secondary to increased 
handling of the gastrointestinal tract, could be sufficient to drive reduced food intake and 
resultant weight loss. Alternatively, based on the difference in harvest liver weights between 
the three surgical groups, one might conclude that it is the presence of the AIW that makes 
the greatest contribution to the observed difference, rather than the type of partial 
hepatectomy performed. This may be an unavoidable consequence of the AIW implant being 
adhered to the left median lobe, acting as a physical barrier to expansion of this lobe following 
partial hepatectomy. Alternatively, the presence of the implant may simply reduce mobility 
and therefore food intake. Because it is not possible to measure both starting liver weight and 
seven-day liver weight in the same mouse, it is also possible that the observed difference in 
seven-day harvest weight could be due to an underlying difference in starting liver weight. 
However, this is unlikely given that mean body weight at the time of surgery did not differ 
between groups. At this stage, it does appear that mice receiving modified partial 
hepatectomy and AIW implantation do experience a retardation in the later stage of liver 
regeneration, despite having similar hepatocyte proliferation at 48 hours post hepatectomy. If 
this occurred secondary to increased weight loss, this may well reduce, or disappear, if the 
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weight loss can be prevented by increased experience with the procedure and better post-
operative management. 
Several caveats should be applied to the results obtained from the validation 
experiments. Although allocation to procedure and the order in which procedures were 
performed were both randomised, it was not possible to blind to the surgery, or at the time of 
tissue harvest and weight measurement. Blinding was in place for all histological assessments. 
Proliferation index and immunostaining were assessed in sections cut through the entire lobe 
of interest. Samples were not embedded in a specific orientation, so it is possible that changes 
occurring only at the surface of the lobe on which the AIW was implanted were missed or 
masked by an assessment which included liver tissue further from the implantation site. 
However, the left median lobe itself is quite small, therefore there are not large amounts of 
tissue distant to the AIW. Other than more narrowly defined fixation, embedding and 
sectioning protocols, the best way to detect changes occurring at the site of AIW implantation 
is through intravital imaging and ex vivo multiphoton microscopy of the liver lobe surfaces. 
Additionally, the data presented here were collected from early attempts at the new technique, 
so not only was standard partial hepatectomy compared to a modified version (with or 
without AIW implantation), but a routinely performed technique was being compared with a 
novel one. In light of this alone, it would not have been surprising if greater differences had 
been observed between the various procedures. The increased variability sometimes observed 
in the groups receiving modified partial hepatectomy may not be inherent to the procedure 
itself, but related more to relative inexperience with the technique, in contrast to the standard 
partial hepatectomy procedure. Indeed, it is highly likely that, as familiarity and technical 
expertise improve, more consistent injury and hepatocyte proliferation will occur in mice 
receiving modified partial hepatectomy and AIW implantation, with a reduction in post-
operative adverse effects, including weight loss. The key conclusion from the totality of the 
validation measurements is that liver injury and regeneration is definitely sufficient, using the 
modified hepatectomy technique, to permit study using intravital imaging via an AIW. 
Surmounting the challenges of modified partial hepatectomy with AIW 
implantation 
The development of a novel partial hepatectomy technique that permitted intravital injury 
posed a number of technical challenges, several of which have been enumerated already. 
Broadly, these can be considered to be peri-operative, post-operative, and related to the ability 
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to acquire high-quality microscopic images in an intravital setting. Many can be solved 
through close attention to the practicalities of the surgery and general anaesthesia. 
To date, over 100 AIW implantations (with and without partial hepatectomy) have been 
performed. As with standard partial hepatectomy, the main adverse effects which may be 
observed during the modified partial hepatectomy procedure are: iatrogenic pneumothorax 
during dissection of the falciform and hepatophrenic ligaments, stenosis of the suprahepatic 
vena cava secondary to overly proximal placement of the right median lobe ligature, and 
haemorrhage. All are avoided by good surgical technique. In addition, trauma to the left 
median lobe, during excision of the underlying left lobe and subsequent AIW implantation, 
can lead to vascular compromise, necrosis and a failure of regeneration. Careful handling is 
essential. The most serious, and somewhat unpredictable, adverse effect relating to AIW 
implantation is displacement of the implant itself from the body wall and purse string suture. 
When this has occurred, it has predominantly arisen during the recovery period, allowing the 
rapid humane killing of the affected animal. However, this does not obviate the need to make 
every effort to ensure that the purse string and body wall are appropriately situated within 
the groove of the AIW, and the suture tightened sufficiently to reduce the risk of displacement 
as far as possible. Once an AIW has been implanted, experimental animals should be carefully 
examined at least twice daily. Any suspicion that the AIW is starting to evert or displace from 
the retaining suture should be immediately acted upon, since unnoticed AIW displacement 
will result in evisceration of the abdominal contents. Failure of the liver to adhere to the entire 
circumference of the AIW allows the possibility of omental or intestinal encroachment. On the 
few occasions that this has occurred, it has usually been benign, at most hindering ongoing 
imaging. However, in the case of entrapment, this can result in intestinal obstruction, so this 
possibility should be considered should a mouse become obtunded, inappetent or show 
reduced faecal output. 
More minor, but more commonly noted, adverse effects associated with AIW 
implantation onto the liver include cavitation of the liver tissue within the aperture of the 
AIW, and the appearance of a biofilm on the liver surface. Neither appear to have any impact 
on animal welfare, but occurrence of either compromises successful intravital imaging. The 
cause of these superficial changes is not entirely clear, but likely relates to the presence of the 
AIW implant and glass coverslip. Measures aimed at minimising the incidence and degree of 
such changes include ensuring that the AIW is well-seated onto the liver surface, such that the 
liver almost protrudes up through the imaging aperture. This is facilitated by the bevelled 
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edges of the new AIW design. It is also recommended that the glass coverslips are coated with 
the biologically inert substance polyethylene glycol prior to use,146 since glass itself is known 
to be relatively reactive and can promote an inflammatory response. 
The longer period under general anaesthesia required to perform the modified partial 
hepatectomy procedure and AIW implantation initially resulted in severe adverse effects in a 
number of cases, necessitating humane killing of three experimental animals. However, the 
incidence of severe adverse effects attributable to general anaesthesia decreased to zero with 
the introduction of a number of small, practical changes, focused on maintaining physiological 
homeostasis as far as possible. Similarly, more careful titration of anaesthetic depth whilst 
performing intravital imaging led to a marked reduction in respiratory artefact in the acquired 
images, even without direct control of respiration through positive-pressure ventilation or the 
ability to link image acquisition to respiratory pattern. These examples illustrate how close 
attention to detail can make huge differences both to experimental animal welfare and, as a 
direct result, the data that can be acquired from such experiments. This was even the case in 
a setting where ideal peri-operative monitoring, including rectal temperature, oxygen 
saturation, heart and respiratory rate, was not available. The ability to monitor these 
additional parameters for the duration of anaesthesia would likely optimise consistency and 
animal welfare still further. Maintaining physiological homeostasis as far as possible also 
serves to minimise the potentially confounding effects of general anaesthesia. In the validation 
experiments comparing modified hepatectomy and AIW implantation with standard partial 
hepatectomy, the time under general anaesthesia was also significantly different between 
groups. Consideration was given to controlling for this by keeping the standard partial 
hepatectomy mice under anaesthesia and with their abdominal cavity open, to match the 
length of time required to perform the modified technique and AIW implantation. However, 
the goal of the validation experiments was to compare the novel technique with the standard 
procedure as it is usually performed. Adding an additional, fourth group (standard partial 
hepatectomy with extended anaesthesia) was considered, but deemed an unnecessary use of 
animals and resources. 
Anaesthesia may protect the liver from acetaminophen toxicity 
Repeated general anaesthesia may have resulted in a protective effect on acetaminophen-
induced liver injury. It might have been expected that clinical signs and liver injury would 
worsen when the standard acetaminophen administration protocol was combined with an 
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abdominal surgery and repeated general anaesthesia for imaging. Paradoxically, although a 
single episode of general anaesthesia for AIW implantation did not alter the degree of injury 
seen following acetaminophen administration, as shown in the validation experiments 
performed by Alexandra Thompson,214 the administration of acetaminophen at the end of a 
baseline imaging session led to reduced and inconsistent injury, as assessed by serum ALT 
and intravital imaging. More than one possible explanation may be posited. Reduced core 
body temperature, as is likely to be present at the end of 60-120 minutes of general anaesthesia, 
may alter the pharmacodynamics of acetaminophen absorption, delivery to the liver, and 
subsequent metabolism in such a way that minimises hepatocyte injury. Similarly, the 
provision of 100% oxygen in the period prior to acetaminophen administration might pre-
condition the liver to limit acetaminophen’s toxic effects. 
Alternatively, the volatile anaesthetic isoflurane may itself alter metabolic pathways 
within the liver to protect it from acetaminophen-induced injury. A possible interaction 
between isoflurane and acetaminophen does not appear to have been studied directly. 
However, almost thirty years ago, sub-anaesthetic concentrations of isoflurane were shown to 
have a protective effect on liver damage in rats when co-administered with carbon 
tetrachloride.219 Isoflurane has also been demonstrated to protect hepatocytes from hypoxia-
reperfusion injury in isolated, perfused rat liver.220 Acetaminophen is converted to its toxic 
metabolite NAPQI by the cytochrome P450 isoform CYP2E1.114 This same isoform has been 
shown to be responsible for a significant proportion of isoflurane metabolism in human 
liver,221 so it is possible that isoflurane competes with acetaminophen and limits the 
accumulation of toxic metabolites. Several studies have also shown that isoflurane induces 
hepatocyte expression of the hepato-protective enzyme heme oxygenase 1.222-224 Alternatively, 
an explanation for the reduction in ALT and visible liver injury may be revealed by studies on 
the range of effects that isoflurane can have on gene expression, including expression of drug-
metabolising enzymes.225-227 Of particular note, pathway analysis of genes upregulated by 
isoflurane anaesthesia, detected by microarray of rat liver, suggested a link to glutathione 
metabolism, the precise pathway responsible for detoxification of acetaminophen 
metabolites.227  
Whatever the underlying mechanism, the challenge posed by the decreased response to 
acetaminophen of mice receiving multiple episodes of isoflurane anaesthesia was the inability 
to achieve sufficient, repeatable levels of liver injury to allow subsequent study of the 
regenerative process. This was surmounted in the short term by increasing the length of fast 
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prior to acetaminophen administration and a small increase in the dose of acetaminophen 
administered. A similar effect has not been noted with partial hepatectomy and repeated 
intravital imaging, perhaps because in this model the injury occurs during the first general 
anaesthetic, at the time of AIW implantation. However, since the modified partial 
hepatectomy with AIW validation experiments were performed without subsequent imaging 
sessions, the possibility that these have an effect on the regenerative time course post 
hepatectomy should be borne in mind. 
The modification to the standard acetaminophen protocol can be viewed in the same light 
as the changes to partial hepatectomy that were made to permit AIW implantation. The aim 
of both these models is to cause liver injury and stimulate regeneration which can then be 
studied through an intravital approach. A level of fidelity to previous animal models is 
desirable so that any findings can be compared and validated, but exact recapitulation of the 
injury models in an intravital setting is unnecessary. The original animal models themselves 
only broadly replicate the clinical courses they are aimed at modelling, but they must not 
become so far removed as to lose all translational relevance. However, further exploration of 
the interesting phenomenon that repeated anaesthesia appears to protect from 
acetaminophen-induced liver injury should be considered, given the existing body of 
evidence showing protective effects in other forms of liver injury, and the tantalising 
possibility that a previously unknown and clinically employable hepato-protective 
mechanism may underlie the reduced injury response observed. 
Intelligent design 
Re-designing the AIW and baseplate in conjunction was undertaken with the aim of 
improving intravital image quality and the reliability with which useable images could be 
obtained. The primary goals were to minimise the distance between liver and coverslip, and 
assist with immobilisation of the AIW, and by extension the liver, during imaging. It was also 
necessary to produce an AIW with a smaller aperture, to fit onto the left median lobe following 
partial hepatectomy. 
The AIW improvements detailed above certainly assist in minimising the distance 
between liver and coverslip, although the narrower AIW groove and enlarged outer 
circumference do make seating the implant within the body wall more challenging. Also, the 
underlying principle of the current design, with the coverslip adherent to the upper surface 
of the removable inlay, whilst facilitating coverslip replacement, continues to make perfect 
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apposition of liver and coverslip challenging. The presence of dead space appears to 
encourage the formation of a biofilm, which limits the depth of imaging and can be 
challenging to remove. The ever-present coverslip, even when coated with polyethylene 
glycol, no doubt also alters the local environment of the liver lobe. No longer does it sit inside 
of the body wall, bathed in peritoneal fluid. Rather, it is separated from the ambient 
temperature of the outside world by 170µm of glass. The medium- and long-term effects on 
cellular health and function remain uncertain. To minimise any such adverse effects, 
consideration could be given to a more protected design. For example, a more insulated seal 
could be screwed into the implant, in place of the removable inlay, with a fresh inlay and 
coverslip substituted for each imaging session. 
Alongside the improvements in AIW design, the imaging baseplate modifications have 
improved image acquisition by reducing respiratory-related movement of the AIW. The new, 
central location of the imaging aperture also allows the mouse to be placed in a more 
comfortable, neutral position. However, the present design of the AIW recess, although 
preventing movement in two planes, does not immobilise the AIW completely, so a degree of 
movement in the z plane can sometimes occur. Ideally, a baseplate would be designed to allow 
simple yet total immobilisation of the AIW during imaging. Others have attempted to achieve 
this with quite complex, interlocking designs, the downsides of which are the time and skill 
required to fix them in place, along with the inability to rapidly release the AIW should this 
be required for reasons of mouse welfare.147 One elegant approach would be to incorporate an 
electromagnet into the plate design, which could allow instant immobilisation of the AIW. 
However, this would also require that the AIW was manufactured from a more strongly 
ferromagnetic metal, as opposed to the current titanium. 
Summary 
This chapter describes how the traditional standard partial hepatectomy technique was 
successfully modified to permit AIW implantation. Thus, it is now possible to image liver 
regeneration following partial hepatectomy with cellular resolution, in vivo, at multiple time 
points during the regenerative process. A number of readouts were assessed to demonstrate 
that this new procedure does indeed cause an appropriate level of injury and drive subsequent 
hepatocyte proliferation in a comparable fashion to that which occurs in the standard partial 
hepatectomy model. However, a retardation of the return to normal liver weight was observed 
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at seven days. Although this difference from the standard model may reduce as experience 
with the new procedure increases, it should be borne in mind when studying the later phase 
of liver regeneration. In addition to developing a new model of liver regeneration for 
compatibility with intravital imaging, multiple optimisations were made to the design of the 
AIW itself, the imaging baseplate, and the procedural elements relating to implantation and 
subsequent imaging. This led to improvements in both image quality and experimental 
animal welfare. The developments described in this chapter lay the groundwork for novel 
insights into the cellular processes underpinning liver regeneration following partial 
hepatectomy or acetaminophen-induced liver injury in mice. The following chapter describes 
how fluorescent reporter mice, exogenous labelling techniques, and label-free imaging using 
multiphoton microscopy, can be combined with these injury models to study liver 
vasculature, sinusoidal blood flow, lipid deposition, non-parenchymal cell populations, and 
the regenerating hepatocyte. Thus, it is possible to study the dynamic changes that occur in 
vivo, in the same experimental animal, during the time course of liver regeneration. 
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Chapter 6 – Intravital microscopy of the regenerating 
liver 
Introduction 
The combination of implantation of an AIW onto the surface of the liver with multiphoton 
microscopy provides a powerful tool with which to study cellular physiology in the liver, both 
during normal homeostasis and following injury. The previous chapter described the 
development and validation of a murine model to permit intravital microscopy of liver 
regeneration following partial hepatectomy. The implantation of the AIW at the time of injury 
subsequently allows multiple imaging sessions to be performed, such that the time course of 
regeneration can be tracked in the same experimental animal. The ability to perform partial 
hepatectomy and AIW implantation complements the AIW insertion and acetaminophen-
induced liver injury model previously developed and validated by colleagues within the 
Henderson group.214 Thus, in addition to using AIW implantation alone to study the uninjured 
murine liver, these two novel injury and imaging models (outlined schematically in Figure 6 
- 1) provide enormous opportunity to study many aspects of the cellular and physiological 
response to liver injury, and improve our understanding of the hepatocyte proliferation and 
liver regeneration that follow. 
Implantation of the AIW renders intravital multiphoton microscopy technically feasible, 
by bringing the liver into contact with a glass coverslip through which light can pass 
unhindered whilst the abdominal cavity remains sealed. However, as well as the ability to 
deliver photons directly into the liver tissue, consideration must be given to the readouts that 
can be obtained using this technique. A key benefit from performing multiphoton microscopy 
in the mouse is the wide range of options through which to label fluorescently those cells 
comprising, or entering into, the liver. As outlined in Chapter One, this can be achieved 
through transgenic approaches, targeting fluorophore expression to one or more cell types of 
interest. One common approach is to harness the Cre-lox system, to switch on expression of a 
fluorescent reporter protein in the cell type of interest. The flexibility of this system means that 
different ‘Cre driver’ alleles, expressing Cre recombinase under the control of a cell type-
specific promoter, can be combined with any one of a range of fluorescent reporter alleles. 
Expression of Cre recombinase in the cell type of interest leads to a recombination event which 
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results in ongoing expression of the fluorescent protein in both the cells in which 
recombination occurs and any daughter cells. 
An alternative transgenic labelling approach is to link the fluorescent reporter protein 
directly to a cell type-specific promoter, using a promoter sequence for a gene that is primarily 
or exclusively expressed in the cell of interest. Whenever this gene is expressed, the ‘knock-
in’ fluorescent reporter gene is also transcribed. These differing transgenic labelling 
approaches can be combined, through use of different reporter proteins, to result in labelling 
of more than one cell type in the same experimental animal. Furthermore, fluorophores 
conjugated to antibodies, or specific dyes (such as those binding DNA), can be administered 
topically or systemically to label cells or structures of interest. Readouts from fluorescent 
labelling can also be combined with the previously introduced ‘label-free’ techniques, such as 
SHG and CARS. Importantly, it is often possible to acquire multiple readouts simultaneously 
or in rapid succession, which is a clear advantage in an intravital context. The transgenic 
toolkit currently available to our research group to permit imaging of the multiple facets of 
liver regeneration is summarised in Table 6 - 1. 
Overall, the opportunities afforded by intravital multiphoton microscopy are vast and 
constantly evolving, in relation to the cells, structures and processes which can be imaged. 
This chapter attempts to demonstrate the breadth of opportunity this technique offers to the 
study of liver regeneration, with examples of the types of images that can be obtained and the 
quantitative analysis that may be performed. 
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Figure 6 - 1 Experimental models for intravital imaging of liver injury and regeneration. 
Model 1 (upper): the AIW is implanted two days before acetaminophen-induced liver injury. Intravital 
imaging is performed immediately prior to acetaminophen administration and then may be repeated, at 
intervals, until seven days post injury. i.p., intra-peritoneal. Model 2 (lower): Partial hepatectomy and AIW 
implantation are performed at the same surgery. Intravital imaging of regeneration may be performed 
repeatedly from 24 hours to seven days post injury. 
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Table 6 - 1 A transgenic toolkit for intravital multiphoton microscopy of liver injury and 
regeneration 
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Results 
Intravital microscopy of Fucci transgenic mice permits visualisation of the 
hepatic regenerative niche 
The Fucci reporter mouse 
Fluorescent labelling of specific cell populations is widely used to facilitate visualisation and 
map cell fate. However, in order to study liver regeneration, and specifically the hepatocyte 
proliferation that underpins it, the ability to identify cycling cells is essential. Ex vivo studies 
have suggested a zonal pattern to the hepatic regenerative response,180 but the precise 
combination of local factors that combine to drive proliferation in any particular hepatocyte 
has yet to be fully elucidated. The concept of the hepatic regenerative niche, a localised region 
within the lobular anatomy of the liver, is an attractive one, since it might allow identification 
and characterisation of a subset of hepatocytes predisposed to proliferate in response to liver 
injury. Equally plausible is the possibility that all hepatocytes are created equal and it is 
changes in the cellular environment, be that from secreted factors, variations in sinusoidal 
blood flow, altered extracellular matrix stiffness, or interaction with non-parenchymal or 
inflammatory cells, that drive the hepatocyte to begin cycling. 
The ability to assess cell cycle stage in hepatocytes, in vivo, would assist greatly with 
attempts to understand the local factors driving hepatocyte proliferation. We therefore 
obtained an R26Fucci2aR (Fucci) reporter mouse that was recently generated by colleagues at 
the University of Edinburgh.164 Following Cre-mediated recombination, nuclear accumulation 
of the mCherry fluorescent reporter protein occurs whilst the cell is in the G1 stage of the cell 
cycle. This transitions to predomination of the mVenus fluorescent reporter protein as the cell 
enters S-phase, and persists through G2 and M phases, disappearing immediately prior to 
cytokinesis. The G1/S transition is identified by co-localisation of both proteins within the 
same nucleus (Figure 6 - 2a). 
An initial attempt to drive reporter expression, by generating mice carrying both the 
hepatocyte-targeting Alb-Cre and R26Fucci2aR alleles, did not lead to widespread labelling of 
nuclei (data not shown). However, excellent nuclear labelling was seen in the liver following 
a breeding strategy which led to constitutive, germline expression of the Fucci2a construct 
(Figure 6 - 2b). Briefly, mice carrying the R26Fucci2aR allele were interbred with mice carrying 
the CAG-Cre allele. This germline Cre drives recombination at the zygote stage, with a 
permanent, heritable excision of the floxed STOP codon which would previously have 
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prevented reporter protein expression. As such, subsequent generations continue to express 
the Fucci2a proteins constitutively without the requirement for further Cre-mediated 
recombination. 
	
Figure 6 - 2 The Fucci reporter mouse allows fluorescent labelling of cycling hepatocytes in vivo. 
a) Schematic showing the R26Fucci2aR construct and how nuclear labelling changes through the cell 
cycle. Reprinted from Cell Cycle,232 ©2015, with permission from Taylor & Francis. b) Constitutive 
expression of the Fucci2a construct results in widespread labelling of hepatocyte nuclei with mCherry 
(red, G1) and/or mVenus (green, S/G2/M). The image shown is a three-dimensional reconstruction of a 
z-stack obtained by multiphoton microscopy of freshly harvested, whole liver from a CAG-Cre;Fucci 
mouse, 48 hours after acetaminophen administration. Scale bar 50µm. 
Intravital visualisation of the cell cycle following partial hepatectomy 
Partial hepatectomy and AIW implantation were performed in mice carrying the recombined 
R26Fucci2aR allele. Intravital microscopy was performed at 24, 48 and 72 hours post partial 
hepatectomy, with imaging at 96 hours performed on liver in a dish immediately after culling. 
This revealed the expected peak in hepatocyte cycling around 48 hours, with a gradual 
decrease in the number of mVenus-positive nuclei thereafter (Figure 6 - 3). 
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Figure 6 - 3 The Fucci reporter allele allows repeated assessment of hepatocyte cell cycle state 
using intravital imaging following partial hepatectomy. 
Intravital multiphoton microscopy of the same CAG-Cre;Fucci mouse at 24, 48 and 72 hours following 
partial hepatectomy, and of freshly harvested, whole liver at 96 hours, demonstrates the peak in cycling 
hepatocytes that occurs around 48 hours after partial hepatectomy. mCherry, red (G1); mVenus, green 
(S/G2/M). Scale bar 100µm. 
 
This study marked the first occasion on which hepatocytes were directly observed undergoing 
proliferation during liver regeneration, repeatedly, in the same mouse. Although an important 
step forward, the Fucci reporter alone provides limited information, since fluorescent labelling 
is restricted to the nucleus. Some morphological information can be gleaned through 
acquisition of the CARS signal (Figure 6 - 4a). However, the depth penetration for CARS is 
generally lower than that for detection of fluorescent reporters. Furthermore, the increase in 
hepatocyte lipid in the immediate aftermath of partial hepatectomy results in such a strong 
CARS signal that it is challenging to obtain good morphological detail as well (Figure 6 - 4b). 
Further, the design of the multiphoton microscope used for this work necessitated the manual 
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substitution of mirrors and re-tuning of the pump laser between Fucci and CARS acquisition. 
Therefore, Fucci reporter mice were interbred with mice carrying the Cdh5-Cre and mTmG 
alleles. This produced a triple transgenic mouse with the Fucci cell cycle label, fluorescent 
labelling of all cell membranes (membrane-targeted tdTomato), and the option to induce 
membrane-targeted eGFP labelling of LSECs through prior administration of tamoxifen 
(Figure 6 - 4c,d). 
	
Figure 6 - 4 Combining the Fucci cell cycle label with visualisation of hepatic morphology. 
a) The CARS signal allows visualisation of hepatocyte and sinusoidal morphology in combination with 
nuclear cell cycle label (CARS, grey; Fucci-mCherry, red). However, following partial hepatectomy (b), 
the CARS signal becomes dominated by the accumulation of hepatocyte lipid (orange arrows). Images 
obtained from freshly harvested, whole liver, either uninjured (a) or 96 hours post partial hepatectomy 
(b). (c) Combining Fucci and mTmG alleles allows concurrent visualisation of hepatocyte cell cycle stage 
(mCherry, red, G1, white arrow; mVenus, green, S/G2/M, blue arrow) and hepatocyte morphology 
(tdTomato, red, all cell membranes). Intravital multiphoton microscopy at 48 hours after acetaminophen. 
d) Tamoxifen administration in the Fucci;Cdh5-Cre;mTmG mouse leads to cellular and nuclear labelling 
as described in (c), with additional labelling of LSECs (membranous eGFP, green, white arrows). 
Intravital multiphoton microscopy of uninjured liver. Scale bars 100µm (a,b,d) or 50µm (c). 
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Intravital imaging of the hepatic regenerative niche following acetaminophen-induced 
liver injury 
The combination of the mTmG and Fucci alleles is particularly useful for intravital microscopy 
following acetaminophen administration, since labelling of the hepatocyte cell membrane 
makes it much easier to identify areas of centrilobular injury and relate these to cycling 
hepatocytes (Figure 6 - 5). As predicted, and previously observed in BrdU 
immunohistochemistry of liver, the mVenus-positive, cycling hepatocytes appear to cluster 
on the periphery of the injured zone. 
	
Figure 6 - 5 The Fucci;mTmG reporter mouse allows intravital imaging of hepatocyte injury and 
cell cycle state following acetaminophen-induced liver injury. 
Co-expression of fluorescent nuclear cell cycle (mCherry, red, G1; mVenus, green, S/G2/M) and cell 
membrane (tdTomato, red) labels facilitates visualisation of centrilobular injury (white asterisk) with 
surrounding hepatocyte proliferation (white arrows). Image obtained by intravital multiphoton microscopy 
at 48 hours after acetaminophen. Scale bar 100µm. 
Visualising hepatocyte division in vivo 
The concentration of cycling hepatocytes around the centrilobular injury in acetaminophen-
induced liver injury lent themselves to an attempt to visualise hepatocyte division in vivo. 
The University of Edinburgh local regulations for imaging of experimental animals permit a 
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maximum of six hours of imaging under terminal anaesthesia. As such, AIW implantation 
was performed and followed by baseline intravital imaging and administration of 
acetaminophen. A mouse with good quality baseline images was then anaesthetised at 42 
hours post acetaminophen to allow imaging to be performed around the time of peak 
hepatocyte proliferation. An area containing several mVenus-positive nuclei was selected and 
short stacks through this area were obtained every 10 minutes (Figure 6 - 6). 
	
Figure 6 - 6 Timelapse intravital imaging of injured liver tissue with actively cycling hepatocytes. 
Intravital multiphoton microscopy in a Fucci;mTmG mouse, beginning at 42 hours after administration of 
acetaminophen. Z-stacks of a 200x200x28µm volume were obtained every 10 minutes. This 
representative three-dimensional projection shows a swathe of injured hepatocytes with loss of the 
membrane tdTomato signal (red). Prominent, actively cycling hepatocyte nuclei (mVenus, green, 
S/G2/M) surround this. mCherry (red) nuclei indicate cells in G1. Scale bar 30µm. 
 
On the image series obtained, it is clearly possible to see the imaged hepatocytes progressing 
through the cell cycle (Figure 6 - 7). Initially, specks of mVenus fluorescence start to appear in 
an otherwise mCherry-dominated nucleus (Figure 6 - 7, 0 minutes). The amount of mVenus 
gradually increases, with a concomitant reduction in the mCherry signal (Figure 6 - 7, 30-100 
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minutes). Within three hours only mVenus is visible within the nucleus (Figure 6 - 7, 160 
minutes). Consistently, it was also noted that hepatocytes containing mVenus-positive nuclei 
progressed to a stage in which speckled mVenus fluorescence was visible throughout the cell 
cytoplasm (Figure 6 - 8, 70 minutes). This likely fits with breakdown of the nuclear membrane 
in preparation for cytokinesis. However, although this is a feature which could be useful to 
identify cells close to cytokinesis, it also results in the loss of the fluorescent signal, hampering 
further visualisation (Figure 6 - 8, 100 minutes). 
	
Figure 6 - 7 Intravital imaging of cycling hepatocytes following acetaminophen-induced liver 
injury. 
Selected time points (number indicates time in minutes from the start of the series) from images obtained 
by intravital multiphoton microscopy in a Fucci;mTmG mouse, 42 hours after acetaminophen 
administration. White circles identify the same hepatocyte progressing through the cell cycle. Nuclear 
labels comprise mCherry (red, G1) and/or mVenus (green, S/G2/M); cell membranes are labelled by 
TdTomato (red). Scale bar 10µm. 
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Figure 6 - 8 Disappearance of the Fucci nuclear label towards completion of the cell cycle. 
Selected time points (number indicates time in minutes from the start of the series) from images obtained 
by intravital multiphoton microscopy in a Fucci;mTmG mouse, 42 hours after acetaminophen 
administration. White circle identifies a binucleate hepatocyte progressing through the cell cycle. The 
mVenus nuclear signal fades before dispersing throughout the cytoplasm and subsequently 
disappearing. The white arrow highlights a linear structure, fluorescing in the red channel, which could 
be consistent with the early formation of cell membrane as the cell prepares to divide. Nuclear labels 
comprise mCherry (red, G1) and/or mVenus (green, S/G2/M); cell membranes are labelled by TdTomato 
(red). Scale bar 20µm. 
 
To attempt to address the loss of the nuclear signal at the point of cytokinesis and cell division, 
the experimental protocol outlined above was repeated with the addition of a further nuclear 
label, the nucleic acid stain Hoechst, administered at the start of the terminal imaging session. 
This was effective in co-labelling both mCherry- and mVenus-positive hepatocytes (Figure 6 
- 9). The Hoechst signal did remain detectable after progression of mVenus-positive nuclei to 
the point of dispersion of the fluorescent reporter protein into the cytoplasm (Figure 6 - 9, 150 
minutes). Unfortunately, over the time course of imaging in this experiment, no hepatocyte 
was observed to progress beyond this stage, so it is unknown whether the Hoechst signal will 
remain detectable throughout cytokinesis. 
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Figure 6 - 9 Combining the Fucci cell cycle reporter with the nucleic acid dye Hoechst. 
Selected time points (number indicates time in minutes from the start of the series) from images obtained 
by intravital multiphoton microscopy in a Fucci;mTmG mouse, 41 hours after acetaminophen 
administration. mVenus-positive nuclei are visible in a binucleate hepatocyte. The Hoechst label remains 
detectable even after the mVenus signal fades. Nuclear labels comprise Hoechst (blue), mCherry (red, 
G1) and/or mVenus (green, S/G2/M); cell membranes are labelled by TdTomato (red). Scale bar 10µm. 
Imaging the sinusoidal vasculature following partial hepatectomy 
Using the Cdh5-Cre to label LSECs 
Imaging of the sinusoidal vasculature was achieved by using the inducible Cdh5-Cre to drive 
fluorescent reporter expression in LSECs, either eGFP (in mice carrying the mTmG allele) or 
Ai14. Each fluorescent reporter offers its own potential advantages. The use of the mTmG 
allele maintains constitutive express of membranous tdTomato in all other cell types, and 
therefore offers the benefit of being able to visualise hepatocyte morphology in addition to 
LSECs (Figure 6 - 10). Conversely, the cytosolic expression of the Ai14 reporter protein gives 
strong and extremely well-defined reporting of the LSEC (Figure 6 - 11). The Ai14 reporter 
can also be combined easily with additional labelling strategies, such as the PBAG constitutive 
reporter allele utilised to label HSCs (see below). 
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Figure 6 - 10 Labelling the sinusoidal vasculature using the Cdh5-Cre;mTmG mouse. 
Following tamoxifen administration, widespread membranous eGFP expression (green) is visible in 
LSECs, allowing three-dimensional reconstruction of the sinusoidal vasculature (a). Images obtained by 
intravital multiphoton microscopy. In addition to eGFP labelling of LSECs (b), constitutive expression of 




Figure 6 - 11 Labelling the sinusoidal vasculature using the Cdh5-Cre;Ai14 mouse. 
Following tamoxifen administration, widespread cytosolic Ai14 expression (red) is visible in LSECs (a), 
allowing three-dimensional reconstruction of the sinusoidal vasculature. Images obtained by intravital 
multiphoton microscopy. Scale bars 50µm. 
Reconstruction and analysis of the sinusoidal vasculature network 
During initial optimisation of multiphoton microscopy of the Cdh5-Cre;Ai14 mouse, partial 
hepatectomy was performed and livers harvested at 24, 48 and 72 hours for imaging. Image 
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review suggested that the vascular network might become less dense between 48 and 72 hours 
post partial hepatectomy (Figure 6 - 12). This would be consistent with hepatocyte expansion, 
either in size or number, prior to a later wave of LSEC proliferation. However, this was purely 
a subjective interpretation with one mouse per time point. Therefore, in a subsequent 
experiment, AIW implantation, with or without partial hepatectomy, was performed in Cdh5-
Cre;Ai14 mice, with intravital imaging at 24, 48 and 72 hours post partial hepatectomy. Livers 
were also imaged in a dish immediately after harvest at 96 hours. 
	
Figure 6 - 12 Multiphoton microscopy of freshly harvested, whole liver from Cdh5-Cre;Ai14 mice 
following partial hepatectomy. 
Three-dimensional projection of the sinusoidal vasculature at 48 (left) and 72 (right) hours following 
partial hepatectomy. Scale bar 50µm. 
 
	
Figure 6 - 13 Intravital imaging of Cdh5-Cre;Ai14 mice allows three-dimensional reconstruction 
of the sinusoidal vasculature. 
a) Representative z-stack projection obtained at 24 hours after AIW implantation. b) Three-dimensional 
surface reconstruction of the image shown in (a). Scale bar 50µm. 
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Post-imaging reconstruction of the sinusoidal vasculature in three dimensions from z-stacks 
obtained by intravital microscopy is feasible in Cdh5-Cre;Ai14 mice (Figure 6 - 13). This was 
achieved using Imaris software, as detailed in Chapter Two. However, few useful metrics are 
currently obtainable following such reconstruction, namely the surface area and volume of 
the reconstructed structure. This failed to demonstrate any marked difference between mice 
in which partial hepatectomy had been performed and AIW-only controls (Figure 6 - 14). It is 
possible that increased numbers would detect a significant reduction in the mean percentage 
vascular volume or vascular surface area in the early post-partial hepatectomy phase; 
however, calculation of additional metrics would also be more informative. What the current 
data does demonstrate is the repeatability of the measurement between imaging sessions in 
control mice. The relatively low value obtained for mouse 80 at 48 hours may be due to the 
fact that 13% (by volume) of the reconstructed z-stack at this time point did not contain liver 
tissue. An attempt was made to reflect this (by adjusting the measured values for the actual 
volume of liver contained within the image), however, this may still have led to a falsely low 
value at this time point. The drop in calculated vascular volumes at 96 hours, the time point 
at which multiphoton microscopy was performed on excised liver in a dish, illustrates the 
benefit and importance of intravital image acquisition in comparison to ex vivo analysis. It 
also suggests that this type of vascular reconstruction and volume analysis could be used as a 
surrogate indicator of sinusoidal perfusion. 
	
Figure 6 - 14 Intravital imaging of Cdh5-Cre;Ai14 mice allows sequential analysis of the sinusoidal 
vascular network following partial hepatectomy. 
Sinusoidal vasculature surface area (a) and volume (b) in uninjured (blue) and post partial hepatectomy 
(orange) mice calculated from images obtained during intravital multiphoton microscopy. Analysable 
images were not obtained at all time points for all mice. Images at the 96-hour time point were obtained 
immediately following harvest. Values obtained for mouse 80 at 48 hours were divided by 0.87 to account 
for the absence of liver tissue in 13% of the z-stack volume. 
 
An alternative tool for vascular network analysis has been described, called Angiotool.169 
This identifies vessels within an image and computes a range of parameters, including the 
area occupied, number of junctions, branching index, vessel length and lacunarity. 
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Unfortunately, the analysis is currently only possible on two-dimensional images. Therefore, 
maximal intensity projections of the three central slices (4µm total depth) from the z-stacks 
used for the three-dimensional analysis described above were produced. Following 
optimisation of the detection parameters, the tool appeared able to identify accurately the 
sinusoidal vascular network (Figure 6 - 15a,b) Analysis of vascular area gave similar results 
to the vascular volumes previously calculated with the three-dimensional analysis (Figure 6 - 
15c). Both total vessel length and the total number of junctions per image appeared to be 
consistently lower in mice that underwent partial hepatectomy when compared to control 
mice (Figure 6 - 15d,e). This would fit with a relative reduction in the number of sinusoids 
contained within the imaging area, which may occur as a result of proliferation peaking earlier 
in hepatocytes than in LSECs. However, increased sample sizes are necessary to confirm this. 
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Figure 6 - 15 Two-dimensional analysis using Angiotool of the sinusoidal vascular network 
following partial hepatectomy. 
Maximal intensity projections (a) were produced from three sequential slices (4µm depth) and analysed 
in Angiotool.169 The software detects both vasculature (yellow outline) and branch points (blue dots) (b). 
This was used to calculate vessel density (c), total vessel length (d), and junction number (e) following 
intravital multiphoton microscopy in uninjured (blue) and post-partial hepatectomy (orange) mice. 
Analysable images were not obtained at all time points for all mice. Images at the 96-hour time point 
were obtained immediately following harvest. Vessel length and junction number values obtained for 
mouse 80 at 48 hours were divided by 0.84 to account for the absence of liver tissue in 16% of the image 
area. Scale bar 100µm. 
Use of the confetti reporter can facilitate the study of angiogenesis following injury 
The inducible nature of the Cdh5-Cre driver provides the opportunity for it to be employed in 
fate-mapping studies. Typically, tamoxifen is administered to induce Cre-mediated 
recombination over a defined time period prior to the induction of injury or, in developmental 
models, the time point of interest. The location of labelled cells and any change in labelled 
fraction can be used to test a hypothesis that the labelled population expand or migrate. 
In the partial hepatectomy model of liver regeneration, it is known that sinusoidal 
angiogenesis occurs after the majority of hepatocytes have proliferated.180 However, the exact 
mechanism through which the sinusoidal architecture is restored following injury remains 
unclear. Do sinusoids simply elongate to accommodate the division of hepatocytes in the 
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remnant lobe? Or does sprouting occur to create new sinusoids and in this manner maintain 
hepatocyte-sinusoidal contact? In either case, do all LSECs have equal proliferative potential 
or are a limited number of specialised LSECs (potentially in defined anatomic locations) 
responsible for the vascular proliferation that occurs as a necessary part of liver regeneration? 
Although recombination can be induced in Cdh5-Cre;Ai14 or Cdh5-Cre;mTmG mice to 
study hepatic sinusoidal structure as described above, they are unable to detect expansion of 
a subpopulation of LSECs. However, the Confetti reporter has previously been used to 
examine clonal expansion of progenitor cells in the liver.229 This is a multi-colour reporter 
allele in which Cre-mediated recombination leads to permanent, heritable expression of one 
of four fluorescent proteins in a stochastic manner. Therefore, mice carrying either the Cdh5-
Cre or Confetti allele were interbred to generate the Cdh5-Cre;Confetti line. 
	
Figure 6 - 16 Multi-colour fluorophore expression in the vasculature of the Cdh5-Cre;Confetti 
mouse. 
Tamoxifen administration leads to widespread recombination in the vasculature of liver (a), heart (b), 
lung (c), and kidney (d). Stochastic expression of either mCerulean, yellow, red or green fluorescent 
protein occurs in each endothelial cell in which recombination occurs. Three-dimensional projections of 




Administration of tamoxifen to Cdh5-Cre;Confetti mice according to the standard schedule 
revealed widespread labelling of the LSEC population (Figure 6 - 16). Approximately equal 
numbers of LSECs expressed the mCerulean, yellow or red fluorescent proteins, with less 
frequent expression of GFP. Similar findings were also observed in the vasculature of heart, 
lung and kidney (Figure 6 - 16). As expected, a reduced tamoxifen dosing schedule resulted 
in decreased recombination (Figure 6 - 17). This sparse labelling is ideally suited to detect 
clonal expansion of a subset of LSECs during angiogenesis after liver injury. Hence, the Cdh5-
Cre;Confetti mouse is a useful tool with which to study the mechanics of sinusoidal 
regeneration following liver injury. 
	
Figure 6 - 17 Tamoxifen dose reduction decreases the number of labelled LSECs in the livers of 
Cdh5-Cre;Confetti mice. 
Tiled images obtained from multiphoton microscopy of freshly harvested whole liver are shown. Scale 
bar 200µm. 
Imaging sinusoidal blood flow in the liver 
Imaging and measuring blood flow in any tissue can only be performed in a living subject. 
AIW implantation facilitates blood flow analysis in the liver, in situ. Specifically, it also allows 
assessment of flow in individual sinusoids, which provides the opportunity to investigate the 
impact of localised changes in blood flow on the surrounding parenchyma, even where 
regional or whole organ haemodynamics remain under homeostatic control. 
Techniques to allow measurement of red blood cell velocity in a single sinusoid 
It is possible to use CARS to visualise red blood cells and this was the first approach that was 
pursued in attempting to visualise and measure sinusoidal blood flow.168 The technique 
involves orientating the multiphoton scan direction to match the direction of flow in the vessel 
of interest. Pixel dwell time is then adjusted to try to match the speed at which the red blood 
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cells are flowing through the sinusoid. This then allows calculation of red blood cell velocity. 
When successful, the sight of red blood cells streaming through the sinusoid is visually 
impressive (Figure 6 - 18). However, the challenges in obtaining a consistent CARS signal to a 
reasonable depth and with the necessary resolution have already been alluded to. Also, it can 
be difficult to differentiate the smears created by individual red blood cells. Therefore, an 
alternative fluorescent labelling approach was explored. Red blood cells were harvested from 
a donor mouse of the same line and labelled fluorescently. These were then injected into the 
recipient mouse, after AIW implantation and prior to intravital imaging. The method for 
calculating red blood cell velocity has previously been described,170 and is explained in detail 
in Chapter Two. Scan direction and speed are adjusted in a similar manner to that described 
above for CARS imaging of blood flow. This results in a fluorescent streak when a labelled 
donor red blood cell flows through the vessel under study (Figure 6 - 19a). Resolving the 
length of a smear, made by a single object of known size, against the elapsed time between 
scanning its first and last pixel, allows the calculation of an individual blood cell’s velocity as 
it travels through the sinusoid. Measuring multiple smears in a single sinusoid over a period 
of time allows estimation of red blood cell velocity for that specific location. 
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Figure 6 - 18 CARS imaging allows label-free, intravital visualisation of red blood cells in the 
hepatic sinusoid. 
Sequential scans (scan duration 0.85s) obtained by intravital multiphoton microscopy in a Cdh5-
Cre;PBAG;Ai14 mouse show individual red blood cells stacked in the right-hand sinusoid (white arrow). 
In the left-hand sinusoid, scan speed is matched to red blood cell velocity, resulting in smears as the red 
blood cells pass down the sinusoid (orange arrow). LSECs (red), HSCs (green) and collagen (cyan) are 




Figure 6 - 19 Labelled red blood cells permit measurement of red blood cell velocity in the hepatic 
sinusoid. 
a) Sequential scans obtained by intravital multiphoton microscopy in a Fucci;mTmG mouse. In the centre 
image, three green smears (orange bars) are visible, created by labelled, donor red blood cells as they 
pass through the sinusoids. None are visible in the preceding (top) or subsequent (bottom) image. b) 
Mean red blood cell velocity in the hepatic sinusoids of control mice, and 24 hours after acetaminophen 
administration or partial hepatectomy. Scale bar 20µm. 
Measurement of sinusoidal red blood cell velocity is possible in uninjured and injured 
liver 
Following AIW implantation and injection of labelled red blood cells, timelapse images of 
sinusoidal blood flow were recorded in uninjured livers and at 24 hours following 
acetaminophen administration. Images were also obtained in a separate cohort of mice 
following partial hepatectomy and AIW implantation. Mean sinusoidal red blood cell velocity 
was similar in uninjured liver and following acetaminophen (Figure 6 - 19b).§ However, 
increased red blood cell velocity was observed in mice that received partial hepatectomy. The 
increase in velocity observed following partial hepatectomy is likely the result of a similar 
volume of blood perfusing through a reduced number of sinusoids. Overall, the calculated 
values were consistent between mice within the same cohort, suggesting that this is a valid 
and useful technique for assessment of red blood cell velocity at the level of the sinusoid. 
	
																																																						
§ Data analysis performed by K. Conroy. 
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Using label-free imaging to track hepatic lipid following partial hepatectomy 
As well as detecting signal from fluorescent reporter proteins, the multiphoton system also 
provides the ability to generate ‘label-free’ images. The CARS modality generates an image of 
the tissue through differences in the vibrational properties of its constituent molecules. Lipid 
creates a particularly strong CARS signal and therefore intravital multiphoton microscopy is 
ideally suited to study the dynamic changes in parenchymal lipid content that can occur 
during liver injury. There is a marked accumulation of lipid within hepatocytes in the 
immediate aftermath of partial hepatectomy. The effect of this accumulation on, or its 
relationship to, subsequent hepatocyte proliferation remains unclear. 
Parenchymal lipid was imaged using CARS following partial hepatectomy and AIW 
implantation in two independent cohorts of mice. Z-stacks were reconstructed into three-
dimensional volumes and the percentage of lipid within the parenchymal volume was 
calculated (Figure 6 - 20a,b). This revealed that parenchymal lipid peaks at 48 hours post 
partial hepatectomy, but returns to baseline by 96 hours (Figure 6 - 20c,d). Interestingly, 
experimental mouse 151 had a similar parenchymal lipid profile to that of the uninjured 
control, despite partial hepatectomy being performed. Retrospective review revealed that this 
mouse had the lowest proportion of liver tissue excised at the time of partial hepatectomy 
(2.0% vs 2.2% (ID165), 3.1% (ID152)), suggesting insufficient injury may have occurred to 
trigger lipid accumulation. 
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Figure 6 - 20 Analysis of hepatic lipid dynamics following partial hepatectomy, using intravital 
multiphoton microscopy. 
The accumulation of lipid in hepatocytes occurring after partial hepatectomy can be visualised with CARS 
(a, orange arrows) and reconstructed in three dimensions (b, white arrows). mCherry (red) nuclei are 
also shown. c,d) Percentage volume of hepatic lipid in control mice (blue) and following partial 
hepatectomy (orange) in two independent experiments. Scale bar 50µm. 
Intravital imaging of non-parenchymal cell populations 
Visualising hepatic stellate cells in vivo 
Using the PBAG transgenic mouse to label HSCs has previously been described,29 but this 
strategy has not been used to image HSCs in vivo. PBAG mice were crossed to the Chd5-
Cre;Ai14 line to produce triple transgenic reporter mice, with constitutive expression of eGFP 
in HSCs and inducible expression of Ai14 in LSECs following administration of tamoxifen. 
Intravital imaging demonstrated well-defined labelling of the hepatic sinusoids, with the close 
apposition of HSCs in the space of Disse, with their expected filamentous projections (Figure 
6 - 21a,b). A noticeably increased density of eGFP-positive cells was noted close to the surface 
of the liver (Figure 6 - 21c,d,e). To exclude the possibility of this being an experimental artefact 
due to the presence of the AIW, ex vivo multiphoton microscopy was performed in freshly 
harvested, uninjured whole liver (Figure 6 - 22). This confirmed the previous observations, 
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suggesting that either there is an increased number of HSCs peripherally or, more likely, that 
mesothelial cells in the liver are also labelled in the PBAG mouse. 
	
Figure 6 - 21 Visualisation of sinusoidal vasculature and HSCs with intravital multiphoton 
microscopy. 
a) Constitutive labelling of HSCs (green) and tamoxifen-inducible labelling of LSECs (red) in the Cdh5-
Cre;PBAG;Ai14 mouse. b) The same image as (a), showing only HSCs (green). c,d) The PBAG allele 
also labels a population of cells (green, contained within the dotted white lines) immediately beneath the 
collagen-rich liver capsule (shown in cyan in (c)). e) The expected density of HSCs (green) is present at 
30µm beneath the capsule. Scale bars 50µm. 
 
	
Figure 6 - 22 The PBAG allele labels a population of cells at the liver capsule. 
Multiphoton microscopy of freshly harvested, uninjured, whole liver from Cdh5-Cre;PBAG;Ai14 mice 
confirmed the increased density of eGFP-positive cells (green) at the level of the liver capsule, shown in 
cyan in (a) and removed from the image in (b). c) This density of eGFP-positive cells does not persist at 
30µm beneath the surface of the liver (LSECs, red). Scale bar 50µm. 
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Investigating the possibility of using the MacGreen reporter mouse to label Kupffer 
cells 
Having demonstrated the ability to label hepatocytes, LSECs and HSCs fluorescently for 
intravital microscopy, a means of visualising Kupffer cells in vivo was also explored. Others 
have used antibody labelling strategies to label macrophages in the liver for intravital 
imaging.143,233 Alternatively, the MacGreen knock-in reporter mouse expresses eGFP in colony-
stimulating factor 1 receptor-positive myeloid cells.163 In liver, reporting location and 
morphology matches that of F4-80+ macrophages.163 
MacGreen mice were interbred with mice carrying the mTmG allele to allow assessment 
of eGFP reporting on a background of membranous tdTomato expression by all cells, thus 
facilitating visualisation of the hepatic parenchyma. The initial investigations using 
multiphoton microscopy of the uninjured liver were promising, with a strong eGFP signal in 
the expected sinusoidal location (Figure 6 - 23a). However, when intravital microscopy was 
performed in Fucci-MacGreen-mTmG triple transgenic mice following acetaminophen 
administration, with the aim of tracking the macrophage response to injury and relating this 
to the hepatic regenerative niche, it became clear that the lack of total specificity of the 
MacGreen mouse for the macrophage population drastically limits the conclusions that can 
be drawn using this labelling approach. The size and morphology of many of the eGFP-
positive cells flooding the injured liver suggested that neutrophils as well as macrophages 
were being labelled by the MacGreen allele (Figure 6 - 23b,c). Expression of eGFP has been 
reported in neutrophils in MacGreen mice.231 This makes accurate identification of 
macrophages particularly challenging in the neutrophil-rich inflammatory response that 
occurs following acetaminophen-induced liver injury. Hence, although the MacGreen allele 
could be employed to examine the leukocyte response to liver injury in vivo, the inability to 
distinguish readily between neutrophils and macrophages is a major disadvantage. 
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Figure 6 - 23 MacGreen labelling of inflammatory cells in the liver. 
a) Three-dimensional projection of images obtained by multiphoton microscopy of freshly harvested, 
uninjured, whole liver from a MacGreen;mTmG mouse. b,c) Intravital multiphoton microscopy performed 
24 hours after acetaminophen administration in a Fucci;MacGreen;mTmG mouse. MacGreen (cytosolic 
eGFP, green), nuclei (mCherry, red, G1; mVenus, green, S/G2/M) and cell membranes (tdTomato, red). 
Scale bars 30µm (a) and 100µm (b,c). 
Discussion 
The principal aim of the body of work described in this chapter was to explore the wide-
ranging capabilities of two novel models of AIW implantation, liver injury and repeated 
intravital multiphoton microscopy, and demonstrate their potential to improve our 
understanding of multiple facets of liver regeneration. These models are still in their infancy, 
and certainly present logistical and technical challenges, but the potential rewards for 
continued perseverance are great. For example, by performing partial hepatectomy and AIW 
implantation in a single mouse, it is possible to image sinusoidal vasculature in three 
dimensions, examine the cellular and nuclear morphology of cycling hepatocytes in the 
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regenerative niche, measure blood flow in multiple individual sinusoids, and track lipid 
metabolism. All in the living animal. All at multiple time points. In fact, the greatest challenge 
is probably that of designing a streamlined and efficient workflow to cope with the wealth of 
data that can be produced. 
Using the Fucci reporter allele to identify the hepatic regenerative niche 
Transgenic mice expressing nuclear Fucci2a reporter proteins are an extremely useful tool as 
they enable in vivo visualisation of cycling hepatocytes and the regenerative niche. Nuclei 
progressing through the S phase of the cell cycle and beyond are easily identifiable through 
the dominance of the mVenus reporter protein. Although an attempt at hepatocyte-specific 
Fucci2a expression did not result in highly efficient recombination, the distinctive 
morphology of the hepatocyte and its large nucleus make hepatocyte nuclei easy to identify 
following germline Cre-mediated recombination of the R26Fucci2aR allele, which in theory 
leads to constitutive reporter protein expression in all cells. This germline labelling strategy 
also offers the fortuitous benefit of visualising cell cycling in other cell types within the liver, 
although the utility of this remains to be confirmed. 
The ability to watch individual hepatocytes in vivo as they progress through the cell cycle 
allows examination of whether there are particular hepatocyte features, or an anatomic 
localisation, that predispose a particular hepatocyte to have a regenerative advantage over 
another. There are a large number of bi-nucleate hepatocytes in the liver and it would be 
interesting to examine how the cell cycle, and subsequent division, progresses in this subset 
of cells. 
The major disadvantage of the Fucci system is the loss of nuclear labelling immediately 
prior to cytokinesis, which prevents confirmation of cell division using this system alone. This 
can potentially be surmounted through the use of an additional nucleic acid label, such as 
Hoechst. In the study reported above, Hoechst was administered topically to the surface of 
the liver. Although nuclear labelling was achieved with reasonable efficacy, intravenous 
administration would likely result in more consistent labelling throughout the parenchyma. 
In addition, the long-term effects of most nucleic acid dyes are unknown, so at present these 
labels are only administered in terminal imaging procedures. An easily detectable nucleic acid 
label that does not interfere with the process of mitosis, and is therefore safe to use in longer-
term studies would be preferable. This might also solve another technical challenge posed by 
the use of Hoechst in the current multiphoton setup. Due to the nature of their respective 
	 166	
excitation spectra, it was not possible to acquire Fucci and Hoechst images simultaneously. 
Sequential scans are feasible, if somewhat inconvenient. They also increase the potential for 
tissue movement, reducing the final image resolution, and add to the post-acquisition 
workload because of the need to pair individual scans.  
An additional challenge to the feasibility of intravital imaging of hepatocyte division 
during liver regeneration is a temporal one. Although coordinated entry into the cell cycle 
occurs following partial hepatectomy, hepatocytes are not the fastest of cells to complete the 
cell cycle. Indeed, there can be considerable variation in the time taken to progress from S-
phase to mitosis. Extrapolating from data reported by Matsuo et al., hepatocyte mitosis 
following partial hepatectomy appears to occur 4-12 hours after S-phase.120 Given that local 
regulations limit the extent of intravital imaging to a maximum of six hours, further 
consideration may need to be given as to how best to maximise the extent of hepatocyte 
proliferation that can be imaged. The mVenus reporter predominates from early S-phase right 
through to M-phase, so if an individual nucleus appears mVenus-positive at the start of an 
imaging session, it is difficult to know whether this cell is in early S-phase or close to 
cytokinesis. One clue may lie in the observation that the mVenus signal disperses into the 
cytoplasm in a proportion of imaged cells. If this does indeed signify the breakdown of the 
nuclear membrane in preparation for imminent cytokinesis, then a shift in focus onto 
hepatocytes exhibiting this feature might well assist in optimising the visualisation of 
hepatocyte division in vivo. 
Reconstructing the sinusoidal vasculature from Cdh5-Cre-labelled LSECs 
As previously demonstrated in Chapter Three, the Cdh5-Cre provides a highly efficient way 
to drive recombination in LSECs. Combination with either the Ai14 or mTmG fluorescent 
reporter alleles, and tamoxifen induction, results in clear labelling of the entire liver 
vasculature. Intravital multiphoton microscopy then allows three-dimensional imaging of the 
sinusoids in their native, perfused state. Repeated imaging of the same mouse, at baseline and 
throughout the time course of regeneration, offers an excellent means through which to study 
how sinusoidal structure adapts during regeneration. 
Although the currently available image analysis tools can assist in generating visually 
striking reconstructions of the complex branching structure of the hepatic sinusoids, their 
ability to analyse such networks remains limited. The Imaris package produces excellent 
reconstructions of the sinusoidal network in three dimensions, as shown above. However, its 
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filamentous analysis tools are optimised for neural networks and so do not cope well with the 
tubular nature of the sinusoids. This limits its analysis to more simplistic, global measures, 
such as total vascular volume. Conversely, the Angiotool software is able to assess a range of 
parameters in vascular networks, including vessel length, degree of branching and 
lacunarity.169 However, at present this analysis can only be performed on two-dimensional 
images. 
The ability to link sinusoidal analysis with the hepatic regenerative niche is offered by 
the combination of Cdh5-Cre, mTmG and R26Fucci2aR alleles in the same mouse. Whilst this 
provides the opportunity to home in on sinusoids contouring cycling hepatocytes, it again 
poses its own challenges. Practically, mVenus and eGFP have overlapping emission spectra, 
so accurate vascular reconstruction for analysis would require prior masking of all mVenus-
positive nuclear signal. This is certainly feasible, particularly given the different shape of the 
spherical nucleus and the linear LSEC. However, an alternative would be to make use of 
another LSEC reporter protein, with different excitation or emission spectra. Injectable dyes 
have also been used to label the hepatic vasculature,233 but their administration would add an 
additional layer of procedural complexity, and adequate signal may not endure repeated 
imaging over a number of days. Philosophically, there remains the question of how to define 
whether or not a particular sinusoid, or part thereof, contributes to the regenerative niche. 
This might prove easier in acetaminophen-induced liver injury, with its distinct centrilobular 
focus. However, it would still be necessary to produce objective criteria on which to make any 
distinction, and confirm the cell cycle status of hepatocytes surrounding the sinusoid on all 
sides. 
The inducible nature of the Cdh5-Cre allows the exciting possibility of teasing apart how 
sinusoidal angiogenesis occurs during liver regeneration. Titration of tamoxifen induction to 
achieve sufficient, but sparse, labelling of LSECs with the stochastic, multi-colour Confetti 
reporter should enable assessment of whether all LSECs have equal proliferative potential or 
if instead there are a subset of ‘progenitor’ LSECs, in a restricted anatomical niche. A similar 
approach could also be applied to other cell populations in the liver. 
Measuring hepatic blood flow at the level of the sinusoid 
Both label-free imaging of red blood cells with CARS and fluorescent staining of donor red 
blood cells were explored as a means of assessing sinusoidal blood flow. Although a CARS-
based technique has the advantage of initial simplicity, the variability in the quality of signal 
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hampered repeatable analysis at depth. Red blood cell velocity in the hepatic sinusoid can be 
calculated following administration of labelled red blood cells and adapting the measurement 
technique previously utilised to measure blood flow in tumours of the brain.170 Further 
optimisation to the donor protocol is required. Current labelling efficiency is relatively poor, 
with only around half of the donor red blood cells exhibiting positive staining when imaged 
prior to injection into recipient mice. It also appears that, although labelled cells can be 
detected in the sinusoids at least seven days after injection, donor red blood cells may have a 
decreased lifespan in the circulation or be more prone to sequestration within the liver and 
subsequent macrophage phagocytosis. These factors, combined with the obvious dilutional 
effect that occurs when 100µL of labelled cells in suspension are injected into the entire 
circulating blood volume, mean that timelapse imaging of individual sinusoids must be 
performed over 10-15 minutes to produce sufficient events for quantification. This therefore 
limits the number of sinusoids in which red blood cell velocity can be assessed during each 
recovery imaging session. We plan to improve donor red blood cell labelling efficiency 
through use of mice carrying the miR-144/451eGFP allele, in which all red blood cells are labelled 
with eGFP.234 
Analysis of pilot data revealed that sinusoidal red blood cell velocity appears to increase 
after partial hepatectomy but not acetaminophen-induced liver injury. The values obtained 
are of the same order of magnitude as those reported in a previous study comparing 
sinusoidal red blood cell velocities of uninjured rats and those in which partial portal branch 
ligation had been performed.235 However, velocities a factor of ten slower were reported in 
two much older studies of sinusoidal red blood cell velocities in rats and mice.236,237 Clearly, 
these preliminary findings need further interrogation. However, they are not overly 
surprising at a global level, given that after two-thirds partial hepatectomy it is reasonable to 
assume that the same volume of blood is forced to pass through one-third of the original 
volume of parenchyma. Conversely, despite the marked tissue injury which occurs following 
acetaminophen, the total volume of liver tissue remains the same. Direct comparison of the 
sinusoidal flow between the two models is challenging but could shed light on the role that 
changes in sinusoidal blood flow play in driving the hepatocyte regenerative response. What 
will also be interesting to examine is how sinusoidal blood flow varies within the hepatic 
lobule, particularly between areas of greater and lesser injury, and how differences in red 
blood cell velocity relate to hepatocyte proliferation. As with analysis of the sinusoidal 
vasculature itself, making the distinction between injured and uninjured, or more or less 
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regenerative, areas of liver should ideally be objective. This may require use of a more 
localised model of injury, such as focal thermal injury,238 but would still benefit from the 
advantages offered by AIW implantation and intravital multiphoton microscopy throughout 
the time course of regeneration. 
As well as consideration of the injury model, the potential effects of anaesthesia on blood 
flow should not be neglected. Despite the ability of isoflurane to produce dose-dependent 
vasodilation and hypotension systemically, in the hepatic sinusoid it appears to cause 
sinusoidal narrowing, although the effects on blood flow are offset by increased red cell 
velocity.239 The use of anaesthesia during intravital microscopy is not optional. Isoflurane is 
currently the agent of choice because of its overall safety profile and the ability to titrate its 
administration readily to the lowest effective dose. Fortunately, the non-invasive and non-
stimulatory nature of multiphoton microscopy via an AIW means that extremely low inspired 
fractions of isoflurane can be administered. Imaging at multiple time points also means that 
each mouse is able to act as its own experimental control, with relative changes in sinusoidal 
flow more important than the absolute values. 
The method used to calculate red blood cell velocity, as a surrogate measure of sinusoidal 
blood flow, is validated but relatively simplistic. Post-acquisition modelling of sinusoidal 
blood flow, taking into account sinusoidal morphology as well as red blood cell velocity, may 
provide additional information, such as estimation of shear forces at the sinusoidal wall.240 
Such parameters may play a greater role than red blood cell velocity alone in the regenerative 
process. 
Intravital imaging of hepatic metabolism 
The primary function of the liver is metabolism. As such, real-time imaging of metabolic 
processes during liver injury and regeneration, using intravital microscopy, allows 
assessment of hepatic health and functional capacity at a cellular level. The CARS images and 
subsequent analysis presented above demonstrate the feasibility of imaging hepatic lipid, 
following partial hepatectomy, in vivo and in three dimensions. Indeed the consistency 
between mice at each time point is striking and bodes well for future studies. Not only does 
multiphoton microscopy permit the three-dimensional imaging of lipid stores, at multiple 
time points during regeneration, it negates possible issues with post harvest processing 
artefact. 
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It may be purely coincidental that parenchymal lipid peaks at the time of peak hepatocyte 
proliferation following partial hepatectomy, but this is an observation that merits further 
consideration. It is certainly feasible to relate hepatocyte lipid stores to cell cycle status, by 
acquiring CARS images following partial hepatectomy in Fucci reporter mice. The only 
practical inconvenience under the current setup is that a manual adjustment to the mirror 
cubes is required between acquiring Fucci and CARS signals. Sequential acquisition and post-
imaging reconstruction is still possible. 
More precise, molecular assessment of liver metabolism has also been reported, although 
not yet applied to liver regeneration per se.154 Most commonly, this utilises the intrinsic, but 
variable, fluorescent properties of molecules such as NADH (nicotinamide adenine 
dinucleotide hydride), NADPH (nicotinamide adenine dinucleotide phosphate) and FAD 
(flavin adenine dinucleotide). The degree of fluorescence of these molecules alters with redox 
state and therefore its measurement allows assessment of cellular metabolism. An additional 
microscopy technique, fluorescence lifetime imaging (FLIM), can be performed using 
multiphoton microscopy. This technique creates an image from the lifetime of an emitted 
signal, rather than its intensity. In the context of liver metabolism, it allows distinction 
between the protein-bound, mitochondrial NADH/NADPH, involved in the production of 
ATP via aerobic respiration, and the free, cytosolic NADH/NADPH, that contributes to 
anaerobic glycolysis.  
Intravital microscopy of hepatic stellate cells 
The PBAG reporter mouse provides an excellent means through which to observe HSCs 
during liver injury and regeneration. This is most informative when combined with one or 
more additional fluorescent labels since it allows the interaction of HSCs with other cell types 
in the liver to be clearly observed. The Cdh5-Cre;PBAG;Ai14 mouse allows examination of the 
interaction between HSCs and LSECs, whilst combining PBAG and non-recombined mTmG 
would permit HSCs and hepatocytes to be imaged simultaneously. The incorporation of the 
Fucci reporter allele, in addition to PBAG and mTmG, permits assessment of HSCs in relation 
to cycling hepatocytes. Unlike the challenges of defining whether a sinusoid is within the 
regenerative niche, it would be relatively simple to measure HSC distance from the nearest 
cycling hepatocyte, even in three dimensions. 
Whilst HSCs are well-known to be a central mediator of hepatic fibrosis, as the principal 
collagen-producing cells in the liver,241,242 their role in liver regeneration is less clear. The 
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PBAG reporter facilitates the study of their behaviour following partial hepatectomy or 
acetaminophen-induced liver injury. Although the PBAG reporter is primarily useful as a 
means to identify HSCs, its strong cytoplasmic eGFP expression could be used to detect the 
morphological changes that typically accompany activation. Similarly, the retinoic acid 
droplets present in quiescent HSCs are auto-fluorescent and can be imaged using multiphoton 
microscopy.142,147 As HSCs activate to a myofibroblast phenotype, they have been reported to 
lose vitamin A,243 so the degree of auto-fluorescence could potentially be used to assess HSC 
activation status in vivo. 
The explanation for the increased PBAG-positive cells observed peripherally, at the level 
of the liver capsule, is unconfirmed. An obvious biological explanation for increased numbers 
of peripheral HSCs is not immediately apparent, but should not be ruled out. Mesothelial 
cells, which form a layer of squamous epithelium on the surface of the liver, have been 
suggested as a source of HSCs in a mouse model of liver fibrosis.244 Mesothelial cell expression 
of PDGFRβ has not been widely reported, although they have been shown to express other 
HSC markers, including PDGFRα.245 The current literature has focused on the potential of 
mesothelial cells to act as mesenchymal progenitors during development and after liver 
injury.245 Whether the increased number of PBAG-positive cells observed near the surface of 
the liver does indeed represent mesothelial cells, with potential to differentiate into HSCs and 
trickle centrally into the liver parenchyma, would need to be confirmed through assessment 
of further mesothelial cell marker expression and ideally a fate-mapping experimental 
approach. Given that the increased number of superficial PBAG-labelled cells was also present 
on imaging of freshly harvested, uninjured, whole liver, this might suggest that mesothelial 
cells act as a source of HSCs during homeostasis as well as following injury.  
Intravital microscopy of inflammatory cell populations in liver injury and 
regeneration 
The role of inflammatory cells in the response to liver injury is a dynamic process which is 
ideally suited to study with intravital microscopy techniques. Most, if not all, intravital 
microscopy studies of inflammatory cell populations in liver injury have thus far been 
performed following externalisation of the liver.213,233,238,246 This obviously limits the study to a 
single imaging session per mouse, with a resultant focus on the immediate inflammatory 
response to injury. Imaging of hepatic inflammatory cell populations via the AIW permits 
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their study at multiple stages during both the initial inflammatory response and subsequent 
regenerative phase. 
The MacGreen reporter allele was examined as a potential fluorescent labelling strategy 
for macrophages. However, intravital microscopy following acetaminophen-induced liver 
injury suggested frequent labelling of neutrophils in addition to macrophages. Expression of 
eGFP in both neutrophil and dendritic cell populations has been reported in MacGreen 
reporter mice, in which eGFP expression is driven by the promoter for the colony-stimulating 
factor 1 receptor.230,231 This lack of specificity clearly limits the utility of such a strategy to target 
macrophages alone. A LysM-Cre has also been used to drive highly efficient recombination in 
macrophages, but suffers from the same drawback of concomitant neutrophil targeting.247 
At present, antibody labelling strategies may be the most specific means through which 
to label macrophages and macrophage subpopulations in vivo.143 Looking beyond the 
challenges of transgenic targeting of the entire macrophage population, labelling restricted 
macrophage subpopulations would offer greater clarity as to their differing roles. In 
particular, the ability to target Kupffer cells, the resident macrophage within the liver, would 
greatly assist in expanding our knowledge of their functions in liver injury and repair. 
Recently, Clec4f has been identified as a Kupffer cell-specific gene.181 A mouse containing a 
Clec4f-Cre construct has been generated, and the first publications using this targeting strategy 
are eagerly anticipated. 
Using AIW and multiphoton microscopy to visualise liver regeneration with 
subcellular resolution 
Whilst the combination of AIW insertion and multiphoton microscopy revolutionises our 
ability to study liver regeneration in situ, it is not without its own challenges and limitations. 
For example, the current multiphoton setup, with two laser lines and four detectors, limits the 
breadth of simultaneous multi-fluorophore image acquisition to below that of many confocal 
microscopy systems. The multiphoton system was optimised for CARS imaging when built 
and, as a result, does not perform particularly well at the lower and upper extremes of 
wavelengths detectable with light microscopy. A further limitation is the fact that most 
transgenic fluorescent reporter and intravital labelling systems have traditionally focused on 
proteins with emission spectra in the red and green regions of the visible light spectrum. The 
simultaneous detection of nuclear mCherry and cell membrane tdTomato is relatively easy to 
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differentiate with the human eye, but resolving these signals for automated image analysis 
and quantification is challenging. 
Further improvement is also possible in several aspects of the image acquisition process, 
the result of which will be more consistent, biologically-relevant, analysable images. At 
present, the two biggest limitations to repeatable, high-quality image acquisition are loss of 
contact between liver and coverslip, and tissue movement during imaging. The former is 
reduced by improved surgical technique, and optimising AIW design and coverslip 
preparation, as described in Chapter Five. The latter is reduced by improved stabilisation of 
the AIW during imaging, also discussed previously, and better titration of anaesthetic depth. 
Improved anaesthetic monitoring, with measurement of heart rate, pulse oximetry and 
temperature, not only facilitates maintenance of the lightest possible plane of general 
anaesthesia, but also maximises consistency between experimental animals and imaging 
sessions. Together these improvements should result in images that are of sufficient quality 
for analysis. However, should further post-acquisition processing be required, it is possible to 
correct movement artefact, both between and within images.149,150,248 
The underlying principles of the multiphoton technique, with image generation on a per-
voxel basis, do place a limit on the rate at which images can be acquired with acceptable 
resolution. Whilst more than adequate for imaging the architecture of the liver as a whole, and 
most of the dynamic processes such as cell cycling, it is not able to track fast-moving objects, 
such as red blood cells in the sinusoids. Matching scan speed to red blood cell velocity offers 
a workaround to facilitate estimation of velocity. Additionally, high-speed video imaging of 
blood flow in the superficial sinusoids that are visible via epifluorescence microscopy, 
available as part of the current multiphoton setup, could offer complementary information. 
The varied opportunities offered by the wide range of transgenic reporter alleles are 
described in detail above. So too is the potential for CARS imaging of parenchymal 
morphology, red blood cells, and hepatic lipid. However, the second label-free imaging 
capability provided by multiphoton microscopy, that of SHG, was not explored to its full 
potential. SHG can be used to detect collagen and is therefore ideally suited to imaging the 
capsule of the liver and the extracellular matrix. Although extracellular matrix changes do 
occur during acute liver injury and subsequent regeneration, little or no signal was detected 
within the liver parenchyma within the first three to seven days following partial hepatectomy 
or acetaminophen administration. As such, utilisation of this modality is best suited to study 
of the behaviour of the liver capsule itself or for intravital microscopy of models of liver 
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disease which generate a more marked fibrotic response, such as bile duct ligation or chronic 
carbon tetrachloride administration. Intravital imaging of chronic liver disease via an AIW 
could be extremely informative, but would require demonstration of the feasibility of long-
term maintenance of mice with AIWs and the ability to achieve consistently usable images 
over an extended period. Alternatively, it should be possible to develop a model of late 
implantation of the AIW, after the onset of chronic liver injury. Even without deposition of 
significant parenchymal collagen, visualisation of the liver capsule using SHG serves as a 
useful reference point both for image acquisition and during subsequent analysis. 
Although AIW implantation itself is minimally invasive, and does not appear to have 
major effects on liver injury and subsequent hepatocyte proliferation (see Chapter Five and 
the work of Alexandra Thompson214), the presence of cyanoacrylate adhesive, a titanium 
implant, and a glass coverslip (albeit with a biologically inert coating) may have local effects 
at the liver capsule and parenchyma immediately underlying it. Careful handling of the liver 
during AIW implantation and subsequent changing of the coverslip is required to minimise 
any superficial trauma and biofilm accumulation. Uninjured controls at every imaging time 
point are also essential to be able to determine confidently whether the observed findings are 
a result of the model of liver injury or simply the presence of the AIW alone. 
A disadvantage of the experimental model of partial hepatectomy and AIW implantation 
is the inability to obtain baseline images prior to liver injury. Within the current setup, there 
is also an enforced delay of twenty-fours between surgery and imaging, on welfare grounds 
and because of the need to transfer experimental animals to the imaging facility. These issues 
could be surmounted, at least in part, by situating imaging facilities within the animal units 
themselves, allowing surgery and imaging to be performed under the same general 
anaesthetic. 
Studying liver regeneration using intravital multiphoton microscopy, in combination 
with a wide range of cellular, structural and dynamic labels, is an exciting technique with 
huge potential.  However, it results initially in primarily descriptive data, following the time 
course of injury and subsequent regeneration and making comparisons between time points 
or the uninjured state. Whilst this alone may suggest novel therapeutic targets or 
interventions, the true benefit will come from formulating and testing the hypotheses that 
result from these observations. These same experimental models are also ideally suited to 
examine the effects of targeted genetic depletion or administration of exogenous substances 
on the dynamics of liver regeneration, in real time and at high resolution. However, the 
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volume of data that such studies generate and the importance of efficient, high-fidelity image 
analysis workflows must not be under-estimated. Appropriate systems must be in place to 
reap the maximum benefit from these experimental models. 
Summary 
The ability to combine intravital multiphoton microscopy with two different mouse models 
of liver injury and regeneration, and multiple combinations of fluorescent reporter alleles, 
provides extraordinary capacity to study multiple facets of the regenerative process, often 
simultaneously. Key benefits include the ability to image the same animal repeatedly during 
the time course of liver regeneration, at subcellular resolution. This permits evaluation of 
dynamic processes, including cellular metabolism and sinusoidal blood flow.  Combinations 
of cellular labels facilitate visualisation of cellular interactions during regeneration. 
Fluorescent labelling of cell cycle stage offers the opportunity to study the microenvironment 
around proliferating hepatocytes. This will allow us to both deepen and expand our 
understanding of how the injured liver coordinates the regenerative response. Having 
identified novel mechanisms and potential therapeutic targets, these intravital systems 




Chapter 7 – Reflections and future work 
Introduction 
The ultimate goal of the body of work described in this thesis was to improve our 
understanding of, and ability to study, the process of liver regeneration. Progress in this field 
is essential because of the huge global burden of liver disease and the lack of effective 
therapies, other than liver transplantation, for both acute and chronic liver failure. The concept 
of encouraging the sick liver to heal itself is an attractive one, given the extraordinary 
regenerative potential of the healthy organ. Our current inability to intervene effectively in 
this regard is frustrating and renders even more stark the bleak irony that this remarkable 
organ fails completely when we need it most. 
The role of αv integrins in liver regeneration was explored because of recent evidence 
that they promote the development of liver fibrosis.29 In chronic liver disease the development 
of collagen-rich scar tissue goes hand in hand with the loss of functional capacity. As such, 
potential therapies that can reduce or reverse fibrosis whilst simultaneously promoting 
hepatocyte proliferation and restoration of functional liver mass are particularly attractive. 
The vast majority of studies examining αv integrins show that their primary role is to activate 
latent TGFβ. In the context of liver fibrosis, TGFβ is a major pro-fibrotic cytokine, so it is 
reassuring that depleting or inhibiting HSC αv integrins has been demonstrated to lead to a 
reduction in fibrosis through a decrease in the amount of active TGFβ.29 There is also a 
historical body of literature demonstrating the growth-inhibitory effect of TGFβ on epithelial 
cells, including hepatocytes. Therefore, it is eminently feasible that αv integrin-mediated 
activation of TGFβ could regulate hepatocyte proliferation following liver injury. This might 
also explain, at least in part, why the restoration of functional capacity fails in the TGFβ-rich 
environment of the end-stage liver. 
Alongside attempts to improve our understanding of the molecular regulation of 
hepatocyte proliferation and liver regeneration, it is important that the field takes advantage 
of technological advances that offer the potential for new insight into liver regeneration. 
Multiphoton microscopy is arguably the best technology currently available to study the 
regenerative process at a subcellular level because it facilitates intravital imaging and offers 
additional imaging modalities not available using standard confocal techniques. Liver 
regeneration is a process ideally suited to intravital study. It is a dynamic process, requiring 
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multicellular coordination, that in rodent models completes over a concise period of time. 
Thus, there is the potential to reap great scientific benefit by studying how the liver 
regenerates in three dimensions, in the living animal, from start to finish. Equally, intravital 
imaging of liver regeneration does present its own challenges. Principally, these comprise 
achieving induction of sufficient liver injury to kick-start the regenerative process in 
conjunction with obtaining artefact-free access to the in situ regenerating liver, in a manner 
which does not significantly impact either the welfare of the experimental animal or the 
regenerative response under study. 
Integrin αvβ8 in liver regeneration 
Depletion of integrin αvβ8 on hepatocytes leads to increased hepatocyte proliferation and 
accelerated liver regeneration in the mouse partial hepatectomy model of liver regeneration. 
This appears to be primarily an autocrine effect, since targeted depletion of HSC integrin αvβ8 
did not lead to the same phenotype. LSECs do not appear to express integrin αvβ8, at least in 
the uninjured liver. Kupffer cell expression of integrin αvβ8 was not examined in this body of 
work and, although they too may not express this particular integrin,43 it would be preferable 
to confirm this. 
Unfortunately, the same positive effect on hepatocyte proliferation of hepatocyte integrin 
αvβ8 depletion was not seen at 48 hours after acetaminophen-induced liver injury, nor when 
a β8 integrin subunit blocking antibody was administered to wild-type mice at the time of 
partial hepatectomy. Possible reasons for the failure to recapitulate the previously observed 
positive effects on liver regeneration are discussed in detail in Chapter Three. Whilst these 
findings could be seen as disappointing, they do not necessarily sound the death knell for 
integrin αvβ8 as a potential therapeutic target to promote liver regeneration. However, an 
improved understanding of the precise circumstances in which targeting integrin αvβ8 can 
promote liver regeneration is required before this integrin can be confidently put forward as 
a viable therapeutic target. 
It is reassuring that human hepatocytes appear to express integrin αvβ8 in both health 
and disease. One option for further study would be to examine the effects on proliferation of 
inhibiting integrin αvβ8 in human hepatocytes. Clearly this would need to be performed in 
vitro in the first instance. Primary human hepatocytes may be challenging to obtain and 
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maintain in culture, so human hepatocyte cell lines might need to be utilised. This would bring 
its own set of caveats to any findings. 
An alternative would be to continue to assess the pro-regenerative effect of hepatocyte 
integrin αvβ8 depletion or inhibition in animal models. Acute carbon tetrachloride injury is a 
relatively straightforward model of liver injury and regeneration that could be examined. A 
more challenging, but potentially more informative and translationally relevant, model would 
allow examination of hepatocyte proliferation in the context of liver fibrosis. Chronic carbon 
tetrachloride or thioacetamide administration are both commonly used to study liver fibrosis. 
Alone, their use may not result in sufficient stimulation of hepatocyte proliferation to enable 
detection of a pro-regenerative phenotype following integrin αvβ8 depletion or inhibition. 
However, an additional stimulus, such as partial hepatectomy or a one-off increased dose of 
carbon tetrachloride, could be employed after fibrosis has been established, to promote an 
adequate regenerative response. Such models have been previously reported.249 Were an 
intervention such as integrin αvβ8 inhibition shown to be both anti-fibrotic and pro-
regenerative, there would certainly be keen interest in attempting to develop it into a therapy 
for chronic liver disease. 
The αv integrins share a common feature, the RGD binding domain, which allows them 
to activate latent TGFβ. However, as we gradually piece together the subtleties that 
distinguish individual members of the αv integrin family, it is apparent that the different αv 
integrins are not interchangeable. The combination of their molecular structure, and cellular 
and temporal expression patterns, results in members of the αv integrin family having 
distinct, and potentially unique, functions. It would be intellectually interesting to examine 
whether hepatocyte depletion of other αv integrins in isolation also results in a pro-
regenerative phenotype. However, the time and cost of such an enterprise, particularly if one 
were to characterise the entire time course of regeneration following partial hepatectomy in 
each case, prevented this from being undertaken in the present body of work. To investigate 
the pro-regenerative potential of integrin αvβ8 on other hepatic cell types, assessment of 
hepatocyte proliferation at a single time point was performed. This is justifiable, since if any 
effect on regeneration were to occur, one would expect it to be most evident around the time 
of peak hepatocyte proliferation in this model. However, it should be borne in mind that such 
an approach takes only a single snapshot of the regenerative process, and differential effects 
at both earlier and later time points could occur. This emphasises the need for, and benefit of, 
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experimental systems in which multiple time points during liver regeneration can be assessed 
in the same experimental animal. 
Mechanistic studies of hepatocyte integrin αvβ8 
Uncovering and validating a phenotype forms only half of a scientific story; it is always 
preferable to be able to confirm the explanation for an observed effect. In the case of integrin 
αvβ8 regulating hepatocyte proliferation, there was an obvious mechanistic candidate: the 
TGFβ signalling pathway. Given that multiple studies have shown the primary role of integrin 
αvβ8 to be activation of latent TGFβ, and active TGFβ is well-documented as a repressor of 
hepatocyte proliferation, it seemed but a small matter to demonstrate that integrin αvβ8 on 
hepatocytes was performing its expected function. To misquote Shakespeare: the course of 
true science never did run smooth. 
The mRNA expression time course for hepatic integrin αvβ8 matches precisely what 
might be expected of a cell surface molecule with a homeostatic role in the regulation of 
proliferation. Immediately following partial hepatectomy, with the liver suddenly bereft of 
sufficient hepatocytes, expression of Itgb8 reduces, potentially releasing a tonic brake on 
hepatocyte proliferation. Subsequently, not only does Itgb8 expression return to normal, but 
in the later phase of liver regeneration it increases 10-fold, suggesting it may have a role in 
terminating the regenerative response as the liver approaches its pre-injury mass. 
Unfortunately, despite multiple attempts, it was not possible to demonstrate hepatocyte 
activation of TGFβ in vitro. This raises more questions than it provides conclusive answers. 
Could this be simply a technical or operator error with the performance of the assays 
themselves? The reporter cell system was certainly responsive when active TGFβ was 
supplied, but TGFβ activation by an HSC cell line was not detected, discordant to what might 
have been expected. Do hepatocytes not activate sufficient TGFβ for detection? Whilst this is 
always possible, the assays themselves do appear to be reasonably sensitive, capable of 
detecting levels of active TGFβ as low as 1pg/mL. Is it possible to accept, at least in part, the 
‘null’ hypothesis and conclude that hepatocyte integrin αvβ8 does not promote hepatocyte 
proliferation and liver regeneration through activation of TGFβ? Or could it be that, whilst 
hepatocyte integrin αvβ8 is capable of activating TGFβ, hepatocytes themselves are even 
better at binding it? Certainly, the proposed mechanism requires that the TGFβ that is 
activated by hepatocyte integrin αvβ8, binds and signals directly, in an autocrine manner. 
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These challenges with detecting changes in amounts of active TGFβ in the environs of 
the hepatocyte led to the attempts to demonstrate alterations in hepatocyte TGFβ signalling. 
Again, this proved taxing. Canonical TGFβ signalling does occur in hepatocytes following 
partial hepatectomy, as demonstrated by the detection of nuclear pSMAD3. Unsurprisingly, 
however, this is not a highly active pathway, particularly around the time of peak hepatocyte 
proliferation. As such, demonstrating a reduction in signalling, when the baseline is already 
low, is not easy. This likely also explains why the effects of integrin αvβ8 inhibition on TGFβ-
responsive genes, as assessed in the custom qPCR array, were predominantly small. The 
inhibition of tonically active TGFβ signalling, in uninjured primary hepatocytes, would not 
be expected to result in mirror-image changes of the same magnitude that occur when 
exogenous active TGFβ is provided to hepatocytes. 
On a more positive note, the finding that inhibition of hepatocyte integrin αvβ8 leads to 
increased expression of Plat, the gene encoding tPA, does provide a possible mechanism 
through which liver regeneration might be promoted. Not only is tPA expression responsive 
to TGFβ, tPA has been demonstrated to activate HGF, one of two direct hepatocyte mitogens. 
As well as confirming this observation at the protein level, it would be interesting to assess 
levels of tPA activity in post-partial hepatectomy liver tissue, in both control and 
Itgb8flox/flox;Alb-Cre mice. It would be expected that the latter mice would show increased levels 
of active tPA at the same time as, or preceding, increased hepatocyte proliferation. 
Developing models to study liver regeneration using 
intravital microscopy 
The benefits of studying liver regeneration through an intravital imaging approach have been 
repeatedly extolled throughout the preceding chapters. However, in order to undertake such 
studies it was necessary to develop and validate an appropriate experimental model. Partial 
hepatectomy in the mouse is a widely-used model of liver regeneration, and the possibility of 
adapting the standard technique to allow placement of an AIW for subsequent intravital 
multiphoton microscopy was explored and subsequently validated. 
Hepatocyte proliferation does not significantly differ between standard partial 
hepatectomy and the modified procedure that was developed. Nor was it altered by the 
presence of the AIW. However, a degree of increased weight loss was seen at the seven-day 
time point, combined with a reduction in total liver weight. If this is primarily due to the initial 
	 182	
procedure itself, or a reduction in food intake in the post-surgical period, then it should be 
possible to reduce or even eliminate this difference with improved experience and supportive 
husbandry measures. Future work could repeat the original validation studies to contribute 
additional data and assess the effect of increased experience. Nevertheless, the modified 
partial hepatectomy and AIW implantation technique does appear to drive sufficient 
hepatocyte proliferation and liver regeneration in the AIW lobe to allow study of the 
regenerative process. 
Improvements in the design of both the AIW and the imaging baseplate were necessary, 
in order to maximise the success of the two liver regeneration models and obtain high-quality 
intravital images for analysis. This process provided exposure to the world of product design 
and engineering, and salient lessons in pursuing such endeavours. Most of all, it highlighted 
that a thorough understanding of the model and the key features of the product being 
designed are critical to a successful outcome. Furthermore, with every improvement there 
may be potentially negative consequences that should be considered in advance. For example, 
the changes to the external diameter of the AIW and the depth of the central groove were 
instituted to assist with bringing the liver lobe closer to the coverslip and anchoring the AIW 
in the imaging baseplate. However, in combination, they make seating the purse string suture 
within the AIW groove, a critical step in the implantation procedure, more challenging. The 
earlier modification that moved the coverslip onto a removable inlay facilitates its 
replacement but compromises contact with the liver surface. It would be interesting to explore 
the possibility of completely re-designing the AIW. The key features of any new version 
should be ease of implantation, biological inertia (including of the optical window), and 
minimising the distance between the liver and the microscope objective. Advances in three-
dimensional printing in plastic, and laser-controlled machining, facilitate prototype 
development and relatively inexpensive production. 
Possibly the most interesting finding from the early work optimising the two models of 
liver injury and AIW implantation was the reduction in acetaminophen-induced liver injury 
in mice receiving additional periods of general anaesthesia for intravital imaging. 
Unfortunately, there was not the opportunity to explore this potentially novel phenotype 
further, but it could be investigated relatively easily. In the first instance, one could simply 
compare liver injury in mice receiving acetaminophen with or without a prior period of 
general anaesthesia with isoflurane. Were a reduction in injury confirmed, then as well as 
dissecting the underlying mechanism, it would be fascinating to see whether a protective 
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effect could also be translated into a therapeutic one. Isoflurane is used on a daily basis in 
human medicine, so would be extremely easy to re-purpose. 
Intravital multiphoton microscopy of liver regeneration 
The development, validation and refinement of two models of AIW implantation and liver 
injury allow intravital multiphoton microscopy of liver regeneration. The extraordinary 
breadth of transgenic strategies now readily available to label specific cells or structures in 
mice, combined with exogenous labelling techniques and the label-free imaging possibilities 
of multiphoton microscopy, open numerous, exciting avenues for exploration. Indeed, when 
contemplating the range of opportunities now available, the feeling is akin to that of a child 
in a toy shop before Christmas. The true challenge lies in determining how to derive the best 
value from the many possible investigations that could be performed with these techniques. 
The route to surmounting this lies in defining precise research questions, the answers to which 
will advance our knowledge of liver regeneration. 
The Fucci cell cycle label is an extremely useful tool, as it enables the investigator to focus 
their attention on individual cells at the most relevant time point. Observing an individual 
hepatocyte dividing, in situ, may be somewhat indulgent, but could reveal interesting features 
that invite further study, particularly because of the heterogeneity that hepatocytes display 
with regard to nucleus number and ploidy. More immediately, the Fucci label offers the ability 
to distinguish regions of increased hepatocyte proliferation and compare these 
contemporaneously with less proliferative areas in the same liver. 
In addition to observing cycling hepatocytes, fluorescent labelling of cells themselves 
permits morphological assessment. Integral to the process of regeneration is the preceding 
injury. Although only touched upon in this body of work, the changes that occur in 
hepatocytes in response to acetaminophen, ultimately leading to necrosis, would be extremely 
interesting to characterise in the living mouse, particularly with the option to track the 
behaviour of inflammatory cell populations simultaneously. Observing the interaction of two 
or more labelled cell types in their native environment is one of the opportunities offered by 
intravital microscopy. 
Along with the Fucci reporter mouse, the Cdh5-Cre allele stands out as a particularly 
useful genetic tool. For an inducible Cre, the recombination observed following tamoxifen 
administration is extremely impressive. It permits fluorescent labelling of the entire sinusoidal 
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network, allowing assessment of the changes that occur in this complex structure during liver 
injury and regeneration. The ability to obtain three-dimensional images of perfused sinusoids 
in the living organism could also be used to help construct in silica models of sinusoidal flow. 
Not only would this potentially reduce experimental animal use in the future, its combination 
with data on the cell cycle status of surrounding hepatocytes could be used to explore how 
modulating sinusoidal flow might promote hepatocyte proliferation and liver regeneration. 
Until such time as accurate computer models of cell behaviour and blood flow in the liver 
exist, intravital microscopy is really the only way to study these dynamic processes. 
Ultimately, liver function is entirely a product of blood flowing through the sinusoid, so 
understanding the haemodynamic alterations that occur during liver injury and regeneration 
is critical, in order to uncover ways in which we can promote hepatic function and 
regeneration following injury. Hepatic metabolism goes hand in hand with sinusoidal 
perfusion, and this again is another field in which intravital multiphoton microscopy comes 
into its own. There is no other means to assess the metabolic state and activity of a hepatocyte 
in its native environment over the time course of liver injury and regeneration. Optimising the 
multiphoton system that was used in the current work, to be able to perform fluorescence 
lifetime imaging and obtain information about the metabolic state of individual hepatocytes 
during liver regeneration would provide extremely useful data and allow real-time 
assessment of how hepatocyte function responds to injury and therapeutic intervention. 
Concluding remarks 
These forays into researching liver regeneration hopefully demonstrate the fascinating, 
exquisitely controlled processes at play in the response to liver injury. It is also apparent that 
teasing apart the key molecules contributing to the regulation of the regenerative process can 
be challenging and at times frustrating. Hepatocyte integrin αvβ8 contributes to the regulation 
of hepatocyte proliferation, but whether this can be translated into a therapeutic approach 
which can promote regeneration of a patient’s own liver remains to be seen. It also proved 
difficult to elucidate the precise mechanism through which targeting integrin αvβ8 produced 
the pro-regenerative effect. In part, this was due to the need to abstract hepatocytes from their 
native environment within the regenerating liver, in order to examine potential mechanistic 
pathways. The development of systems that allow direct observation of liver regeneration, at 
subcellular resolution, paves the way for studies that assess individual cellular or signalling 
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responses as they occur in the model organism. In the future, it may even be possible to move 
beyond experimental animal models, and utilise these systems to examine the cellular 
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Notes: c, Coulouarn et al.;137 Cont, control; down, downregulation; Q1, Qiagen TGFβ signalling targets 
array (330231, PAMM-235Z); Q2, Qiagen TGFβ-BMP signalling pathway array (330231, PAMM-035Z); 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 3 – FIJI macro to calculate percentage positive 
DAB staining in multiple images 
Prior to running the below macro, the Trainable Weka Segmentation tool in FIJI is trained to 
identify positive DAB staining. This is achieved by loading a stack of representative images 
from the experiment in question and indicating areas of positive and negative staining in an 
iterative manner, until the tool is able to differentiate positive and negative staining with 
acceptable accuracy. Recommended minimum training features are Gaussian blur and Sobel 
filter. Additional features can be added, but this can dramatically increase processing time 
without significant improvement in classification. All other settings are left at their default 
values. The final classification algorithm is then saved as a .model file. 
 
/* 
 * DAB staining analysis macro v3 19/08/16 
 * Stephen Greenhalgh 
 * Input: a working directory containing RGB TIFF images. 
 * Input: a WEKA segmentation model file for classifying the above images. 
 *  
 * Credits: 
 * Elements of code from 
 * BrdU pos/neg nuclei counter v3 28/8/15 by Stephen Greenhalgh and John Wilson-
Kanamori 
 * TrainableWekaMacro v1.1 by Sébastien Tosi (IRB / Barcelona) 
 */ 
 





//workaround required in Mac OS X 10.11 otherwise dialog boxes do not display correctly 
 
//define current FIJI Trainable Weka Segmentation version 
//this part of the code may need to be updated to reflect the current version 
WekaVersion = "Trainable Weka Segmentation v3.1.2"; 
SaveClassification = true; 
// this second line may be surplus 
 
// Find all files in the image folder 
InputFile = File.openDialog("Select an image file from the folder you wish to analyse"); 
open(InputFile); 
 
OutputLocation = getDirectory("Select location of output files"); 
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DialogTitle = "Enter name of results folder"; 
 
Dialog.create("Enter name of results folder"); 
  Dialog.addString("Results folder name: "," "); 
  Dialog.show(); 
  ResultFolderName = Dialog.getString(); 
 
SegOutFolder = OutputLocation + ResultFolderName + File.separator; 
File.makeDirectory(SegOutFolder); 
 
classifier = File.openDialog("Please select your classifier..."); 
 
// Initialize Trainable Weka 
run("Trainable Weka Segmentation"); 
wait(500); 
 
//ensure correct Weka version is entered here 
selectWindow("Trainable Weka Segmentation v3.1.2"); 
call("trainableSegmentation.Weka_Segmentation.loadClassifier", classifier); 
 
//get the input directory 
 dir = getDirectory("Choose a Directory "); 
//set the batch mode to true 
   setBatchMode(true); 
//declare and initialise variable count 
   count = 0; 
//run user-defined function countFiles 
   countFiles(dir); 
//declare and initialise variable n 
   n = 0;  
//run user-defined function processFiles 
   processFiles(dir); 
//print number of file processed in log in window 
   print(count+" files processed"); 
 
//user-defined countFiles function 
   function countFiles(dir) { 
//list of items in input directory (files and subfolders) 
      list = getFileList(dir); 
//start of loop through the list of items 
      for (i=0; i<list.length; i++) { 
//if item end with / it is a folder 
          if (endsWith(list[i], "/"))  
//if a folder run the user-defined countFiles functions 
              countFiles(""+dir+list[i]); 
          else 
//else ad +1 to the file count 
              count++; 
      } 
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  } 
 
function processFiles(dir) { 
//list of items in input directory (files and subfolders) 
      list = getFileList(dir); 
//start of loop through the list of items 
      for (i=0; i<list.length; i++) { 
//if item end with / it is a folder 
          if (endsWith(list[i], "/")) 
//if a folder run the user-defined processFiles(dir) function 
              processFiles(""+dir+list[i]); 
          else { 
//if a file 
             showProgress(n++, count); 
//declare the variable path 
             path = dir+list[i]; 
//run the user defined processFile(path) function 
             processFile(path); 
          } 
      } 
  } 
 
//user-defined processFile(path) function 
  function processFile(path) { 
//if the file is a tif file 
       if (endsWith(path, ".tif")) { 
//open the image 
           open(path); 
//run wekaSegment function 
           wekaSegment(path); 
            
      } 
  } 
// Main loop over all .tif images in the folder 
 
function wekaSegment(path){ 
  selectWindow(WekaVersion); 
  call("trainableSegmentation.Weka_Segmentation.applyClassifier", dir, list[i], 
"showResults=true", "storeResults=false", "probabilityMaps=false", ""); 
  selectImage("Classification result"); 
  saveAs("Tif",SegOutFolder+"Segmented "+list[i]); 
 } 
 
//measure positive staining percentage 
 











 setAutoThreshold("Default dark"); 
 run("Threshold..."); 
 setThreshold (0.51, 1.00); 






Appendix 4 – Imaris surface generation algorithms 
Vascular surface algorithm applied to Ai14 channel in Cdh5-Cre;Ai14 mice 
Enable Region Of Interest = false 
Enable Region Growing = false 
Enable Tracking = false 
[Source Channel] 
Source Channel Index = 3 
Enable Smooth = true 
Surface Grain Size = 1.99 um 
Enable Eliminate Background = true 
Diameter Of Largest Sphere = 7.45 um 
[Threshold] 
Enable Automatic Threshold = false 
Manual Threshold Value = 47.9868 
Active Threshold = true 
Enable Automatic Threshold B = false 
Manual Threshold Value B = 2240.56  
Active Threshold B = true 
[Classify Surfaces] 
"Number of Voxels" not activated 
Lipid surface algorithm 
Enable Region Of Interest = false 
Enable Region Growing = false 
Enable Tracking = false 
[Source Channel] 
Source Channel Index = 5 
Enable Smooth = true 
Surface Grain Size = 1.00 um 
Enable Eliminate Background = true 
Diameter Of Largest Sphere = 5.00 um 
[Threshold] 
Enable Automatic Threshold = false 
	 210	
Manual Threshold Value = 991.494 
Active Threshold = true 
Enable Automatic Threshold B = false 
Manual Threshold Value B = 3869.72 
Active Threshold B = false 
[Classify Surfaces] 
"Number of Voxels" above 1.00 
	  
	 211	



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Notes: Undetermined samples set to Ct of 40; *ΔCt=Ct(gene of interest) - Ct(arithmetic mean of 
housekeeping genes); housekeeping genes are Actb and Gapdh; RTC, reverse transcription control; 
























































































































































































































































































































































































































































































































































































































































































































































Appendix 6 – HO-1 and tPA immunohistochemistry 
	
Immunostaining of post-partial hepatectomy liver for HO-1 (a, b – isotype control) and tPA (c, d – isotype 
control) reveal only non-specific background staining. Scale bar 50µm. Immunostaining protocol as for 
GR1 (see Chapter Two), with HO-1 antibody (Abcam, 52947, 1:100) and tPA antibody (Abcam, 157469, 
1:500). Rabbit IgG isotype control was added at an equivalent concentration (Santa Cruz, SC-2027) 
	
